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Resumo 
Esta tese teve como objectivo determinar os mecanismos e 
consequências de dois genes virais de evasão à resposta do 
interferão (IFN), expressos pelo economicamente importante, e 
frequentemente fatal, Vírus da Peste Suína Africana (VPSA). De modo 
a sobreviverem, os vírus de ADN, tal como o VPSA, têm 
frequentemente múltiplas estratégias/genes que modulam positiva ou 
negativamente a biologia celular do hospedeiro, bem como a resposta 
imunitária. Os dois genes aqui apresentados funcionam em benefício 
do vírus, inibindo um das principais componentes da resposta imune 
inata, a resposta do IFN. 
O gene I329L foi recentemente reportado como sendo capaz de inibir 
as respostas celulares, controladas pelo TLR3, que levam à indução e 
secreção de IFN-β, bem como à activação do NF-κB. Aqui, é 
demonstrado que o I329L não só inibe a indução e secreção de IFN-β 
pelo TLR3, mas também inibe a activação do NF-κB após estimulação 
pelo TLR4. Demonstrou-se ainda, bioquimicamente, que a proteína 
I329L interage com a proteína adaptadora TRIF, o que é consistente 
com a inibição observada de ambas as vias do TLR3 e TLR4. De 
forma a caracterizar a modulação da resposta do IFN tipo I pelo I329L, 
bem como determinar o papel de cada domínio do I329L nesta 
inibição, foram construídos plasmídeos que expressam mutantes 
truncados, com apenas o domínio extracelular ou intracelular. Estes 
mutantes foram testados por ensaios de luciferase. O domínio 
extracelular apenas inibe a activação do IFN-β e NF-кB induzida por 
estímulo com Poly (I:C), enquanto o domínio intracelular é capaz de 
inibir a mesma via quando esta é induzida por expressão ectópica de 
TRIF. Além disso, demonstrou-se que a proteína I329L é 
proteoliticamente processada durante a infecção viral e após 
vi 
estimulação da via do TLR3. Com base nos resultados, é proposto um 
modelo em que o domínio extracelular inibe a activação da resposta 
pelo TLR3 através da formação de um heterodímero não-funcional 
I329L-TLR3, e o domínio intracelular interfere com a transmissão do 
sinal através do TRIF. 
Demonstrou-se que duas variantes distintas do gene não-conservado 
MGF360-18R do VPSA, uma da estirpe patogénica Benin97/1 e outra 
da estirpe adaptada à cultura celular Ba71V, inibem a indução do IFN-
β, e a resposta do hospedeiro à expressão de IFN tipo I e tipo II. 
Ambas as variantes da proteína MGF360-18R afectam a proteína 
MAVS, uma proteína adaptadora da via citosólica RLR que é 
essencial para a indução do IFN-β. Por outro lado, apenas a variante 
‘patogénica’ afecta o factor de transcrição IRF-3, o que confere uma 
vantagem adicional ao vírus, em resultado de uma supressão mais 
eficiente da resposta do IFN, in vivo. Adicionalmente, demonstrou-se 
que ambas as variantes da proteína MGF360-18R impedem a 
resposta da célula à expressão de IFN tipo I e tipo II (via da Jak-
STAT), induzindo a degradação do factor de transcrição STAT1 pelo 
proteasoma 26S. 
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Summary 
The objective of this thesis was to determine the mechanisms and 
consequences of two non-homologous host evasion genes of the 
economically important, frequently fatal African Swine Fever Virus 
(ASFV). In order to survive, large DNA viruses, such as ASFV, 
typically have multiple genes/strategies for positive and negative 
modulation of host cell biology and immune responses. The two genes 
presented here inhibit a major component of innate immunity, the 
Interferon (IFN) response, and so function to the benefit of the virus. 
The conserved I329L gene was recently reported to impair the cellular 
responses controlled by TLR3 that lead to both IFN-β secretion and 
NF-κB activation. Here, this observation is extended by demonstrating 
that I329L not only inhibits both induction and secretion of IFN-β, but 
also inhibits TLR4 stimulated activation. The I329L protein was also 
biochemically demonstrated to target the adaptor protein TRIF, 
consistent with the observed inhibition of both TLR3 and TLR4 
pathways. To further characterize the modulation of the type I IFN 
response by I329L, as well as to assess the role of each domain, 
truncation mutants expressing either the ectodomain or the 
intracellular domain were designed and tested by luciferase reporter 
assays. The extracellular domain inhibited activation of IFN-β and NF-
кB via Poly (I:C) in a dose dependent manner, whereas the 
intracellular inhibited activation of IFN-β stimulated by ectopic TRIF. In 
addition, the I329L protein was shown to be proteolytically processed 
during virus infection or after stimulation of the TLR3 pathway. On the 
basis of these results, a testable working model is proposed, with the 
I329L extracellular domain inhibiting activation of the TLR3 response 
through the formation of a non-signalling I329L-TLR3 heterodimer, and 
the I329L intracellular domain interfering with signal transmission 
through TRIF. 
viii 
Two distinct variants of the non-conserved MGF360-18R gene, one 
from the pathogenic Benin97/1 virus and the other from the Ba71V 
tissue culture adapted virus, were shown to inhibit both the induction of 
IFN-β and the host cell response to type I and type II IFN. Both 
variants of the ASFV MGF360-18R protein target MAVS, a key adaptor 
protein of the RLR pathway for induction of IFN-β, while only the 
‘pathogenic’ variant targets IRF-3, which may give the virus an extra 
advantage as a result of a more efficient suppression of the IFN 
response in vivo. Additionally, both variants of the ASFV MGF360-18R 
protein were shown to impair the host cell response to both IFN-α and 
IFN- (Jak-STAT pathway), inducing STAT1 degradation by the 26S 
proteasome. 
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1 
1. Introduction 
The immune system of multicellular organisms evolved as a direct 
consequence of the selective pressure imposed by infectious 
microorganisms. The most ancient defence mechanisms, also known 
as the innate immune system, evolved to initiate an immediate and 
robust response against the invading microbes, and depend on 
relatively few germ-line encoded receptors. Emergence of the 
vertebrates was accompanied by the additional evolution of the 
adaptive immune system, which introduced a fundamental evolutionary 
advancement: more precise mechanisms of immune recognition and 
long-term immunological memory, based on an essentially infinite 
repertoire of receptors generated by gene rearrangements (reviewed 
by Hirano et al., 2011). [1] 
In the mammalian immune system, these two very different, innate and 
adaptive immune systems are interconnected, enabling efficient 
detection and protection against a wide variety of rapidly-evolving 
pathogens that can cause disease. The adaptive immune response 
requires signals that provide information about the origin of the antigen 
and the type of response to be induced. These signals are thought to 
be provided by the innate immune system. Understanding the 
molecular mechanisms responsible for the generation of these signals 
would be crucial for the development of new approaches to vaccine 
formulation and immunotherapy (reviewed by Schenten & Medzhitov, 
2011). [2] 
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1.1. Immune response to viruses 
Viruses are particularly well adapted pathogens, capable of 
parasitizing all cellular life forms, exploiting the host’s cellular 
machinery for their survival and replication. Over millions of years of 
evolution, the organisms that are hosts to viruses have evolved anti-
viral defences, but viruses have also responded through the evolution 
of multiple strategies to modulate, or inhibit host defences, so that the 
virus is able to complete the infectious process and then infect new 
hosts. The interactions between virus-infected cells and the host 
defence mechanisms determine the harmful pathological 
consequences that can occur during viral infection. These 
consequences reflect, not only the strategies that a given virus uses 
during infection, but also how the host resists infection. A highly 
virulent virus is not necessarily the most successful, as its very 
pathogenicity could lead to death of the host before the virus has 
spread. The concept that viruses benefit by mutating to less virulent 
forms, led to the assumption that virulence can be the result of 
incomplete adaptation of the virus to the host. A virus–host association 
that has existed for a long period is likely to have evolved a 
relationship in which the host suffers little or no harm. However, when 
a virus extends its host range into a new species, for example, recently 
emerged haemorrhagic viruses, typically will be much more virulent in 
the new host than in the old [3,4]. 
The effect of viral diseases on the well-being of societies is a powerful 
motivation to comprehend the nature of viruses, how they replicate and 
how they cause disease. The understanding of viral mechanisms of 
infection, as well as its evasion strategies, may provide a rational basis 
for the development of more effective means for prevention, diagnosis 
and treatment of virus diseases through the production of vaccines, 
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diagnostic reagents and techniques, and antiviral drugs. Virus host 
evasion mechanisms have also an enormous potential as a source of 
strategies for immunomodulation [3]. 
The host defence mechanism against viral infection consists of a 
complex relationship between components of the innate and the 
adaptive immune system. A key point in trying to understand this 
balance is the biology of the virus and its life style; as an obvious 
example, highly acute viruses, such as the recently virulent avian 
influenza, present a totally different challenge to the immune system 
than persistent viruses such as HIV, and this will not only dictate the 
most appropriate immune effector response necessary for effective 
protection, but also provide the rational framework for the development 
of novel therapeutic approaches. 
The innate immune response represents a rapid first line of defence, 
and it is sometimes sufficient by itself to clear a viral infection. In these 
circumstances, innate immune mediators play a very important role in 
keeping the virus load low. Equally important, components of the 
innate response shape the adaptive immune response and direct the 
subsequent effector phase. 
When virus replication outpaces innate host defence, second line 
defences (adaptive immune response) are necessary. The adaptive 
immune response towards viruses is mediated by T and B cells 
expressing antigen-specific receptors and responsible for cellular and 
humoral immunity, respectively. Activation and differentiation of T and 
B cells is instigated and controlled by cell interactions between T cells 
and antigen presenting cells and T cells and B cells, leading to the 
generation of the proper type of adaptive immune response. The 
optimal activation of the innate immune system is also important for 
shaping the inflammatory response, which is essential for clearance of 
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virus infection, and may result in associated immunopathology. 
Appropriate regulation of all these processes is necessary in order to 
have a successful immune response against an infection. Dissection of 
the critical cellular pathways that control these processes will 
eventually unveil opportunities for manipulating the host immune 
response to control viral infection and control pathogenesis (reviewed 
by Christensen & Thomsen, 2009) [5]. 
Both innate and adaptive immune responses and their role in 
protecting against viral infections will be briefly described below. 
1.1.1. Innate immunity 
Upon microbial infection, host survival critically depends on the 
establishment of a rapid and appropriate innate response. 
Characteristically, innate immune responses start within minutes or 
hours of infection, while activation of an effective antibody and 
activated cytotoxic lymphocyte response to the infectious agent takes 
several days. Initial control of viral spread is thus the responsibility of 
innate immunity. In addition, innate immunity, largely through the 
spectrum of secreted chemokines and cytokines, regulates the 
direction of the adaptive immune response. However, given that 
continued activation of the innate response may cause damage to the 
host, it must be itself tightly regulated and transient [6,7]. 
Cells of both hematopoietic and nonhematopoietic origin undertake the 
responsibility of orchestrating the innate immune response. Cells of 
hematopoietic origin include monocytes, macrophages, natural killer 
(NK) cells, mast cells, neutrophils and eosinophils. Other cellular 
elements involved in both innate and adaptive responses are NK T 
cells and dendritic cells. In addition to hematopoietic cells, the skin and 
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the epithelial cells lining the respiratory, gastrointestinal, and 
genitourinary tracts bear receptors that recognize conserved molecular 
structures expressed by a large variety of microbes, and so may also 
provide a component of innate immunity [6,8].  
Cellular and humoral elements (complement system) of the innate 
immunity work together to constrain the virus spread and eliminate 
virus-infected cells, building an effective defence system against 
pathogenic microorganisms. The secretion of high levels of cytokines 
directs not only the activation and differentiation of the adaptive 
immune response but also the subsequent recruitment of antigen-
primed effector T cells to the sites of viral replication (reviewed by 
Christensen & Thomsen, 2009) [5].  
When exposed to a pathogen, epithelial cells and tissue resident 
macrophages are potent producers of cytokines. These are 
polypeptides that act as immunomodulating agents. They coordinate 
important aspects of the immune response, including inflammation, 
cellular recruitment, activation, proliferation and differentiation, being 
critical to the development and functioning of both the innate and 
adaptive immune responses. According to their function, cytokines can 
be divided into proinflammatory cytokines, anti-inflammatory cytokines 
and chemokines (chemoattraction mediators). Finally, cytokine 
expression is not restricted to cells of the immune system, e.g. 
epithelial cells can secrete cytokines such as IFN [6,9]. 
The initial host response to viral infection includes the production of 
potent cytokines by infected cells. These cytokines bind to receptors 
on sentinel DCs, macrophages and neighbour uninfected cells, leading 
to a cascade response, with simultaneous or sequential expression of 
more cytokines, mainly by the activated cells of the innate immune 
system. The first cytokines to be produced are the type I interferons 
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IFN-α and IFN-β, followed by TNF-α, IL-6, IL-12, IL-18 and type II 
interferon, IFN-. In addition to inducing a local antiviral response, 
cytokines also have a more general effect by inducing acute-phase 
proteins that are important and necessary for tissue damage repair 
and to clear infection (reviewed by Christensen & Thomsen, 2009) [5]. 
TNF-α, a proinflammatory cytokine, is able to regulate the expression 
of adhesion molecules on the endothelium of nearby capillaries. This 
action induces changes which attract and facilitate the extravasation of 
leukocytes to the site of infection. When binding to receptors on 
infected cells, TNF-α is also able to induce an antiviral response that 
eventually leads to apoptosis (reviewed by Rahman & McFadden, 
2006) [10]. 
Type I IFNs are key contributors for both the innate and adaptive 
immune responses to viral infection. When an infected cell produces 
and releases type I IFNs, they will bind to the type I IFN receptors 
(IFNAR) of neighbouring cells. The consequent transcription of over 
300 antiviral genes results in the inhibition of several steps of the viral 
life cycle. Furthermore, IFN-α/β are able to amplify the IFN original 
signal, inducing an augmented antiviral state that result in secretion of 
high levels of cytokines and chemokines. Cells of the innate immune 
system are recruited to virus-infected tissues, where they are activated 
and in turn facilitate the induction of the adaptive immune response 
(reviewed by Le Bon & Tough, 2008) [11] 
Chemokines coordinate the localization and collaboration between the 
cells of the immune system. Functionally, they can be divided into 
inflammatory (inducible), homeostatic (constitutively expressed) and 
dual-functional chemokines. Although most chemokines are secreted 
molecules, they are most likely mainly sensed by leucocytes while 
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bound to the extracellular matrix or to cell surfaces through 
proteoglycans. Chemokines need to interact with specific cell surface 
receptors in order to exert their biological function. The two major 
families of chemokine receptors are the CXC chemokine receptors and 
the CC chemokine receptors (CCR), which bind CXC and CC 
chemokines, respectively (reviewed by Christensen & Thomsen, 2009) 
[5]. 
The intracellular signal transduction pathways responsible for 
expression of the multiple cytokines and chemokines released during 
viral infection, are activated as a consequence of pathogen recognition 
receptor (PRR) signalling in cells such as epithelial cells, macrophages 
and DCs. Germline-encoded PRRs are able to detect and distinguish 
between self and invariant microbial molecular structures (Pathogen 
Associated Molecular Patterns – PAMPs) shared by all pathogens of a 
given class. These molecular signatures are usually indispensable for 
the pathogen life cycle and are different from the molecular structures 
found in the host. In turn, the PRRs are similarly invariant. In response 
to PAMP recognition, PRRs execute the first line of host defensive 
responses and later participate in the control and direction of the 
second line of host defence, the adaptive immunity. The selective 
specificity of PRRs avoids activation of the immune system by self 
molecules. However, viruses usually replicate using host strategies 
and consequently generate molecular structures that resemble the 
molecular patterns found in the host. This poses a particular problem 
for innate recognition of viral infections (reviewed by Diebold, 2010) 
[12]. 
PAMPs, according to their origin and nature, activate distinct classes 
of PRRs, which include Toll-like receptors (TLRs) retinoic acid 
inducible gene-I (RIG-I)-like receptors (RLRs), nucleotide binding and 
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oligomerization domain (NOD)-like receptors (NLRs), C-type lectin 
receptors (CLRs) and DNA receptors (cytosolic DNA sensors). This 
variety of PRRs ensures the existence of multiple sensor systems that 
can detect and respond to almost any infection of the host.  During 
viral infections, nucleic acid- and glycoprotein-PAMPs interact with 
particular classes of PRRs, which include certain Toll-like receptors, 
retinoic acid inducible gene-I (RIG-I), melanoma differentiation-
associated gene 5 (MDA5), and the cytosolic DNA receptors. Interplay 
between TLRs and RLRs in different cell types during viral infection 
plays an important role in antiviral responses, as well in controlling 
adaptive immunity. While the cytoplasmic PRRs are responsible for 
limiting virus spread locally and for generating an inflammatory 
environment, the nucleic acid-sensing TLRs are crucial for 
orchestrating the adaptive anti-viral immune response that eventually 
leads to the elimination of the virus and virus-infected cells. To 
circumvent the fact that viral nucleic acids are structurally similar to 
eukaryotic nucleic acids, recognition occurs in a specialised 
endosomal compartment and not at the cell surface, in contrast to the 
TLR sensing bacterial, fungal and protozoan ligands (reviewed by 
Christensen & Thomsen, 2009, Diebold, 2010 and Kaway & Akira, 
2011)  [5,12,13].  
PAMPs TLR usage PRRs involved in recognition 
DNA TLR9 AIM2, DAI, IFI16 
RNA TLR3, TLR7, TLR8 RIG-I, MDA5, NALP3 
Structural protein TLR2, TLR4  
Table 1.1 – Viral PAMP detection by TLRs and other PRRs. 
(adapted from Kaway & Akira, 2011) 
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Sensing of the invading viral pathogen through the appropriate PRR(s) 
triggers multiple and distinct signalling pathways, activating 
transcription factors such as interferon regulatory factor (IRF) 3 and 7 
as well as Nuclear Factor-kappaB (NF-кB). Activation of these 
pathways leads to the secretion of proinflammatory cytokines and 
chemokines that are involved in both innate and adaptive immunity. 
Some of the most critical mediators in the innate host response to viral 
infection are the type I IFNs (e.g. IFN-α and IFN-β). Type I IFNs induce 
the expression of hundreds of IFN-stimulated genes that may have 
direct antiviral activity and/or modulate innate and adaptive immunity 
by activating immature DCs, enhancing NK-cell function and promoting 
survival and effector functions of T and B cells (reviewed by 
Christensen & Thomsen, 2009) [5]. 
1.1.2. Adaptive immunity 
The adaptive immunity consists of both cellular and humoral immune 
responses. Cell-mediated immunity involves the activation of cells from 
both the innate (macrophages, NK cells) and adaptive immune 
responses (antigen-specific cytotoxic T-lymphocytes), responsible for 
the release of several cytokines in response to an antigen. The 
humoral immune response is mediated by the secretion of clonally 
distributed antigen-specific recognition receptors (antibodies) produced 
by cells of the B lymphocyte lineage. Together, T and B cells are able 
to identify and eliminate pathogens through the expression of 
antibodies. In addition, they are able to generate long-lived 
immunological memory, which will allow the organism to respond more 
rapidly to a secondary infection by the same pathogen. This 
competence of the “memory” components of the adaptive immune 
system is the fundamental basis of vaccines (reviewed by Bonilla & 
Oettgen, 2010) [14]. 
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For T cells, two main functionally distinct sublineages exist, one 
expressing an αβ T cell receptor (TCR) and the other expressing a 
δ TCR. αβ TCRs specifically recognize antigens bound to MHC 
molecules, and participate in the activation of T cells in response to the 
presentation of antigen. The δ T cells, however, are thought to 
participate at the levels of both innate and adaptive immunity, and 
some, at least, recognize antigens directly, without the requirement for 
antigen presentation (reviewed by Born et al., 2011 and Chen, 2011) 
[15,16] 
Immature αβ T cells leave the thymus as either CD4+ or CD8+ T cells.  
During viral infection, CD4+ T cells can differentiate into a variety of 
effector subsets, while CD8+ T cells differentiate into cytotoxic T 
lymphocyte (CTL),  killing virus-infected cells, and also capable of 
releasing a range of effector cytokines. A subset of CD4+ T cells, 
known as regulatory T cells (Treg), regulates immune responses by 
suppressing them. T cells can only recognize peptides that have been 
degraded and bound to MHC class I or II. The MHC class I molecules 
(displaying endogenous peptides) are expressed on most somatic cells 
and interact with CD8+ T cells, whilst MHC class II (displaying 
exogenous, phagocytosed peptides) have a more limited expression, 
being restricted to professional APCs (such as DCs or B cells), and 
interact with CD4+ T cells (reviewed by Bonilla & Oettgen, 2010) [14]. 
Upon interaction with cognate antigen presented by professional 
APCs, such as DCs, CD4+ T cells can differentiate into classical Th1 
cells and Th2 cells, the more recently defined Th17 cells, follicular 
helper T (Tfh) cells, and induced regulatory T (iTreg) cells. 
Differentiated Th cell subsets secrete different cytokines that engage 
other leucocytes including macrophages, mast cells, eosinophils, 
neutrophils, natural killer (NK) cells, and B cells. Moreover, they can 
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express different profiles of cell-surface molecules that determine their 
effector cell capacity. The effector T cells had been thought to be 
terminally differentiated lineages, but it now appears that there is 
considerable plasticity allowing for conversion to other phenotypes 
(reviewed by Zhou et al., 2009) [17]. 
When immature CD8+ T cells interact with MHC class I – peptide 
complexes presented by professional APCs, they differentiate into 
CTLs that actively destroy any infected cells presenting the recognized 
foreign peptides. Activated CTLs up regulate perforin expression, 
which is stored in cytotoxic granules and released upon the recognition 
of an infected cell. Perforin is a pore-forming protein that leads to 
osmotic lysis of the target cells and subsequently enables granzymes 
to enter the target cells and initiate apoptotic cell death. In addition, the 
high levels of cytokines secreted by CD8+ T cells, induce an antiviral 
state in neighbouring cells, and apoptosis of the infected cell (reviewed 
by Smith-Garvin et al., 2009) [18]. Unfortunately, in cases of large-
scale killing of virus-infected cells, the CTL activity may result in some 
degree of damage to the host organism. 
Naive B cells express clonally distributed Immunoglobulin antigen 
receptors on their surfaces that can be activated in a T-cell dependent 
or independent manner; however, two signals are always required to 
initiate activation. During T cell-dependent activation, an APC 
(macrophage or DC) presents a processed antigen to a Th cell, 
priming it. When a B cell processes and presents the same antigen to 
the primed Th cell, the T cell releases cytokines that activate the B cell. 
B cell activation can also occur through recognition of native antigen, 
or if a macrophage presents several copies of the same antigen in a 
way that causes cross-linking of antibodies on the surface of B cells. 
As a result of the subsequent initiation of specific signal transduction 
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pathways, naive B cells undergo clonal proliferation and terminal 
differentiation into short-lived antibody producing plasma cells or long 
lived memory B cells. Antibodies of all Ig classes can be produced in 
response to viral infections, and can significantly influence the 
outcome of the infection (reviewed by Bonilla & Oettgen, 2010) [14]. 
The function of antibodies in response to viral infections can be 
diverse. The major mechanism is antibody-mediated viral 
neutralization, occurring when antibodies bind the virus molecule that 
interacts with its cell-surface receptor, preventing virus attachment. 
Antibodies can also aggregate many infectious particles, resulting in 
their phagocytosis, therefore reducing the number of viruses that can 
effectively infect cells. Additionally, antibodies can act in concert with 
the complement system, IFN and other cytokines in order to clear 
viruses from persistently infected cells.  
Following virus elimination, the pool of specific T and B cells 
substantially contracts, leaving a small population of antigen-primed 
memory cells, from which two major subsets of memory T cells are 
evidenced. A first line of specific defence is provided by effector 
memory T cells, in case of reinfection with the same or an antigenically 
related pathogen. Additionally, an expanded population of so-called 
central memory cells persists in the secondary lymphoid organs; these 
cells serve as a pool from which secondary waves of effector T cells 
may rapidly be derived, should the pathogen challenge overwhelm the 
forward defences (reviewed by Bonilla & Oettgen, 2010) [14]. 
In conclusion, evolution has shaped the immune system according to 
its challenges resulting in different strategies to control different 
infections. These strategies are selected according to the replication 
site of the organism (intracellular or extracellular), and other critical 
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factors such as the route of entry and form of antigen presentation 
pathway used by the pathogen, which in turn determine selection of 
the most appropriate component of the immune response (e.g. 
antibody or T cell). Whatever the balance of the acquired immune 
system that is selected, it must be precisely regulated. It is necessary 
to have a fast and potent innate response as a first line of defence and 
as a signal to activate the specific and adequate adaptive immune 
response, in which both T cells and B cells act in concert to clear virus 
infection. It is equally important to terminate the response (see 
Fig.1.1). 
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Figure 1.1 – Activation of host-defence mechanisms. 
Host-defence mechanisms can be induced directly, by engagement of PRRs, 
or indirectly, by T cells and/or antibodies. Each module is characterized by 
distinct antimicrobial defence mechanisms and can instruct the adaptive 
immune system to mount a response involving a module-specific effector 
class. After an adaptive immune response has been initiated, it results in 
antigen-specific activation of the same innate immune module that instructed 
the adaptive immune response (adapted from Medhzitov, 2007). 
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1.2. The Interferon System 
In 1957, Isaacs and Lindenmann described the occurrence of a factor 
secreted by infected cells, able to inhibit viral replication in cells 
infected with homologous or heterologous viruses. They baptized this 
factor interferon (IFN) and conclusively demonstrated that IFN was a 
cellular product, acting to protect cells from viral infections [19,20,21].  
The IFNs are now also recognized as central regulatory mediators of 
the immune response. The functions of IFNs are represented by three 
major biological activities: antiviral activity, antitumor activity and 
immunoregulatory activity. Fifty years have passed since the discovery 
of the interferon system, and much has been learnt about induction of 
IFN, IFN receptor signalling and IFN-dependent antiviral immunity. 
IFNs produced by infected cells are released and stimulate an antiviral 
state in neighbour cells, inducing the expression of proteins that 
interfere with viral processes, whereby viral replication is blocked or 
impaired. IFNs also have a major role in activation of the adaptive 
antiviral immune response. Immature plasmacytoid DCs (pDCs) are 
natural IFN-producing cells, and one of the key cells in the IFN-α 
response to immune stimuli. pDCs differentiate into mature antigen-
presenting DCs, which have a crucial role in T and B cell activation 
(reviewed by Fitzgerald-Bocarsly & Feng, 2007) [22].  
Interferon was the earliest described member of the class of protein 
molecules now known as cytokines: a soluble product released from 
stimulated cells that serves to communicate between cells of the 
immune system [22]. IFNs are key cytokines in the establishment of a 
multifaceted antiviral response. Three distinct types of IFNs are now 
recognized (type I, II, and III), based on their structural features, 
receptor usage and biological activities.  
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Type I IFNs (IFN-α/β/ω/ɛ/κ in humans) possess strong antiviral activity, 
and are able to induce a potent antiviral state in a wide variety of cells. 
However only IFN-α and IFN-β are induced directly in response to 
virus infection. In humans, there are 30 genes coding for type I IFN, 
including 13 IFN-α genes, one IFN-β gene, one IFN-ω gene, one IFN-ɛ 
gene, one IFN-κ gene and 13 additional pseudogenes of the IFN-α and 
-ω families. The functional activities of this complex gene family are yet 
to be explored. These molecules signal through a ubiquitously 
expressed receptor composed of two chains: IFN-αR1 and IFN-αR2 
(reviewed by Chelbi-Alix & Wietzerbin, 2007 and Hardy et al., 2004) 
[23,24]. 
There is only one type II IFN, known as IFN-, and which is secreted 
mostly by activated Th1 cells and NK cells and stimulates cell-
mediated immune responses that are critical for the development of 
host protection against pathogenic intracellular microorganisms, such 
as the activation of macrophages for microbicidal activity. It also plays 
a central role in the development of antitumor immune responses, and 
it can amplify the induction of antiviral activity by IFN-α or -β, although 
antiviral activity is not the primary biological function of IFN-. Type I 
and type II IFNs often work together to activate a variety of innate and 
adaptive immune responses that result in the induction of effective 
antitumor immunity and the elimination of viral infections. It signals via 
a ubiquitously expressed receptor composed of the IFN-R1 and IFN-
R2 subunits (reviewed by Young & Bream, 2007) [25]. 
The most recent addition to the IFN family, the type III IFNs, 
demonstrate structural features of the IL-10-related cytokines, but also 
elicit a similar antiviral response as IFN-α/β in a variety of target cells. 
In humans, the type III IFN family is composed by 3 distinct but closely 
related IFN-λ proteins: IFN-λ1, -λ2, and -λ3. The IFN-λ proteins bind 
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and signal through a receptor complex composed of the unique IFN-
λR1 chain. Like the type I IFNs, their tissue distribution, specificity and 
regulatory mechanisms are not well understood (reviewed by Donnelly 
& Kotenko, 2010) [26]. 
Different human IFN-α’s and IFN-β, IFN-, and IFN-λ’s can establish 
an anti-viral state in vitro; this is the essential signature of IFNs. 
However, the existence of three types of IFN, using three different 
receptors, raises the possibility of different roles in host defence 
against viruses and other pathogens. 
1.2.1. Induction of IFN expression 
Upon viral infection, cells are able to recognize the invading 
microorganism and, through multiple distinct routes that culminate in 
the induction of IFN, rapidly initiate antiviral mechanisms. The 
importance of any individual route of IFN induction depends upon the 
specific virus, the nature of the cell being infected or the stage of 
infection. Cells express PRRs that recognize viral PAMPs, 
differentiating them from self. Whenever a cell senses a virus infection, 
signal transduction pathways are activated, inducing the expression of 
type I IFN, a major component of the innate immune system. Type II 
IFN, in turn, is produced by activated lymphocytes and further 
amplifies the IFN response to infection (reviewed by Zhang et al., 
2008) [27]. 
Both type I and type II IFNs are important in the coordination of the 
innate and adaptive immune responses to a viral infection, making 
IFNs powerful and eventually hazardous molecules, if not tightly 
regulated. For this reason, mechanisms have evolved to control the 
expression of IFN at both transcriptional and post-transcriptional 
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levels. The pathways leading to expression of either type of IFN are 
quite distinct, and so will be described separately. 
1.2.1.1. Induction of Type I IFN 
Virus infection of a cell induces the development of an antiviral state 
within the infected cell and due to the concomitant secretion of IFN, 
establishes an anti-viral state in nearby cells. The first potent IFN 
inducer to be identified was double-stranded RNA (dsRNA), a 
molecular pattern associated with viral infection, because it is 
produced by most viruses at some point of their replication [28]. It was 
postulated that dsRNA can mimic IFN induction by viruses. This finding 
facilitated investigations of the mechanism of IFN induction without the 
complexity of an associated viral infection [23]. Currently, the best 
studied model is the production of IFN-β in fibroblast cells in response 
to either RNA viruses such as Sendai virus (SeV) or the synthetic 
chemical that mimics dsRNA, the polyinosine-polycytidylic acid 
(Poly (I:C)).  
Type I IFN expression can be induced by several different 
mechanisms. However, the downstream kinases and transcription 
factors are common to all. Virus- or dsRNA-induced expression of type 
I IFN is controlled by sequences present in the 5’ flanking region of the 
IFN-α/β genes. 
Two families of transcriptional factors play a major role in the 
transcriptional activation of type I IFN genes: the family of NF-кB and 
the family of interferon regulatory factors (IRF). 
In unstimulated cells, NF-кB proteins (p65 and p50) exist as homo- or 
heterodimeric proteins which are retained in the cytoplasm by 
association with inhibitory кB (IкB) proteins. Upon virus infection, 
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stimuli derived from the antiviral response activate the IкB kinase 
(IKK). This kinase is responsible for the phosphorylation of serine 
residues within the N-terminal destruction box of IкB proteins (e.g. S32 
and S36 of IкBα). Phosphorylated IкB is subsequently ubiquitinated 
and degraded by the proteasome, thus unmasking the nuclear 
localization signal of the NF-кB proteins, which translocate into the 
nucleus and bind to type I IFN promoter [29]. 
The family of IRF transcription factors mediate virus-, bacteria- and 
IFN-induced signalling pathways and as such play a critical role in 
antiviral defence, immune response, cell growth regulation and 
apoptosis. To date, IRF-1, IRF-3, IRF-5, IRF-7 and IRF-9 have been 
described as major regulators of type I IFN transcription, in concert 
with the transcription factor NF-кB [30]. 
The availability of genetically modified mice, which have distinct IRF 
deleted, has revealed the function of the members of the IRF family. 
Table 1.2 summarises what is known about IRF involved in the 
transcription of type I IFN genes: 
IRF Defects 
IRF-1 Apoptosis, iNOS, IL-12 
IRF-3 Down modulation of type I IFN induction 
Increased susceptibility to infection 
IRF-5 Induction of inflammatory cytokines (IL-6, TNF-α and IL-12) 
IRF-7 Block in the type I IFN induction 
IRF-9 Type I and II IFN signalling, induction of IRF7, IFN-α and ISG 
Table 1.2 – Phenotypic changes in IRF null mice. 
(adapted from Paun & Pitha, 2007) 
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IRF-1 was identified by its ability to bind to the positive regulatory 
domain 1 (PRDI) in the virus-responsive element (VRE) of the IFN-β 
gene, where it was assumed to function as an activator of transcription 
[31]. However, although IRF-1 is present in the IFN-α and IFN-β 
enhanceosomes, binding to the respective promoter regions, it does 
not have a critical role in the virus stimulation of type I IFN genes. 
Instead, IRF-1 was shown to be involved in the antiviral defence 
mediated by IFN- and to play a critical role in the inducible expression 
of MHC class I and apoptosis [32,33]. More recently, it was 
demonstrated that IRF-1 is not required for IFN expression, but it is 
needed for expression of interferon-stimulated genes (ISGs) [34]. 
Thus, IRF-1 may uniquely control IFN-independent signalling events 
that lead to ISG expression and antiviral immunity. 
IRF-3 and IRF-7 were identified by their ability to activate the 
promoters of IFN-α and -β genes. The identification of these two IRFs 
and their role in the transcriptional activation of Type IFN genes had a 
major impact on the understanding of the molecular mechanism of the 
pathogen-induced innate antiviral response [35,36]. Although pathogen 
recognition may be mediated by distinct cellular receptors and 
signalling pathways, they all lead to the activation of IRF-3 or IRF-7 
which are critical for the transcriptional activation of Type I IFN genes 
[37,38]. The IFN-β enhanceosome not only contains IRF-3 but also 
IRF-7 [39]. In addition, several authors have gathered evidence 
suggesting that relative levels of IRF-3 and IRF-7 in cells determine 
the levels of expression of individual IFN-α subtypes (reviewed by 
Paun & Pitha, 2007) [40]. 
IRF-3 is ubiquitously expressed in a variety of cells, but remains in the 
cytoplasm as an inactive monomer until detection of a viral PAMP, 
such as dsRNA, a common signature of virus-infected cells [35]. Both 
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TLR-3 and RIG-I/MDA-5 signalling pathways lead to the 
phosphorylation of IRF-3 at the carboxyl-terminal region (serines 385 
and 386) and at the serine/threonine cluster (between region 396 and 
405), by the IKK-related kinases, TANK-binding kinase (TBK)-1 and 
IKKɛ.  Serine 386, at C-terminal region, is critical for activation, as it is 
predicted to lead to a conformational change that allows IRF-3 to 
homo- or heterodimerize with IRF-7 [38,41,42]. Following translocation 
to the nucleus, IRF-3 associates with the co-activator CREB binding 
protein (CBP)/p300  and stimulates transcription of IFN-β [43], as well 
as some ISGs, such as CCL5/RANTES and ISG54 [44]. 
Several observations underline the importance of IRF-3 in the 
induction of the antiviral response. First, being ubiquitously expressed, 
IRF-3 is capable of stimulating the antiviral response and synthesis of 
IFN-β in all varieties of infected cells. Second, several viruses target 
IRF-3, thus preventing the induction of Type I IFN. IRF-3 is required for 
type I IFN induction triggered by TLR3/TLR4, cytosolic RNA sensing or 
cytosolic DNA sensing pathways in many cell types, including cDCs, 
but it is not required for type I IFN induction in pDCs [40]. 
Like IRF-3, the IRF-7 transcription factor is also expressed as an 
inactive monomer in the cytoplasm of cells, and after virus induction it 
is phosphorylated on C-terminal serine residues (serines 477 and 479) 
by the same kinases, TBK-1 and IKKɛ. The activated IRF-7 forms 
either homodimers with itself or heterodimers with IRF-3, and then 
translocates into the nucleus. It has been described as being critical for 
the induction of IFN-α and IFN-β gene expression, functioning even in 
the absence of IRF-3 [45]. IRF-7 is also able to form complexes with 
myeloid differentiation primary response gene 88 (MyD88), IL-1 
receptor-associated kinase (IRAK)-4, IRAK-1 and TNF receptor 
associated factor (TRAF)-6 upon TLR7/TLR9 stimulation, resulting in 
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IFN-α production by an IKK-α (and not TBK1) dependent pathway 
[46,47,48]. 
Constitutive expression of IRF-7 is restricted to some lymphoid cells, 
particularly pDCs that express high amounts of IFN-α in response to 
TLR7/8 and TLR9 activation [40]. When induced to differentiate, 
monocytes express IRF-7, which was shown to be a key regulator of 
the differentiation of monocytes to macrophages [49]. Expression of 
IRF-7 can be induced in most cells types, not only by Type I IFN but 
also by TNF-α [50]. Finally, IRF-7 has a short half-life, a characteristic 
that may play a role in the regulation of the transient expression of 
IFN-α genes [51]. 
Constitutive expression of IRF-5 is restricted to few cell types, such as 
monocytes and DCs that express high levels of IFN-α upon viral 
infection. IRF-5 is mainly expressed in the cytoplasm of non-infected 
cells and, upon viral infection, is phosphorylated and activated by 
distinct kinases. The activated IRF-5 forms either homodimers with 
itself or heterodimers with IRF-3 and then translocates into the 
nucleus. Both RNA and DNA viruses can activate IRF-5 nevertheless 
this activation is virus-specific [52]. Like IRF-7, MyD88-mediated 
activation of IRF-5 involves the formation of a complex composed by 
MyD88, IRAK4, IRAK1 and TRAF6. Most likely, this complex 
preferentially assembles with IRF-7 [46,53].  
IRF-5 seems to have a role in DNA-damage-induced apoptosis and 
the innate immune antiviral response [54]. Activated IRF-5 contributes 
to the induction of IFN genes. However, in the presence of high levels 
of IRF-4 or MyD88-activated IRF-7, the role of IRF-5 is limited to the 
transcriptional regulation of early inflammatory chemokines and 
cytokines [55]. Since most of these chemokines have lymphocyte-
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chemotactic activity, it was suggested that IRF-5 may have an 
important role in lymphocyte trafficking [56,57]. Recently, a new role 
was described, in which IRF-5 expression in macrophages is 
responsible for initiating a potent Th1-Th17 response [58].  
The transcription of the IFN-β gene requires an enhancer element 
located upstream of the core promoter that is recognized by three 
distinct sets of transcription factors (NF-кB, IRFs and ATF-2/cJun) and 
by the high-mobility group (HMG) chromatin-associated protein 
HMGI(Y) [59]. This enhancer element is composed by four positive 
regulatory regions (PRDI-IV): PRDI and PRDIII sites are for binding of 
IRF-7 and IRF-3, the PRDII site is for binding of NF-кB, and PRDIV 
site is for binding of ATF-2/cJun heterodimers. Virus infection leads to 
coordinated activation of all three types of transcription factors, which 
assemble on the IFN enhancer region to form a large, multi-subunit 
complex known as the IFN-β enhanceosome [32]. In a first phase, after 
being delivered to a single IFN allele, NF-кB plays a crucial role in the 
recruitment of the remaining factors to the enhanceosome, leading to 
IFN-β transcriptional activation which, in turn, activates transcription of 
IRF-7. At a second phase, the increasing levels of IRF-7 trigger 
enhanceosome assembly on multiple IFN-β alleles, thus amplifying the 
production of IFN-β [60]. In order to have an optimal induction of the 
IFN-β promoter, cooperation between all transcription factors is 
required. Since virus infection is the only known signal that can 
activate all of the IFN-β transcriptional activators simultaneously, 
enhanceosome assembly will not occur in response to other signals 
that can separately activate each of the transcription factors [32,61]. 
However, under conditions in which NF-кB or ATF-2/c-Jun are not 
activated, expression of IFN-β has been reported. In opposition, IRF-3 
and IRF-7 are indispensable for induction [62].   
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The promoter region of IFN-α genes contains only binding sites for 
IRFs, lacking binding sites for NF-кB. Although the identity of the IRF 
members that stimulate IFN-α transcription is uncertain, there is some 
evidence that IRF-7 is required for induction. In pDCs, which 
constitutively express IRF-7 and induce the expression of massive 
amounts of type I IFN, the induction of IFN-α is not dependent on 
primary induction of IFN-β and its feedback loop [62]. 
The activation of the different mechanisms leading to IFN expression 
requires, as a first step, recognition of the viral infection by the host 
cell. The discovery of pattern associated molecular patterns (PAMPs) 
and their recognition by cellular pattern recognition receptors (PRRs) 
has revolutionized our understanding of innate immunity, and explains 
how and why a virtually unlimited number of pathogens can be 
recognized by a small number of innate immune receptors, triggering 
anti-microbial responses.  
PRRs recognize common patterns of a large number of microbial 
molecules, and must be able to differentiate microbial molecules from 
host molecules that often have substantial structural similarity. An 
inappropriate decision in this self-nonself discrimination can be fatal to 
the host. This is particularly important for recognition of viral 
components that are similar to self components. At first sight, and 
paradoxically, host receptors specialized in virus detection have 
evolved to recognise a feature that is common to all living organisms: 
the nucleic acids. In order to be able to discriminate self nucleic acids 
from non-self, viral sensors may be compartmentalized in locations 
where the host cell component is not found, for example, viral DNA is 
sensed in the cytoplasm and viral RNA is detected in the endosomes 
of infected cells. 
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There are at least two major complementary receptor systems (see 
Fig. 1.2 and 1.3) that detect most viral products: one class of receptors 
detects viral nucleic acids in endosomes of specialized cell types, 
whilst the second class of receptors are expressed ubiquitously and 
localized in the cytosol, where they are able to detect viral nucleic 
acids produced upon infection [63]. In addition to viral nucleic acids, 
several viral proteins have been shown to induce IFN, although this is 
not a general feature of viruses. For example, the fusion (F) protein of 
respiratory syncitial virus (RSV) and the glycoprotein G of vesicular 
stomatitis virus (VSV) can activate the synthesis of IFN type I through 
a TLR4-dependent pathway [64]. 
The distinct classes of antiviral PRRs and the strategies employed by 
the host for the successful detection of a viral infection will be briefly 
described.  
1.2.1.1.1. The Toll like receptor pathway 
Toll-like receptors (TLRs) are a family of PRRs that play central roles 
in innate immune defence against infection by binding to microbial 
molecules. 
All TLR family proteins consist of an extracellular ligand binding 
domain, a single transmembrane TM domain and an intracellular 
signalling domain. The extracellular domains of TLRs possess N-
terminal leucine-rich repeats (LRR) motifs, known to be important for 
ligand binding and associated signalling. Each TLR LRR structure is 
distinct, having specific adaptations that allow for improved interaction 
with either its respective ligand or a coreceptor-ligand complex. Given 
that the overall shape of the TLR-ligand complexes is strikingly similar, 
ligand-mediated activation of the receptors can lead to the formation of 
homo- or heterodimers. Dimerization of the extracellular domains 
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requires involvement of the TM domains and directs juxtaposition and 
activation of the intracellular domains. The intracellular signalling 
domains contain an intracellular Toll/IL-1R (TIR) motif, important in 
protein-protein interactions. This motif is also present in the signalling 
adaptors that are recruited to the ligand-activated TLR TIR domains, 
forming the first step in the signalling cascade leading to the 
expression of multiple genes involved in innate and adaptive immunity, 
including type I IFN (reviewed by Kang & Lee, 2011) [65]. 
TLRs are primarily expressed in sentinel APCs of the immune system 
such as macrophages and DCs, but can also be present in epithelial 
cells. The cellular expression of the different TLRs is heterogeneous: 
For example, TLR3 is expressed by mDCs and NK cells, whereas 
TLR7 and TLR9 are expressed by macrophages and both mDCs and 
pDCs, the latter being known to produce high levels of type I IFN in 
response to viral infection (reviewed by Moresco et al., 2011) [66]. 
The cellular localization of TLRs has important consequences for 
ligand accessibility and can also affect downstream signalling 
pathways. TLR1, TLR2, TLR4, TLR5 and TLR6, involved in the 
recognition of microbial membrane components, are located on the cell 
surface, while TLRs recognizing microbial nucleic acids are mainly 
located within endolysosomal compartments (TLR3, TLR7, TLR8, and 
TLR9). TLR4, normally present at the surface can also enter the 
endocytic pathway following ligand-mediated activation. In each case, 
the TIR motif resides in the cell cytoplasm while the LRR domain is 
positioned to detect either extracellular PAMPs (outside of the cell) or 
PAMPs acquired during sampling (within the endosomes). 
Compartmentalization of TLRs is used by the host cell as a strategy to 
limit access to self molecules. The endosomal localization of nucleic 
acid-sensing TLRs (TLR3 for dsRNA, TLR7/8 for ssRNA and TLR9 for 
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CpG DNA motifs) prevents the recognition of self nucleic acids and 
activation of signalling pathways in the absence of infection. In addition 
to its intracellular expression, TLR3 was also detected on the surface 
of a few cell types, including fibroblasts, but until now no studies were 
published on the comparison of the physiological significance of 
intracellular versus cell surface TLR3 (reviewed by Barton & Kagan, 
2011) [67]. Trafficking of endosomal receptors to endolysosomal 
compartments by UNC93B1 and proteolytic regulation of some TLRs 
(TLR7 and TLR9) are other strategies used to further control receptor 
activation [68,69,70]. 
In addition to recognizing distinct ligands, individual TLRs trigger 
different signal transduction pathways. This specificity is achieved by 
the engagement of different adaptors to different receptors, through 
interaction between the corresponding TIR domains. The particular 
signalling adaptor used determines which signalling pathway will be 
activated: TIR-containing adaptor MyD88 induces a pro-inflammatory 
response dependent on the activation of NF-кB and mitogen-activated 
protein (MAP) kinase, whereas TIR domain-containing adaptor protein 
inducing IFN-β (TRIF) is responsible for activation of IRF-3, IRF-7 and 
NF-кB, culminating in the induction of type I IFN and inflammatory 
cytokines (reviewed by Moresco et al., 2011) [66].  
Most TLRs recruit MyD88, although some require the sorting adaptor 
TRIF-related adaptor molecule (TRAM) to facilitate binding between 
the receptor and the signalling adaptor MyD88 in order to initiate the 
signalling transduction pathway [71]. Activated TLR7, TLR8 and TLR9 
also signal through MyD88, not only to induce expression of pro-
inflammatory cytokines and chemokines, but also to initiate the 
expression of IFN-α, through IRF-7 (but not IRF-3). Upon TLR7/9 
stimulation, IRF-7 forms complexes with MyD88 and TRAF6. After 
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being phosphorylated in an IRAK1-dependent manner, IRF-7 
translocates to the nucleus and binds the promoter of the IFN-α gene 
[46]. Combining the observations that pDCs have an efficient 
mechanism for retaining CpG DNA in the endosomes, and also have a 
high constitutive expression of IRF-7, it is not surprising that these 
cells express huge amounts of IFN-α. 
The signalling of TLR3 is induced through TRIF, and not MyD88. 
Activated TRIF associates with TRAF3 and TRAF6 and subsequently, 
with the noncanonical kinases TBK-1 and IKKɛ (Fig.1.2), 
phosphorylates IRF-3 and IRF-7, leading to its dimerization and 
nuclear translocation to bind the promoter of type I IFN. TRIF also 
mediates the activation of NF-кB and activating protein 1 (AP-1) 
through the complex of kinases IKK-α/β/. These two transcription 
factors translocate into the nucleus, together with IRF-3 and IRF-7, 
and bind to the PRDI-IV positive regulatory elements of the IFN-β 
enhancer region [72]. TLR3-mediated signalling also leads to 
phosphorylation of specific tyrosines and the recruitment of 
phosphatiylinositol 3-kinase (PI3K), essential for full activation of IRF-3 
[73,74].  
Virus infected cells mainly depend on TLR3, TLR7/TLR8 and TLR9 to 
induce the expression of type I IFN, following detection of viral nucleic 
acids. However, TLR4 is also capable of inducing type I IFN by the 
recognition of non-nucleic acid ligands, such as lipopolysaccharide 
(LPS). Upon LPS-binding, TLR4 initiates signalling transduction 
pathways through both MyD88 and TRIF adaptors. Signalling through 
MyD88 requires TRAM [71] and culminates in the activation of NF-кB, 
inducing an early pro-inflammatory response. TLR4 is then internalized 
into the endosome [75], where it requires the TIR domain-containing 
adaptor protein (TIRAP) to bind TRIF [76]. Through this pathway, 
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TLR4 induces both a late pro-inflammatory response (NF-кB 
dependent) and type I IFN expression. 
Recently, a TLR2-dependent antiviral signalling pathway leading to the 
production of type I IFN was reported in inflammatory monocytes. Like 
TLR4, TLR2 recognizes certain viral proteins, and when it does so, it is 
internalized into endosomal compartments. However, in contrast with 
TLR4, all TLR2 signalling is MyD88 dependent. Thus, inflammatory 
monocytes are able to use TLR2 to activate unique MyD88-dependent 
pathways culminating in the activation of IRF3, IRF7 and NF-кB [77]. 
TLR signalling and subsequent functions must be under tight negative 
regulation because excessive activation over time contributes to the 
pathogenesis of autoimmune, chronic inflammatory and infectious 
diseases. This regulation is achieved by several kinds of mechanisms, 
from which degradation, deubiquitination, and competition are most 
frequently observed. The establishment of these regulatory 
mechanisms usually use a mode of negative feedback. Termination of 
TLR signalling occurs in response to its overactivation, and can be 
accomplished either by inducing expression of negative regulators or 
by processing constitutively expressed factors (reviewed by Wang et 
al., 2009) [78]. 
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Figure 1.2 – TLR trafficking and signalling. (from Kaway & Akira, 2011) 
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1.2.1.1.2. The cytosolic recognition pathway 
All viruses, even those replicating within the nucleus (herpes viruses), 
include a cytoplasmic phase in their replication strategy; for example, 
viral genome amplification and/or mRNA metabolism and viral protein 
expression. Within the cytosol, there are specific PRRs that recognize 
viral nucleic acids, such as RIG-I-like receptors (RLRs), nucleotide 
binding and oligomerization domain (NOD)-like receptors (NLRs), and 
DNA receptors (cytosolic DNA sensors). Like TLRs, cytoplasmic 
sensors activate signalling transduction pathways leading to the 
production of type I IFN and pro-inflammatory cytokines (reviewed by 
Wilkins & Gale, 2010) [79,80]  
The RLR family is composed by three RNA helicases, RIG-I, MDA-5 
and Laboratory of Genetics and Physiology (LGP)-2. RIG-I and MDA5 
are ubiquitously expressed in most cell types and are able to recognize 
viral RNA in the cytoplasm, leading to induction of IFN. On the other 
hand, LGP2 acts as a negative regulator of IFN gene expression, most 
probably by masking viral dsRNA from recognition by RIG-I and MDA5 
[81,82].  
RIG-I and MDA5 contain a C-terminal DExD/H box RNA helicase 
domain and two N-terminal caspase activation and recruitment 
domains (CARDs). Interaction of the DExD/H box with viral RNA 
induces its ATP catalytic activity and leads to conformational changes 
that allow the interaction between the CARD domains of the helicases 
and a CARD domain containing adaptor, initiating a downstream 
signalling cascade [82]. RIG-I and LGP2 have a C-terminal repressor 
domain, which maintains the molecule in an inactive conformation until 
binding to a nonself ligand. 
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Although structurally similar, RIG-I and MDA5 are not redundant and 
are responsible for IFN induction by different sets of viruses. This virus 
specificity may be the result of the distinct recognition of particular 
RNA structures or nucleotide composition by each sensor. For 
example, RIG-I specifically binds to a free 5´-triphosphate RNA 
structure. This feature probably allows for discrimination between self 
and non-self RNA, since 5´-ends of most endogenous RNAs are either 
capped or post-translationally modified to remove the 5’-triphosphate 
[73,82,83,84].  
The adaptor for RIG-I and MDA-5 was identified and, although named 
differently by different groups, the recommended name is now 
mitochondrial antiviral signalling protein (MAVS) [37,84,85]. The MAVS 
protein is found in the outer mitochondrial membrane, a location 
essential for its function [38,85,86]. The interaction between the CARD 
domains of RIG-I and MDA5 with the CARD domain of mitochondrial 
MAVS leads to the activation of two IкB kinase-related kinases, TBK-1 
and IKKɛ, responsible for the phosphorylation of IRF-3 and IRF-7. In 
addition, MAVS also activates NF-кB by a TRAF6 dependent pathway. 
The activated transcription factors translocate into the nucleus and 
initiate transcription of IFN genes (see Fig.1.3) [37,86,87]. MAVS is 
also present on peroxisomes in several cell types. Peroxisomal MAVS 
leads to the activation of IRF-1 and IRF-3, which trigger the rapid and 
direct expression of ISGs. This differential placement of MAVS allows 
for the diversification of the signalling pathways that are activated after 
RLR-ligand binding. Peroxisomal MAVS is essential for rapid ISG 
expression independent of type I IFN, thus initiating an immediate, 
although transient, antiviral response. Mitochondrial MAVS induces 
ISGs with delayed kinetics and primarily dependent on type I IFN 
secretion, promoting a more sustained response later during infection. 
[88,89] 
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Recognition of viral DNA in the cytoplasm is carried out by specific 
DNA sensors. The first cytoplasmic DNA receptor to be identified was  
the DNA dependent activator of IFN-regulatory factors (DAI). This 
protein binds B-form DNA (particularly poly(dA:dT)), triggering 
activation of NF-кB, IRF-3 and possibly IRF-7, thus being responsible 
for DNA-dependent type I IFN induction in some cell types. However, 
cells that do not express DAI are still able to respond to viral DNA in 
the cytoplasm, suggesting that other DNA receptors must exist [90,91]. 
Recently, two additional proteins involved in the detection of cytosolic 
DNA and subsequent IFN induction have been identified: RNA 
polymerase III and interferon-inducible protein 16 (IFI16) (see Fig. 1.3) 
[92]. RNA polymerase III acts indirectly by transcribing AT-rich DNA 
into uncapped 5′ triphosphate–bearing RNA, which serves as an 
agonist for RIG-I [93,94]. IFI16, a member of the pyrin and HIN200 
domain (PYHIN)–containing protein family, is a sensor for intracellular 
non–AT-rich dsDNA [73]. These studies have shown that detection of 
cytosolic DNA probably requires multiple and possibly redundant 
sensors that converge on the signalling molecule STING and the 
kinase TBK-1 and lead to activation of the transcription factor NF-кB 
and TBK1-mediated phosphorylation of the transcription factor IRF3. 
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Figure 1.3 – Cytosolic recognition pathways. (from Goubau et al., 2010) 
1.2.1.2. Induction of type II IFN 
When pathogens invade the host, an early pro-inflammatory response 
is initiated. Both macrophages and NK cells secrete type I IFNs. Later, 
differentiated T cells, both CD4+ and CD8+, secrete type II IFNs [7,95]. 
The majority of IFN- produced in response to infection is thus not 
directly induced by invading pathogens but is instead part of a 
secondary response. The main cytokine, among others, in the 
induction of IFN- is IL-12, which is also involved in the development of 
a Th1 response, and can also act synergistically with other cytokines 
such as IL-2, TNF-α, and in particular IL-18 [7]. NK cells and CTLs are 
considered to be the main source of IFN-. However, other cell types, 
such as macrophages and DCs, have also been reported to produce 
type II IFN under specific conditions [7,96]. 
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1.2.1.3. Induction of type III IFN 
In 2003, a novel class of IFNs has been identified, and named type III 
IFNs or IFN-λ. Type III IFNs have functional similarities with type I 
IFNs, but unlike type I IFNs, which exert antiviral activity on all cell 
types, type III IFNs target primarily epithelial cells, and consequently 
play an important role in innate antiviral defences at epithelial surfaces, 
which constitute a major portal of entry for viral infections [97].  
In addition to having similar functions, type I and type III IFNs also 
have similar expression patterns. In fact, it was determined that type III 
IFN genes are expressed in response to most classes of viruses and 
to a variety of TLR agonists, the same stimuli responsible for 
expression of type I IFN genes. Computer analysis of promoter 
sequences of type III IFN genes predicted the existence of potential 
binding sites for several transcription factors, some already known to 
be involved in the regulation of type I IFN genes transcription, e.g., AP-
1, NF-кB, and various IRFs [26]. Accordingly, it was recently 
demonstrated that both classes of IFNs are induced by transcriptional 
mechanisms involving IRFs and NF-кB. However, while IFN-β 
induction requires the coordinated action of a multifactor 
enhanceosome, and IFN-α expression is activated by multiple IRF-
binding cis-promoter elements, the type III IFNs are induced through 
independent actions of IRFs and NF-кB. Hence, it was proposed that 
IFN-λ expression is more flexible than IFN-α/β expression, which could 
allow expression of type III IFNs in response to a wider range of stimuli 
compared with type I IFNs (reviewed by Iversen & Paludan, 2010) [98]. 
1.2.2. Signalling responses to IFN 
Although type I IFNs (IFN-α/β), type II IFN (IFN-) and type III IFNs 
(IFN-λ) bind to distinct receptors, they can all activate a common 
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intracellular signalling pathway, regulating many of the same biological 
activities, including a range of antiviral immune responses [26]. The 
JAK-STAT pathway was the first signalling pathway shown to be 
activated by IFNs (Fig.1.4), and extensive studies over the years have 
firmly established its functional relevance in the interferon system. 
Type I IFNs are secreted factors that are recognized by a cell surface 
transmembrane receptor – the type I IFN receptor. This protein is a 
heterodimer composed of two subunits, IFN-α receptor 1 (IFNAR1) 
and IFNAR2, which cytoplasmic domains are associated with the 
inactive Janus tyrosine kinases, Tyk2 and Jak1, respectively. Prior to 
stimulation, IFNRA2 is also bound to STAT2 that is, in turn, weakly 
associated with STAT1. Upon IFN binding to the receptor and 
subsequent stimulation, the two subunits of the receptor associate and 
facilitate the activation of Tyk2 and Jak1. The phosphorylation of the 
tyrosine at position 466 (Tyr466) on IFNAR1 by Tyk2, creates a docking 
site for the SH2 domain of STAT2, and its subsequent phosphorylation 
by Tyk2 at Tyr690, while Jak1 phosphorylates STAT1 on Tyr701 
[64,99,100]. The activated STATs dissociate from the receptor forming 
a stable heterodimer and associate with IRF-9, forming the ISGF3 
tertiary complex that translocates into the nucleus. In this complex, 
IRF-9 is the major DNA binding component and, in the nucleus, binds 
to IFN-stimulated response elements (ISRE) present in the promoter 
region of IFN-stimulated genes (ISGs), inducing their transcription. 
IRF-9 can also form a DNA binding complex with STAT1 homodimers 
and with STAT2 alone, and these complexes can bind to DNA with the 
same specificity as ISGF3 (reviewed by Paun & Pitha, 2007) [40].  
Besides tyrosine phosphorylation, additional posttranslational 
modifications are involved in the type I IFN-induced activation of the 
Jak-STAT pathway. It was recently proposed that a CREB-binding 
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protein (CBP)-mediated acetylation cascade, together with serine 
phosphorylation, also plays a critical role in type I IFN intracellular 
signalling. The cytoplasmic CBP protein is a mediator for the 
acetylation of cytokine receptors and their downstream signalling 
molecules, e.g. IFNRA2, IRF9, STAT1 and STAT2. Acetylation plays a 
major role in the complete formation and activation of the ISGF3 
complex, thus mediating cytokine receptor signal transduction 
(reviewed by Tang et al., 2007) [101]. 
The type II IFN receptor is also a heterodimer composed of  two 
subunits, the IFN- receptor 1 (IFNGR1), which associates with Jak1, 
and the IFNGR2, which constitutively associates with Jak2. 
Dimerization of the receptor, upon binding of IFN-, leads to 
association of Jak1 and Jak2 and subsequent activation of Jak2 which, 
in turn, phosphorylates Jak1. After being phosphorylated by activated 
Jak1 and Jak2, the C-terminus of IFNGR1 creates a pair of binding 
sites for STAT1, allowing for its phosphorylation at Tyr701. The 
phosphorylated STAT1 homodimer dissociates from the receptor and 
translocates into the nucleus, where it binds to unique elements of 
IFN- stimulated genes, the gamma-activation sequence (GAS), and 
induces transcription. Of note is the fact that type I IFN stimulation is 
also able to form STAT1-homodimers, leading to the induction of ISGs 
containing GAS elements in their promoter region (reviewed by 
Goodbourn et al., 2000) [99]. 
IFN-λs exert their biological activities by signalling through a 
heterodimeric receptor complex composed of IFN-λ receptor 1 (IFN-
λR1) chain and the shared IL-10R2 chain, which is also a part of the 
receptor complexes for IL-10, IL-22, and IL-26. Type III IFN receptor is 
different from other IFN receptors, but activation through either IFN-λ 
or IFN-α receptor complexes results in initiation of the same Jak-STAT 
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signal transduction cascade. Although IFN-λR1 is constitutively 
expressed by a broad range of cell lines and tissues, there are many 
cell types that do not express IFN-λ receptors, and, as a consequence, 
cannot respond to this cytokine (reviewed by Donnely et al., 2010) 
[26]. 
Type I and type II IFN also induce phosphorylation of STAT1 on Ser727, 
and although this phosphorylation is not required for either nuclear 
translocation or DNA binding, it is essential for full transcriptional 
activity of STAT1. This reaction is catalysed by protein kinase C 
isoform PKC-δ, which is activated by the PI3K pathway, and directly 
interacts with STAT1 [102,103]. 
An effective antiviral response requires a rapid and efficient induction 
of ISGs by the Jak-STAT pathway, in response to IFNs released by 
infected or activated cells. However, this response must be tightly 
regulated and terminated once the viral threat is over, in order to avoid 
damage to the host, and several negative regulators of the Jak-STAT 
signalling have been already described.  
Phosphatases are important regulators of kinase based signalling 
cascades, inducing dephosphorylation of specific amino acid residues 
and, consequently negatively regulating activation of effector proteins. 
In particular, SH2-containing phosphatase (SHP)-1, SHP-2 and protein 
tyrosine phosphatase 1B (PTP1B) dephosphorylate tyrosine residues 
on the IFN receptors or on Janus kinases, preventing tyrosine 
phosphorylation of STATs and their subsequent activation [104,105]. 
At cytoplasmic level, the Jak/STAT signalling pathway can be inhibited 
by a negative feedback inhibitor – the suppressor of cytokine signalling 
(SOCS). Following cytokine signalling, SOCS are activated and 
recruited to ligand-receptor complexes, causing inhibition or triggering 
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protein turnover of the IFN receptor through ubiquitin-proteasome-
mediated degradation, preventing STAT activation [104,106,107].  
PIAS – proteins that inhibit activated STAT, are a family of proteins 
able to inhibit active STATs at the nuclear level. PIAS1 interacts with 
tyrosine phosphorylated STAT1, blocking its DNA binding ability, while 
PIASy acts as a transcriptional co-repressor of STAT1 [104,108]. PIAS 
proteins can also act as platforms to facilitate both removal and 
recruitment of other regulatory proteins, such as SUMO proteins [109]. 
STAT1 activity can be regulated by another cytoplasmic inhibitor, the 
small ubiquitin-like modifier (SUMO) proteins. SUMO posttranslational 
modification (SUMOylation) is a dynamic and reversible process that 
can both decrease STAT1 tyrosine phosphorylation and indirectly 
facilitate STAT1 dephosphorylation. Phosphorylation of STAT1 at 
Tyr701 and SUMOylation at the adjacent Lys703 are mutually 
exclusive, such that Tyr701-phosphorylated STAT1 remains 
unSUMOylated [110,111]. This results in the formation of 
semiphosphorylated STAT1 dimers that function as competitive 
polymerization inhibitors, increasing the solubility of fully active STAT1 
molecules, thus inducing its dephosphorylation [110]. Together, these 
two mechanisms are able to diminish the amount of transcriptionally 
activate STAT1 in the cell nucleus, protecting cells against hyper 
responsiveness to IFN- [112]. 
STAT1β is a truncated form of STAT1, lacking the transactivation 
domain (TAD). This is a naturally occurring form of the protein, formed 
by differential splicing, that can replace STAT1 in homo- or 
heterodimers formed following receptor activation. However, STAT1β 
is non-functional, thus unable to induce IFN- dependent transcription. 
Nevertheless, in response to IFN-α/β, it retains the ability to be 
incorporated in the ISGF3 complex, and so participate in transcription, 
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probably due to the presence of a functional STAT2. Therefore, this 
protein can function as a dominant negative regulator, either by 
binding to DNA as a non-functional factor, or by interacting and 
sequestering functional STAT1 [99,104]. 
Post-translational modification of STAT proteins via ubiquitination is 
another important means to regulate STAT signalling. Conjugation of 
ubiquitin to proteins results in their degradation by the 26S 
proteasome-dependent pathway. This is a common mechanism for the 
regulation of several cellular processes. Ubiquitination of target 
proteins requires three enzymes, ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). E3 ligase 
confers specificity to the reaction, interacting with both E2 and the 
target protein to facilitate transfer of ubiquitin to the substrate. 
Regulation of IFN-activated STAT1 levels by the ubiquitin-proteasome 
pathway was demonstrated in 1996, by Kim and Maniatis [113] and, 
some years later, PDLIM2 protein was identified as a STAT ubiquitin 
E3 ligase [114]. It was later reported that phosphorylation of PDLIM2 
Ser-137 is required for Ub-P-STAT1 formation and degradation by the 
26 S proteasome system [115]. Ubiquitination is the only regulatory 
mechanism that results in reduced levels of STAT1 in the cell, helping 
to restrain the inflammatory response.  
The Jak-STAT pathway only accounts for some of the biological 
functions exerted by IFNs in the organism. The PI3K pathway was 
already mentioned as necessary for the full activation of STAT1. In 
addition, this pathway can also induce downstream survival or death 
pathways, in response to IFN [103,116]. Other pathways are also 
involved in IFN-mediated signalling, such as CRKL, PI3K, and p38 
kinase pathways [103,116].  
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The CRKL proteins were first identified as cellular homologues of viral 
CRK. These are adaptor proteins that facilitate the formation of various 
signalling complexes in response to various stimuli, including IFN. In 
response to type I and type II IFN, Tyk2 phosphorylates CRKL, which 
binds to STAT5 and forms a complex that translocates into the 
nucleus, binding to GAS elements present in certain ISGs. In addition, 
activated CRLK can also activate RAP1, generating growth-inhibitory 
responses [102,103]. 
The p38 protein is a member of the mitogen-activated protein kinase 
(MAPK) family. Members of this family are typically involved in the 
regulation of gene transcription, apoptosis, and cell cycle. The p38 
protein, in particular, was shown to be necessary for the transcriptional 
regulation of ISGs, in response to type I IFN. This serine-threonine 
kinase does not affect the activation of the Jak-STAT pathway, but 
contributes to the growth-inhibitory effects of interferon [103]. 
In order to exert its diverse biological functions, the produced IFN must 
activate more than one signalling pathway. A combination of more than 
one signalling cascade is often required to generate a given biological 
response. For example, both STAT- and p38-signalling pathways are 
required to elicit the antiviral effects of IFNs [103]. 
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Figure 1.4 – Activation of classical JAK-STAT pathway by type I and type 
II IFNs. (from Platanias et al., 2005). 
1.2.3. IFN-induced antiviral state 
The induction of an anti-viral state is achieved through the IFN-induced 
expression of specific sets of genes, the interferon stimulated genes 
(ISGs), which will limit virus replication and its subsequent spread to 
neighbouring cells. The best characterized IFN inducible components 
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are the enzymes dsRNA-dependent protein kinase (PKR), 2’,5’-
oligoadenylate synthetase (2’5’OAS), and Mx proteins. 
Upon binding to dsRNA, the serine/threonine kinase PKR is activated 
and catalyses phosphorylation of different substrates, such as the α-
subunit of the eukaryotic translational initiation factor eIF2 (eIF2α). 
PKR-induced phosphorylation of eIF2α prevents its recycling, thus 
resulting in the inhibition of initiation of translation. In addition, 
phosphorylated eIF2α mediates autophagy, enabling controlled 
degradation of cell contents. PKR also acts on additional substrates, 
regulating other antiviral mechanisms such as control of cell 
proliferation and apoptosis [64,100,117]. 
The 2’5’OAS protein is also activated by its binding to dsRNA. This 
protein is then able to oligomerize ATP through a 2’5’ phosphodiester 
linkage, synthesizing 2’,5’-oligoadenylates. These molecules bind to 
endoribonuclease L (RNaseL) with high affinity. The subsequent 
activation of RNaseL leads to cleavage of ssRNA (including mRNA) 
and in the inhibition of protein synthesis. 2’5’OAS was also suggested 
to be involved in IFN-induced apoptosis [64,117]. 
Mx proteins are IFN-inducible GTPases that belong to the dynamin 
family of large GTPases. These proteins have been shown to induce 
an antiviral response against RNA viruses. Mx proteins, in particular, 
inhibit viral replication at very early stages of the infection, through the 
recognition of nucleocapsid-like structures. In contrast to PKR and 
2’5’OAS, Mx proteins seem to exhibit a certain degree of specificity to 
certain viruses [100,118].  
Other proteins, such as ISG15, ISG54 and ISG56, ISG20, 
promyelocytic leukaemia (PML) and tripartite motif (TRIM) proteins 
also play significant roles in the IFN-induced antiviral response. ISG15 
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is expressed following IFN stimulation and binds covalently to different 
proteins, protecting them from degradation. Several of these proteins 
are involved in the induction of IFN and regulation of IFN impact on the 
antiviral response, e.g. JAK1, STAT1, PKR, RIG-I and IRF-3. 
Therefore, one of ISG15 major roles appears to be the up-regulation of 
the IFN response [64].  
ISG54 and ISG56 are induced by viral stress. These proteins inhibit 
translation by interaction with different subunits of the elongation 
initiator factor eIF3 complex [119]. The ISG20 protein specifically 
degrades ssRNA through its IFN induced 3’-5’ exonuclease activity. 
When overexpressed, ISG20 inhibits replication of VSV, influenza A 
virus (FluAV), EMCV, and HIV-1 [117]. The PML gene encodes 
multiple isoforms, as a result of alternative mRNA splicing, which 
shuttle between the cytoplasm and the nucleus. PML nuclear isoforms 
are localized in distinct subnuclear structures known as PML-nuclear 
bodies (PML-NBs), PML oncogenic domains (POD), nuclear domain 
10 (ND10), or Kremer (Kr) bodies. The major function of PML-NBs is to 
suppress viral transcription, and this activity is enhanced in response 
to the production of type I or type II IFNs [120]. 
The TRIM proteins control normal cellular functions. These proteins 
are constitutively expressed but are up regulated in response to type I 
IFN in certain cell types. This suggests their involvement in antiviral 
responses. TRIMα5 was reported to be involved in blocking the 
ubiquitination of HIV-1 capsid protein [117]. 
Interferons also induce the activation of downstream signalling 
pathways that direct the expression of genes involved in the 
establishment of a pro-apoptotic state or cell-cycle arrest in target cells 
[62]. 
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1.2.4. Immunomodulation by IFN 
The most studied property of the interferon system is its ability to 
establish an antiviral state. In addition, this system has been shown to 
be linked to several effector responses of both the innate and the 
adaptive immune system, with the ultimate goal of eliminating virus 
infected cells. Accordingly, type I IFNs also regulate the activities of 
natural killer (NK) cells and cytotoxic T cells (CTLs). 
Most somatic cells are capable of producing type I IFN when infected 
by an intracellular pathogen. However, specialized antigen-presenting 
pDCs can produce extremely high levels of IFN-α/β upon stimulation of 
PRRs with virus-derived nucleic acids, without suffering viral infection 
[121]. This is suggestive of a key role for type I IFN in priming adaptive 
responses.  
The activity exerted by type I IFNs is dependent on the cellular context. 
Recognition of viral nucleic acids and associated activation of IFN, can 
initiate cell-integrated apoptosis, as well as the expression of ligands 
for activation of NK cells and CTLs. Type I IFNs can also act on 
neighbouring uninfected cells, to induce an alert state. In the absence 
of other signals, the expression of IFN-inducible genes is activated, 
with the result that the cells are more sensitive to detection and 
elimination of the virus [63]. 
Recently it was demonstrated that IFN-α/β can directly or indirectly 
influence the fate of both CD4+ and CD8+ T cells during the initial 
phases of antigen recognition, by enhancing their IL-15-induced 
proliferation. Secretion of IL-15 by APCs also plays a critical role in the 
proliferation and maintenance of NK cells. Type I IFNs can also 
cooperate with T cell receptor and co-stimulatory signals to drive clonal 
expansion and differentiation of naive CD8+ T cells into effector cells, 
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and help to sustain the survival of the proliferating cells. Some studies 
suggested that there are two types of CD8+ T cells, the ones that 
require type I IFN for expansion and the ones that do not. However, 
only type I IFN-dependent CTLs provide protective immunity to viral 
infection [63].  
Type I IFNs access and regulate antigen-presenting pDCs, enhancing 
their ability for cross-presentation of the antigen through the up-
regulation of the MHC class I pathway. Together with the IFN-induced 
up-regulation of other chemokines and co-stimulatory molecules, type I 
IFNs influence the efficient homing of DCs into secondary lymphoid 
organs and, consequently, CD4+ and CD8+ T cell responses, 
including the induction of CTLs [122].  
IFN-α/β can also control CD4+ T helper (Th) cell functions, by 
regulating the development and stability of long-lived memory cells.  
Type I IFN supports Th1 differentiation, activation of Stat4 signalling 
and IFN- production. At the same time, IFN-α/β acts to restrict the 
development of alternative populations and their associated effector 
functions, such as Th2 and Th17 [123]. 
Regarding the humoral acquired immunity, type I IFNs were shown to 
promote the generation of antibodies, their switching to opsonizing IgG 
classes and the establishment of long-lasting B cell memory. These 
effects are achieved by the action of IFN-α/β on both DCs and B 
lymphocytes [11] 
Type I IFNs can also enhance NK cell-mediated cytotoxicity through 
their collaboration with NK receptors and consequent elimination of 
infected cells [63]. 
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All type I IFN members share the capacity of augmenting the 
expression of MHC class I proteins, therefore promoting CD8+ T cell 
responses, yet only IFN- is capable of inducing the expression of 
MHC class II proteins, hence promoting CD4+ T cell responses 
[99,100].  
Type II IFN affects the processing of key cellular components for the 
adaptive immune responses. These include the immunoproteasomes 
that generate antigenic peptides and also the cellular components that 
target the peptides for interaction with MHC class I molecules. IFN- 
also acts directly on B cells, increasing the expression of MHC class II 
and thus increasing antigen presentation, and also in programming 
immunoglobulin class switching to particular subclasses [124].  
Finally, IFN- is able to regulate the balance between Th1 and Th2 
cells, and the activation of macrophages, as the latter use a variety of 
IFN- induced mechanisms to kill infected cells, such as production of 
reactive oxygen intermediates [99,100]. 
1.3. Viral Mechanisms of Immune Evasion 
The continuous interaction between viruses and their respective hosts 
during the course of evolution, has shaped and determined the survival 
strategies used by viruses and their hosts. As intracellular pathogens, 
viruses must enter the cell and take control of its machinery with the 
purpose of replicating and disseminating themselves. In turn, the 
vertebrate host has evolved an elaborate system of innate and 
adaptive antiviral immune mechanisms, in order to recognize and 
destroy pathogen-infected cells. This created a selective pressure on 
viruses, ultimately leading to the evolution of multiple strategies for 
virus host evasion. The strategies employed by viruses to evade and 
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elude the host defence mechanisms can be divided into three main 
categories: (1) to avoid recognition by the humoral immune response, 
(2) to interfere with the functioning of the cellular immune response, 
and (3) to interfere with immune effector functions. The list of such viral 
mechanisms to manipulate the host immune response is extensive. 
Some will now be briefly described. 
1.3.1. Impairment of the humoral immune response 
Effective evasion from the anti-viral B-cell immunity is particularly 
important for viruses that are sensitive to neutralizing antibodies. A 
typical example is the influenza virus. The human immune system can 
rapidly and successfully develop protective immunity against influenza 
virus type A infections, mostly by directing neutralizing antibodies 
against the major surface protein of the influenza virus, 
haemagglutinin. In order to escape this recognition strategy, the virus 
evolved two forms of antigenic variation, the antigenic drift and the 
antigenic shift [125]. Both lead to the insertion of changes in critical 
residues of the haemagglutinin protein on the viral surface. As a result, 
antibodies produced in response to the viral infection will be unable to 
bind the epitope, allowing the virus to escape from antibody 
recognition and neutralization. 
1.3.2. Impairment of the cellular immune response 
Cell-mediated immune responses play a major role in the elimination 
of virus infections. By targeting MHC class I and II biogenesis and 
transportation pathways, viruses are able to interfere with the 
activation of CD8+ and CD4+ T cells by blocking antigen presentation. 
Several strategies have been developed by viruses to achieve this 
purpose, affecting nearly all steps of generation, processing and 
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presentation of viral peptides or even the processing of MHC 
molecules. 
For example, the Epstein-Barr virus (EBV) codes for a protein called 
nuclear antigen (EBNA)-1 that efficiently blocks antigen processing by 
interfering with proteasomal degradation of viral proteins. The Gly-Ala 
co-repeat (GAr) in EBNA-1 is a cis-acting inhibitor of ubiquitin-
proteasome proteolysis, thereby inhibiting the generation of viral 
epitopes and escaping CTL detection [126]. 
After the degradation of viral proteins by proteasomes in the cytosol, 
the resulting peptides pass to the membranes of the endoplasmic 
reticulum (ER) through translocation by the transporter associated with 
antigen presentation (TAP), for assembly into MHC class I complexes. 
Throughout its life cycle, the human cytomegalovirus (HCMV) 
produces a viral inhibitor of TAP (US6) that stops peptide transport to 
the MHC class I, limiting the presentation of abundantly expressed 
structural viral antigens, such as glycoprotein B [127].  
In addition to mechanisms that interfere with viral peptide presentation 
to T cells, viruses have also evolved strategies to prevent MHC class I 
expression on the cell surface, to promote intracellular retention of the 
MHC complexes, or even to lead to the degradation of MHC class I 
molecules [126]. The U21 protein, expressed by the human 
herpesvirus 7 (HHV-7) is able to bind to and reroute properly folded 
class I molecules from the ER to a lysosomal compartment  [128]. To 
target MHC class I molecules for proteolytic degradation, HCMV 
express proteins US3 and US11, responsible for the ubiquitination of 
the MHC class I molecules, which are then transported from the ER 
back into the cytosol, where they are degraded by the proteasome  
[129,130]. 
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Downregulation of MHC class I complexes on the cell membrane by 
viral proteins results in recognition and killing of the infected cells by 
NK cells. Therefore, viruses have also developed strategies to 
circumvent NK cell-mediated killing, such as the expression of MHC 
homologues by HCMV [126]. 
Using a different strategy, HCMV and murine cytomegalovirus (MCMV) 
interfere with CD4+ T-cell recognition of infected cells by 
downregulating MHC class II expression on endothelial and epithelial 
cells [131]. This affects the activation of CD8+ T cells and B cell 
development, disturbing the immune control of viral disease. 
An MHC complex is recognized by T cells expressing complementary 
T cell receptors (TCR) loaded with a peptide. Simultaneous interaction 
of the MHC molecule with CD4 or CD8 molecules expressed on helper 
and cytotoxic T cell precursors serves as a co-stimulus, respectively. 
The human herpesvirus (HHV)-6A is able to downregulate the 
CD3/TCR complexes at a transcriptional level [132]. The 
downmodulation of the levels of surface CD4 on infected cells is a 
strategy used by the human immunodeficiency virus (HIV). The HIV 
encoded proteins Vpu, Env and Nef, use different mechanisms to 
downmodulate CD4 at different points during infection [133]. 
Viral modulation at the level of the MHC class I and II biogenesis and 
transportation pathways affects antigen presentation, thus preventing a 
sustained immune response (see Table 1.3). 
If viral antigens are still successfully presented, viruses escape the 
immune response by interfering with B and T cell effector functions. T 
cell responses can be inhibited at the level of cytokine induction (see 
Table 1.4), or CTL mediated apoptosis (see Table 1.6). 
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1.3.3. Viral interference with immune effector functions 
In order to replicate and spread in a host population, the virus depends 
on highly specific interactions of viral proteins with infected cells, which 
result in the subversion of multiple cellular signal transduction 
pathways. These strategies are not restricted to modulation of host 
immunity, for example, viral proteins can manipulate cell cycle 
progression of the infected host cell, in order to replicate [134]. 
The attenuation of the various effector mechanisms of the host’s 
immune response is equally important for successful propagation of a 
virus. The first barrier that viruses need to overcome is the innate 
immune response. Several viral strategies are already known, 
including the interference with cytokine synthesis and function (Table 
1.3), particularly the inhibition of IFN (to be discussed in detail in the 
next section), interference with the complement system (Table 1.4), 
and inhibition of apoptosis (Table 1.5). In addition, viruses also encode 
functional Fc receptors, thereby interfering with virus neutralization or 
antibody-mediated cytotoxicity. These receptors can also hide 
antigenic structures by coating the virus or infected cell with 
immunoglobulins [126]. 
Viruses have also evolved strategies to subvert phagocytic activity. 
Some viruses evade nitric oxide and reactive oxygen radicals 
generated by macrophages. Others, such as herpesviruses and 
poxviruses, express surface proteins that mimic CD200, a host 
regulator that delivers inhibitory signals to macrophages [135]. 
 
 
Chapter 1 
52 
Virus protein/gene Mechanism Reference 
HSV-1 – ICP47 Blocks TAP function [136] 
HVS – ORF14 Binds MHC class II [137] 
AdV – E1A Inhibits MHC class II gene transcription [138] 
KSHV – K3 and K5 
Reduces MHC class I surface 
expression 
[139] 
HPV – E5 
Downregulates MHC class I and II 
surface expression 
[140,141] 
HCMV – UL37 Viral MHC-like protein [142] 
Herpes simplex virus-1 (HSV-1); Human papilomavirus (HPV); Herpesvirus saimiri (HVS); Human 
cytomegalovirus (HCMV); Adenovirus (AdV); Kaposis’ associated herpesvirus (KSHV)  
Table 1.3 – Modulation of antigen presentation pathway. 
 
Virus protein/gene Mechanism Reference 
VV – B15R Binds and inhibits IL-1β [143] 
HCMV – US28 Chemokine receptor viral homologue [144] 
EBV – LMP-1 Binds TRAFs; activates TNFR [145] 
HVS – ORF13 Viral IL-17 homologue; T-cell mitogen [146] 
KSHV – ORF74 Chemokine receptor viral homologue [147] 
HIV – Tat Chemokine-like activity [148] 
MCV – MC54 Inhibits IL-18 induced IFN- production [149] 
MHV68 – M3 Viral CКBP; inhibits chemokine system [150] 
VacV-A41L Viral CКBP; anti-inflammatory properties [151] 
Vaccinia virus (VacV); Epstein-Bar virus (EBV); Kaposis’ associated herpes virus (KSHV); Human 
immunodeficiency virus (HIV); Herpesvirus saimiri (HVS); Molluscum contagiosum virus (MCV) 
Table 1.4 – Modulation of cytokines and cytokine responses. 
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Virus protein/gene Mechanism Reference 
HSV – gE and gI Forms IgG Fc-like receptors [152] 
CPXV – IMP 
Sequesters C3 and C4; blocks 
complement cascade 
[153] 
VACV – VCP 
Sequesters C3 and C4; blocks 
complement cascade 
[154] 
HVS – ORF15 
Viral CD59 homologue; blocks terminal 
complement cascade [155] 
Herpes Simplex virus (HSV); Cowpox virus (CPXV); Vaccinia virus (VACV); Herpesvirus saimiri 
(HVS) 
Table 1.5 – Modulation of complement responses. 
Virus protein/gene Mechanism Reference 
HPV – E6 Targets p53 for proteolytic degradation [156] 
EBV – LMP-1 Up-regulates expression of cellular bcl-2 [157] 
HCMV – UL37 Blocks apoptosis by death receptors [158] 
KSHV – K13 
Prevents caspase activation by death 
receptors 
[159] 
MHV – M11 Bcl-2 anti-apoptotic gene homologue [160] 
ASFV – A224L 
Viral IAP homologue; inhibits caspase 
activation 
[161] 
Human cytomegalovirus (HCMV); Murine herpesvirus (MHV); Kaposis’ associated herpes virus 
(KSHV); African swine fever virus (ASFV); Human papilomavirus (HPV) 
Table 1.6 – Modulation of apoptosis. 
Most large DNA viruses code for host evasion proteins that have 
sequence homology to cellular genes. However, non-homologous virus 
host evasion genes have recently been identified and described [162]. 
Such genes represent a challenge, since their function can only be 
determined by functional assays. 
In conclusion, viruses evolved a plethora of mechanisms that favours 
their replication and survival. The knowledge of these evasion 
strategies will help in the understanding of immune and inflammatory 
responses and in the design of novel and effective antiviral treatments 
and vaccines [163]. 
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1.4. Viral Evasion of Interferon responses 
The downregulation of the interferon system, a powerful and first line 
of defence against virus infections is, unsurprisingly, a priority for most 
viruses. The viral strategies are numerous and include the inhibition of 
IFN production, the inhibition of IFN-mediated signalling pathways, and 
blocking the action of IFN-induced enzymes with antiviral activity.  
Given that the induction of IFN is generated in a cascade-like manner, 
viruses have evolved several molecular mechanisms that act in 
concert over different steps in the pathway to subvert the IFN 
response. Many viral antagonists are multifunctional proteins that 
interact with multiple host components, thereby increasing the 
efficiency of their host evasion and also allowing the virus to 
manipulate different biological processes in infected cells. The size of 
viral genomes contrasts with the number of mammalian genes 
dedicated to host defence mechanisms, providing an additional 
selective pressure for the evolution of such viral multifunctional 
proteins [81]. 
During the past few years, much has been learned about the molecular 
mechanisms used by viruses to manipulate and escape the host 
interferon response. The exact strategy exploited by a virus will 
presumably depend on the biology of the infection and will be a major 
factor that will influence the pathogenesis of that virus infection [64]. 
1.4.1. Inhibition of IFN production 
Regarding the inhibition of interferon production, several viral 
strategies have been identified and characterized (see Table 1.7). It 
has been observed that almost 50% of the viruses for which IFN 
antagonists have been identified, interfere with multiple steps of the 
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IFN response. This clearly depicts the necessity for viruses to 
successfully circumvent the IFN response [62]. 
In order to avoid recognition by pattern-recognition receptors (PRRs), 
viruses usually manipulate production of PAMPs to achieve a minimum 
level of expression, thus minimizing IFN production in response to the 
viral infection. This can be achieved, for example, by minimizing the 
production of dsRNA through the regulation of virus transcription and 
replication or, as used by paramyxoviruses and picornaviruses, by 
capping viral RNA, rendering it indistinguishable from cellular mRNA 
[64].  
The majority of IFN antagonists exert their action by one of four 
different strategies: (I) general inhibition of cellular gene expression, 
(II) sequestration of molecules in the IFN circuit, (III) proteolytic 
cleavage of innate immune components, or (IV) targeting these 
components for proteasomal degradation [62]. 
By inhibiting the host cell gene expression and/or protein synthesis, 
viruses affect several cellular functions, including the IFN response. 
Several mechanisms used by viruses are already known, such as the 
matrix (M) protein of vesicular stomatitis virus (VSV), responsible for 
the inhibition of basal transcription, impairment of nuclear-cytoplasmic 
transport of RNAs and proteins and inactivation of translation factors. 
The NS1 protein of influenza A virus (FluAV) inhibits processing and 
export of cellular mRNAs [164]. 
The sequestration of the ligands that bind to host cell PRRs is another 
efficient viral mechanism to inhibit the induction of IFN expression. 
Very well known examples, among others, are the NS1 protein of 
influenza A virus, and the VP35 protein of Ebola virus. These bind 
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dsRNA and can inhibit not only the induction of IFN but also dsRNA 
inducible proteins such as the enzymes PKR and 5’OAS [62]. 
Some viral antagonists directly inhibit components of the TLR and RLR 
signalling pathways, blocking IFN production and suppressing host 
antiviral signal propagation. The 3Cpro cysteine protease of 
coxsackievirus B3 (CVB3) cleaves two key adaptor molecules of the 
innate immunity: MAVS and TRIF, thereby blocking TLR3, TLR4 and 
RLR signalling  [165]. The hepatitis A virus (HAV) uses a 3Cpro 
homologue to achieve the same result [166]. The Vaccinia virus 
protein A46R not only inhibits TLR3 signalling through TRIF-mediated 
IRF-3 activation, but is also capable of binding to other TIR adaptors 
such as MyD88 and TIRAP, interfering with the activation of NF-кB and 
MAP kinase [167]. 
By inhibiting the post-translational attachment of ubiquitin or ubiquitin-
like modifiers (ULMs) to host cell proteins, viruses are able to 
deregulate many cellular processes, including the generation of innate 
and adaptive immune responses to pathogens [168]. For example, the 
Npro protein of both bovine viral diarrhoea virus (BVDV) and classical 
swine fever virus (CSFV) induce proteasome-dependent degradation 
of IRF3 [64]. HIV-1 proteins Vpr and Vif also mediate IRF3 
ubiquitination, leading to proteasomal degradation [169]. Influenza A 
virus NS1 binds and inhibits TRIM25, an E3 ligase required for 
ubiquitin-dependent interaction between RIG-I and its adaptor MAVS. 
NS1 is thus able to prevent activation of IRF3-dependent IFN secretion 
[170]. 
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1.4.2. Inhibition of IFN-mediated signalling 
Interferon-mediated signalling not only induces the expression of host 
cellular anti-viral proteins but also stimulates antigen presentation 
through increased MHC expression. Considering such crucial roles in 
anti-viral immunity, it is not surprising that viruses have evolved 
strategies to inhibit the signal transduction pathways triggered upon 
binding of IFN to its specific receptor. 
Type I and type II IFN signal through distinct receptors, activating 
downstream components that can be either unique or common to both 
signalling pathways. Thus, viruses can block the impact of IFN at 
several levels, inhibiting only one of these two pathways or both (see 
Table1.8). Poxviruses encode soluble versions of cellular cytokine and 
cytokine receptors, which can interfere with the normal function of the 
target cytokines or receptors. For example, B8R protein of VACV binds 
to soluble IFN- and prevents its binding to the cellular receptor. In this 
way, this virus simultaneously inhibits the antiviral effects due to 
signalling through the type II IFN receptor, and also the 
immunoregulatory functions of IFN- [171]. 
Modulation of STAT activity is a very common viral strategy. For 
example, the Dengue virus NS5 protein mediates ubiquitination and 
proteasome-dependent degradation of STAT2 [172]. Members of 
paramyxoviruses encode two different but genetically related proteins, 
C and V, which interfere with STAT function. According to the strain of 
the virus, these IFN antagonists act by binding to STAT proteins 
inducing their degradation, or by inhibiting the Jak kinases [164]. 
Inhibition of signalling through the STAT proteins can also be indirect. 
The VP24 protein of Ebola virus (EBOV) interacts with the NPI-1 
subfamily of karyopherin-α proteins (responsible for transporting 
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dimerised phospho-STAT1 to the nucleus), inhibiting nuclear 
accumulation of STAT [173]. Other indirect mechanism to block IFN 
signalling includes the rapid induction of SOCS-3 expression, a cellular 
inhibitor of the Jak-Stat pathway. This is a strategy explored by 
multiple viruses, such as the FluAV, RSV, HCV, and HSV [62]. 
1.4.3. Inhibition of IFN-induced effector proteins 
Another efficient way to interfere with the interferon response is by 
directly targeting the proteins that mediate the antiviral state. 
Viruses employ different strategies to either inhibit or prevent the 
activation of the IFN-inducible antiviral effector protein PKR, one of the 
major host responses to viral infection. Active PKR dimers 
phosphorylate eIF-2α, preventing the formation of the ternary 
translational complex, thereby repressing translation of RNAs. Since 
viruses require the machinery of the host cell for the translation of viral 
proteins, inhibition of PKR is mandatory [174]. Some viruses express 
RNA-binding proteins that sequester viral dsRNA, thus preventing the 
activation of PKR. The Hepatitis C virus (HCV) protein NS5a is able to 
interact with and inhibit PKR. In addition, the HCV E2 glycoprotein 
competes with eIF-2α for binding to PKR, thus preventing the 
inactivation of translation by PKR. Another strategy used by viruses is 
to encode small RNAs which compete with dsRNA for binding to PKR, 
hence inhibiting its activation [118]. Direct binding and inhibition of 
PKR is a strategy explored by the KSHV protein vIRF-2, which 
prevents PKR activation by inhibiting the autophosphorylation of the 
protein [174]. The cellular PKR inhibitor p58(IPK) is activated during 
FluAV, TMV, and TEV infection and contributes to negative regulation 
of PKR by direct protein–protein interaction [62]. 
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The ISG15, ubiquitin-like protein, has also been shown to be targeted 
by viruses. The N-terminal domain of the L protein of Crimean Congo 
hemorrhagic virus (CCHV) has de-ISGylating and de-ubiquitinating 
activity, while influenza B virus NS1 protein inhibits ISG15 by direct 
binding [64]. Adenovirus, HSV-1, EBV, and HCMV, are able to disrupt 
PML nuclear bodies (ND10) by proteasome-dependent degradation, 
although the relevance of this is debated [118]. 
1.4.4. Applications of viral inhibitors of IFN responses 
It is clear that viruses have evolved multiple mechanisms to evade the 
interferon response. Viral genes that circumvent the interferon 
response can have direct applications in the rational development of 
novel strategies to control viral infections, for example, attenuated 
virus vaccines with virus host evasion genes deleted. Typically these 
host evasion genes are non-structural, and non-essential for virus 
growth in vitro. Therefore viruses with targeted deletions of genes that 
code for IFN antagonists are promising candidates for live attenuated 
vaccines. This approach has already been successful for viruses such 
as influenza virus, and bovine respiratory syncitial virus (reviewed by 
Haller et al., 2005) [81]. A major complication that may arise is that IFN 
antagonists are often multifunctional, and so a gene deletion may 
“over-attenuate” the virus; for example, an IFN-sensitive virus may be 
difficult to grow in culture due to the IFN response of tissue-culture 
cells [64]. 
Viral antagonists may also be targets for novel antiviral drugs and tools 
for immunomodulation. The fact that different viruses target the same 
cellular proteins raises the possibility of designing an antiviral drug with 
a wide spectrum of activity. 
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Our present knowledge of the interplay between viruses and the IFN 
system is still limited to some extent because the IFN system is still far 
from being understood. Further studies and understanding on how 
viruses block this response provide a better control of virus infections 
through novel vaccines and drugs, and also reveal as yet unknown 
functions of the IFN system. 
Virus (protein) Mechanism 
ECMV (leader protein) Prevents IRF3 dimerization 
BUNV (NSs) Inhibit RNA polymerase II 
Reovirus (σ3/A) Sequesters dsRNA 
HCV Inhibits TLR signalling and MAVS 
Influenza A virus (NS1) Inhibits MDA5 and RIG-I 
HPV16 (E6); 
HSV (ICP0); BRSV 
Inhibit or degrade IRF-3 
HPV (E7); AdV (E3) Interfere with IKK complex 
KSHV (IRF orthologues) Interferes with IFN-β promoter activation 
ASFV (A238L) Competitive non-functional IкB homologue. 
Encephalomyocarditis virus (ECMV); Bunya virus (BUNV); Hepatitis C virus (HCV); Bovine 
respiratory syncitial virus (BRSV); Herpes simplex virus (HSV); Human papilomavirus (HPV); 
Adenovirus (AdV); Kaposis associated herpesvirus (KSHV); African swine fever virus (ASFV) 
Table 1.7 – Inhibition of interferon production. 
 (adapted from Versteeg & García-Sastre et al., 2010) 
 
Virus (protein) Mechanism 
HCMV Targets Jak1 for proteasomal degradation 
SeV; BRSV Induces degradation of STATs 
HCV; SeV; HCMV Sequesters STATs or alters their phosphorylation 
HCV (Core); HSV 
(UL13, UL41) 
Induces SOCS-3 
Herpes simplex virus (HSV); Human cytomegalovirus (HCMV); Sendai virus (SeV); Bovine 
respiratory syncitial virus (BRSV); Hepatitis C virus (HCV) 
Table 1.8 – Inhibition of interferon signalling. 
 (adapted from Versteeg & García-Sastre et al., 2010) 
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1.5. African Swine Fever Virus 
African swine fever virus (ASFV) was first described by Montgomery, 
in Kenya, in 1921, when the virus spread from infected warthogs 
(Phacochoerus aethiopicus) to the domestic pigs (Sus scrofa) 
introduced by European colonists, causing a disease with high 
mortality [175]. In pig populations, this virus is highly contagious and 
can be easily transmitted to healthy swines from diseased or carrier 
pigs, by biological vectors (e.g. ticks) or by the ingestion of 
contaminated pig products. Unlike domestic swine, wild natural hosts 
(the warthog, the bushpig (Potamochoerus porcus) and the giant forest 
hogs (Hylochoerus spp.)) infected with ASFV are generally 
asymptomatic with low viraemia titers, reflecting the long term host-
pathogen co-evolution. These species are thought to be natural 
reservoirs of the disease in Africa. This virus also infects different 
species of soft ticks (Ornithodorus mobata and O. erraticus), where it 
can persist for long periods of time [176,177]. The asymptomatic wild 
suids and the transmission among ticks allows a sylvatic cycle that can 
be maintained indefinitively in Africa [178]. 
African swine fever is an exceptionally serious disease of domestic 
pigs, with severe sanitary and socio-economical consequences. The 
lack of a vaccine or an effective treatment makes it an expensive 
disease to eradicate. Control is based on laboratory diagnosis and 
the enforcement of strict sanitary measures that involve elimination 
of all infected and susceptible animals. All these factors translate into 
a significant impact on the national and international trade of pigs 
and pig products, and therefore the World Animal Health 
Organisation (previously called l'Office International des Épizooties 
(OIE)) listed ASF as a notifiable disease [179]. 
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Five different epidemiological scenarios regarding ASF spreading 
and endemicity have been identified and described. The most 
ancient scenario occurs is eastern and southern African countries, 
where the disease is maintained by a sylvatic cycle where wild suids 
and soft ticks (O. mobata) act as ASFV reservoirs. Domestic pigs 
contract the disease mainly by the ingestion of tissues from acute-
infected warthogs or bites from infected ticks. However, in other 
situations, transmission may occur through direct contact between 
domestic pigs or indirect contact between pigs and pork products, 
without apparent involvement of soft ticks. Understanding the different 
epidemiological scenarios and the characteristics of the disease is 
critical for developing successful contingency and eradication plans in 
affected areas [180]. 
Since its first appearance, in 1921, the disease remained confined 
to Africa until it was introduced in Portugal in 1957, causing a 
hyperacute disease with 100% mortality. Until the 1990s, several 
ASFV outbreaks where reported in European countries. Except for 
Sardinia (Italy), where the disease is endemic, all these countries 
managed to eradicate ASF. During the late 1970s, ASFV outbreaks 
were reported in some Caribbean islands, including Cuba and the 
Dominican Republic. The disease was successfully eradicated by 
depopulation [178].  
At the beginning of 2007, the Caucasus region (Georgia) was 
affected and ASF has since spread to the neighbouring countries of 
Armenia, Azerbaijan and Russia. The genetic characterization of all 
ASFV isolates found in the Caucasus region and Russian Federation 
suggests that only one virus arrived in the area in 2007 and 
subsequently spread. This initial ASF virus is closely related to isolates 
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typically found in Mozambique and Madagascar [180,181]. Since the 
introduction of ASFV in this region, more than 270 outbreaks have 
been reported to the OIE. The situation is currently out of control, with 
devastating consequences for pig industry and Russian economy. 
There is a considerable risk of introduction of the disease in European 
countries, since some of the outbreaks occurred very near the EU 
border. Another threat to Europe comes from African countries. Major 
outbreaks of ASFV in Africa are regularly reported to the OIE, and 
there is an increasing commercial trade between countries.  
1.5.1. Virus structure and genome organization 
African swine fever is a complex large icosahedral and enveloped 
double-stranded DNA virus. Unique characteristics of its structure and 
genomic organization led to its inclusion as the only member of the 
family Asfarviridae. It is the only known DNA virus to be an arbovirus, 
infecting soft ticks of the Ornithodoros genus.  
Virions have a complex multi-layered structure, composed by a 30nm 
nucleoid (forming the nucleoprotein system, composed by the viral 
genome and different enzymes required for replication), surrounded by 
an 80 nm core shell, a first lipid layer (inner envelope) and a 170-190 
nm icosahedral capsid. The extracellular virions acquire an external 
membrane during the budding through the cellular plasma membrane 
[182]. 
The ASFV genome varies in length between 170 and 190 kb, 
containing terminal crosslinks and inverted terminal repeats. The 
variation in the genome length between different virus isolates is due 
to gain or loss of sequences in the left and right ends of the genome 
[183].  
Chapter 1 
64 
This virus contains a number of open reading frames, ranging from 
160 to 175, depending on the isolate. Of these, 110 are present as a 
single copy on the genomes of all isolates. The other ORFs belong to 
six different multigene families (MGF100, MGF110, MGF300, 
MGF360, MGF530 and P22 family) located near genome termini. The 
organization of these gene families suggests that they have evolved by 
a process of gene duplication and sequence divergence. Hence, the 
existence of multiple copies of several MGFs might give a selective 
advantage to the virus, representing a mechanism of virus immune 
evasion. In particular, the Vero adapted isolate BA71V and the low 
pathogenic isolates OURT88/3 and NH/P68 have a deletion in the 
same region of the genome, which encodes 6 copies of MGF360 and 1 
or 2 copies of MGF530 [178]. Of the conserved ORFs, 39 encode 
proteins of known function, 42 contain motifs homologous to other 
proteins and 28 are of unknown function. Up to now, 17 ORFs have 
been identified as coding for structural proteins. As ASFV replicates in 
the cytoplasm, genes for enzymes and factors required for gene 
transcription and DNA replication are also included in the virus 
genome. There are many virus proteins that are non-essential for virus 
replication and are involved in interactions with the host, thus 
representing important factors for virus survival and transmission [178]. 
1.5.2. Pathogenesis and host immune response 
There are different ASFV isolates, which share common biological 
features, and the pathogenesis of the disease may range from rapidly 
lethal to very attenuated and chronic disease [184]. 
Macrophages and the monocyte lineage are the cells primarily infected 
by ASFV, and there is some evidence that endothelial cells can also 
be infected later in the infection [185]. The acute disease is 
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characterized by massive apoptosis of lymphocytes and haemorrhagic 
pathology with extensive vascular damage, probably due to molecules 
released from the infected macrophages, although infected endothelial 
cells may also contribute to the pathogenesis [178,185]. The extent of 
lymphocyte apoptosis correlates with the level of ASFV replication and 
the virulence of the virus isolate [186]. In the bushpig, there are lower 
levels of apoptosis and absence of clinical signs together with a 
containment of virus replication [187]. Therefore the level of 
lymphocyte apoptosis may be dependent on the amount of secreted 
cytokines, which in turn depends on the number of infected 
macrophages [186]. In agreement with this hypothesis is the fact that 
increased levels of TNF-α, IL-1α, IL-1β and IL-6 were observed in sera 
from experimentally infected pigs, coinciding with the onset of clinical 
symptoms [188] and also an increased number of macrophages 
expressing these cytokines in areas of lymphocyte apoptosis [189]. On 
the other hand, another study revealed that the transcriptional levels of 
TNFα and IL-6 were increased in macrophages infected with the low 
virulence NH/P68 isolate compared to the highly virulent L60 isolate 
[190].  
During chronic infections, a characteristic feature of ASF is the 
development of a clear hypergammaglobulinaemia [191]. In fact, 
hypergammaglobulinaemia was found to be associated with the 
development of clinical signs after infection with the NH/P68 isolate 
[184]. 
Activation of the B cells as a necessary prelude to 
hypergammaglobulinaemia may result from a direct mitogenic property 
of the virus and also through factors secreted by infected 
macrophages [192]. Indeed, ASFV infected macrophages produce a 
protein, p36, which induces an increase in serum levels of two major 
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B-cell stimulatory cytokines: IL-4 and IL-10 when inoculated in mice 
[193]. Activation of the B cells is followed by extensive apoptosis of the 
same cells, and given that apoptosis of T cells precede that of B cells 
[186] it was suggested that B lymphocytes enter apoptosis because 
they are activated in the absence of a rescue signal (e.g. CD40L) 
provided by T cells [192]. 
The immune response mounted after ASFV infection is highly complex 
and virus elimination probably requires both humoral and cellular 
immunity. Recovered animals are usually resistant to challenge with 
homologous virus isolates, providing a model to study the mechanisms 
of protective immunity [184]. Several experiments have shown that the 
passive transfer of antibodies from recovered, or convalescent pigs, 
delays the onset of clinical signs, reduces viraemia and increases 
survival rates after challenge with a virulent isolate [194,195]. In a later 
study, 85% of the animals receiving anti-ASFV antibodies survived 
infection with the E75 virulent isolate [196]. These results suggest that 
antibody-mediated immunity is not by itself sufficient, but may play a 
role in protection. However, the generation of neutralizing antibodies 
during ASFV infections remains controversial. Three different ASFV 
neutralizing proteins have been proposed: antibodies against p72 and 
p54 inhibit virus attachment, while antibodies to p30 inhibit virus 
internalization [197,198]. However, in later studies it was shown that 
the immunization against p54 and p30 only conferred protection to 
50% of tested animals[199], and the only detected effects were a delay 
in onset of clinical disease and reduction of viraemia [200]. 
Several studies were done to explore the role of cell mediated immune 
responses during ASFV infection. After experimental infection with the 
non-haemadsorbing, non-fatal NH/P68 isolate, a positive correlation 
was observed between the stimulation of NK activity and the absence 
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of clinical symptoms, suggesting that NK cells play an important role in 
this model of protective immunity [184]. In addition to NK cells as 
mediators of protection, the generation of ASFV specific cytotoxic 
lymphocytes was demonstrated in the NH/P68 model [201,202]. 
However, the immunization with a recombinant protein expected to 
stimulate ASFV-specific CTL activity, failed to protect against the 
infection with the highly virulent L60 isolate [203]. On the other hand, 
established immunity of pigs was abrogated by blocking CD8+ T cells 
in vivo with anti-CD8 monoclonal antibody, suggesting that CD8+ T cell 
mediated immunity does play a role in protection [202]. 
Finally, both IFN-α and IFN- were shown to substantially reduce virus 
replication in swine monocytes and macrophages [204], and the 
cooperative action of both was able to cure lytically and persistently 
infected cells [205]. Although these results were interpreted as 
evidence for a role of the IFN response in protection, the IFN treatment 
was done only after 18h post-infection, a time at which the anti-viral 
state was already established. Importantly for the work described in 
this thesis, virus replication of ASFV in IFN-treated cells has been 
reported, an experiment which suggests that ASFV is able to subvert 
the Interferon response [205]. 
In conclusion, the immune response against ASFV is mediated by 
multiple mechanisms of both innate and acquired immune responses 
and another level of complexity is added with the ability of the virus to 
modulate these immune responses. 
1.5.3. Modulation of host defence response 
Large DNA viruses encode many proteins involved in the evasion of 
host immune responses. ASFV, contains approximately 90 proteins 
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predicted to be involved in virus replication, therefore, the remaining 70 
to 85 must include proteins evolved for host evasion [178]. 
As ASFV replicates in macrophages the virus may interfere with both 
the initial innate and later acquired immune response to infection by 
modulation of macrophage immunoregulatory proteins and hence 
macrophage function. Indeed, one of the major strategies used by the 
virus is the manipulation of different signalling pathways that lead to 
the induction of cytokine transcription [178]. 
One of the first evasion molecules described is the A238L protein with 
two dual functions: inhibition of NF-кB [206] and NFAT activities [207]. 
The A238L protein contains ankyrin repeats similar to those present in 
the IкB inhibitor of the host NF-кB transcription factor in the centre of 
the protein [183]. In the cytoplasm of normal cells, IкB binds to the NF-
кB transcription factor retaining it in an inactive state. Upon stimuli, 
such as TNF-α or IL-1, the IкB is phosphorylated by IKK, and 
subsequently degraded by the proteasome, thus liberating NF-кB 
which translocates and binds to specific DNA sequences in the 
nucleus. The mechanism suggested for the inhibition of NF-кB 
mediated transcription of proinflammatory cytokines, chemokines, 
adhesion molecules and anti-apoptotic genes is through direct binding 
to NF-кB and thus preventing its binding to DNA [206,208,209]. The 
other function assigned to the A238L protein is the inhibition of 
calcineurin phosphatase activity and consequent inhibition of 
calcineurin activated pathways such as the activation of the NFAT 
transcription factor [207]. In summary, A238L is predicted to act as a 
potent immunomodulatory protein with diverse inhibitory effects on the 
transcription of cellular genes regulated by NF-кB and NFAT [178]. In 
addition, the A238L protein also inhibits COX-2 expression [210], IL-8 
induction and TNF-α expression [206,211] , and expression of iNOS 
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[212]. Several of these functions are inhibited by targeting the p300 
coactivator of transcription [211,213]. 
A number of other proteins predicted to inhibit host signalling pathways 
are encoded in the ASFV genome. The ASFV j4R protein binds to the 
α-chain of nascent polypeptide-associated complex (α-NAC) [214]. 
The α-NAC protein plays roles in both translation and transcription, 
more specifically as a co-activator of c-Jun and is also a binding 
partner of Fas associated death domain (FADD). The interaction 
between J4R and α-NAC is therefore predicted to modulate the 
transcriptional activation of c-Jun and TNF-α induced apoptosis [178]. 
The ubiquitin-conjugating enzyme, UBCv, of ASFV has been shown to 
interact with a host nuclear protein SMCy and is involved in 
transcriptional regulation [215]. The ASFV DP71L protein is similar to 
the neurovirulence-associated protein (ICP34.5) from herpes simplex 
virus (HSV). Recently, comparisons between the known function of 
ICP34.5 and the unknown function of DP71L, have demonstrated that 
like ICP34.5, DP71L is required for the activation of PP1 phosphatase 
activity that is induced by ASFV infection [216]. 
Inhibition of apoptosis is a common host evasion strategy used by 
viruses and ASFV has three proteins with this activity. The first protein, 
A224L, is similar to the inhibitor of apoptosis protein (IAP) family of 
apoptosis inhibitors, and has been shown to interact with caspase-3 
and to promote cell survival [217]. The second, the ASFV bcl-2 
homologue A179L, has been recently demonstrated to bind to a 
specific Bcl-2 proapoptotic protein and in this way block the induction 
of apoptosis [218]. Finally, the third protein, EP153R, is a C-type lectin 
homologue and the first to be described having anti-apoptotic 
properties, and might also be involved in the control of the activity of 
cellular p53 [219]. 
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Another mechanism used by ASFV to modulate host responses is to 
express transmembrane proteins with similarity to host cell adhesion 
proteins. The characteristic haemadsorption observed in ASFV 
infected cells is due to the interaction between a CD2 like protein 
encoded by the virus (CD2v or EP402R) and its ligand expressed on 
the surface of red blood cells (RBC). This virus protein is also 
incorporated into the virus particle and mediates attachment of the 
virus to RBC [220]. 
ASFV infection leads to the disruption of the trans-Golgi network with a 
consequently inhibition of MHC class I surface expression [221], thus 
providing a possible mechanism for evasion of CTL responses. 
The modulation of the interferon response by ASFV has been 
described in the comparison of transcriptional profiles of macrophage 
cells infected with wild type virus and a deletion mutant virus lacking 
six MGF360 and two MGF530 genes. Microarray analysis revealed an 
up-regulation of several interferon stimulated genes (ISGs) mRNAs 
when the cells were infected with this mutant virus and in comparison 
with wild type, suggesting that MGF360 and/or MGF530 genes are 
involved in the inhibition of IFN response. Indeed, in contrast with the 
wild type virus infection, the mutant virus infected culture supernatant 
contained significant amounts of IFN-α [222]. Notably, in porcine aortic 
endothelial infected cells, the IFN-α induced MHC class I expression is 
down-regulated [185]. 
Recently, the ASFV ORF I329L was described as a host evasion gene 
capable of inhibiting the induction of type I IFN by activation of the 
TLR3 pathway. Although the mechanism of action was not elucidated, 
the data suggest a role in inhibiting the TRIF molecule, a critical 
adaptor protein of the TLR3 pathway [223]. This non-essential gene 
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was identified through the combination of bioinformatic analysis and 
functional assays, an indication of the promising potential of such tools 
in the identification and characterization of viral host evasion genes. 
In order to screen a wide-range of host genes that might be 
differentially regulated by viruses, the microarray transcriptional profile 
analysis is a powerful tool. Using this technique, changes in 
macrophage gene transcription after infection with a highly virulent 
ASFV isolate, has revealed increased gene expression at 4 hours post 
infection, followed by a decrease in expression comparable to the 
mock infected cells at 16 hours post infection. The genes identified in 
this pattern of expression, included proinflammatory cytokines such as 
IL-6, TNF-α and IFN-β, chemokines and adhesion molecules. These 
results suggest that, indeed, ASFV encode proteins that efficiently 
circumvent the early immune response mounted by the host cell 
against the virus [224]. 
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1.6. Aim of the project  
The work presented in this thesis focuses on identifying and 
characterizing anti-interferon (IFN) strategies evolved by the African 
Swine Fever Virus (ASFV), the causal agent of a fatal haemorrhagic 
disease of domestic pigs, characterized by the absence of clinical 
symptoms in its natural hosts, the bushpig and the warthog.  
The ASFV is a large double-stranded DNA virus and is the only 
member of the family Asfarviridae. Although the virus replicates 
primarily in macrophages in vivo and in macrophages and endothelial 
cells in vitro, surprisingly no individual virus gene inhibiting IFN 
responses has been described. Large DNA viruses typically have 
multiple genes/strategies for modulation of host cell biology and 
immune responses. While many viral genes evolved for host 
manipulation will have been acquired from the host and function to 
mimic or block normal cellular functions, the existence of functional 
evasion molecules without structurally homologous cellular 
counterparts is now clear, and the possibility of non-homologous ASFV 
genes evolved for the inhibition of IFN responses was pursued. Two 
such genes (ORF MGF360-18R and ORF I329L) were selected and 
their intracellular targets and mechanisms were investigated. 
In a previous study performed in this laboratory, several ASFV genes 
with unassigned functions were tested for their capability to inhibit the 
expression of IFN-β, including six MGF360 and two MGF530 genes 
absent in a deletion mutant virus that fails to inhibit type I IFN secretion 
following macrophage infection. The ASFV ORF MGF360-18R, a 
member of MGF360, was selected as the focus for this work for its 
ability to inhibit both IFN-β induction and the impact of type I and type 
II IFN. A screening through the available genomic sequences of 
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different isolates of the ASFV revealed that the full length MGF360-
18R gene in pathogenic ASFV isolates is partially deleted in the non-
pathogenic (OURT88-3) and tissue culture-adapted (Ba71V) strains. 
These two distinct variants of the non-conserved ORF MGF360-18R 
were investigated in detail in order to define the mechanisms by which 
this viral gene evolved for both the manipulation of the IFN response 
and the modulation of IFN-mediated signalling. The mechanisms of 
action and potential targets for both MGF360-18R variants are 
presented. 
Recently, the conserved ASFV ORF I329L was described as being 
able to impair the cellular responses controlled by TLR3 that lead to 
both IFN-β secretion and NF-κB activation. Bioinformatics analysis of 
the putative intracellular domain of I329L, at first negative, revealed a 
short possible region of homology with BOX1 and BOX2 of TLR3-TIR 
domain. Although both the described homology and the presented 
results pointed out TRIF as a possible target of this viral host 
modulation gene, the precise mechanism of inhibition remains to be 
elucidated. Therefore the aim of this work is to characterize the 
mechanism by which ORF I329L inhibits the IFN response, defining its 
target and the I329L domains involved in this inhibition. 
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2.  
2.1. Summary 
The African swine fever virus (ASFV) is a large double-stranded DNA 
virus that replicates primarily in macrophages in vivo and in 
macrophages and endothelial cells in vitro. It is the only member of the 
family Asfarviridae, and is characterised by its ability to interfere with 
signalling pathways controlling the transcription of cytokines, including 
interferons. As the Interferon system plays a major role as an early 
host defence system against virus infections, ASFV must have evolved 
a number of counter strategies to antagonise this response.  
The work described in this thesis directly demonstrates an I329L-TLR3 
interaction and further defines the mechanism of I329L inhibition of the 
IFN response. 
Many viral genes evolved for host manipulation are likely to have been 
acquired from the host and function to mimic or block normal cellular 
functions. Recently, the conserved ASFV ORF I329L was reported as 
being able to impair the cellular responses controlled by TLR3 that 
lead to both IFN-β secretion and NF-κB activation. Interestingly, a 
detectable, but very low, homology with BOX1 and BOX2 of TLR3 
intracellular TIR domain was observed, raising the possibility that 
I329L might inhibit activation of IFN-β through interaction with TRIF [1]. 
Formal biochemical proof of an interaction between the I329L protein 
and TRIF was obtained. In addition, to further characterize the 
modulation of the type I IFN response by I329L, truncation mutants 
lacking either the ectodomain or the intracellular domain (TM/IC and 
EC/TM, respectively) were designed and tested by luciferase reporter 
assays for their impact on the TLR3 pathway. Importantly, expression 
of the intracellular domain alone of I329L inhibited induction of IFN-β 
and NF-кB activation by ectopically expressed TRIF. This, and the fact 
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that the extracellular domain of I329L inhibited Poly (I:C) mediated 
activation of IFN-β, but not activation via ectopically expressed TRIF, 
demonstrates that I329L inhibits dsRNA activation via its extracellular 
domain, perhaps through formation of a non-signalling I329L-TLR3 
heterodimer, and may also disrupt signal transduction through the 
impact of its intracellular domain on TRIF. 
Finally, evidence indicating proteolytic processing of I329L was 
obtained by demonstration of such processing as a consequence of 
viral infection or activation of TLR3 signalling. Consistent with the 
requirement of this processing for the inhibitory activity of I329L, a 
mutant I329L lacking a cathepsin L sensitive site continued to inhibit 
Poly (I:C)-mediated activation, but not activation through ectopically 
expressed TRIF. 
2.2. Introduction 
Upon recognition of a viral infection, cells activate different signal 
transduction pathways that culminate in the expression of a diverse 
array of cytokines, which act in both an autocrine and paracrine 
manner to induce the establishment of an antiviral state within the 
infected and neighbouring cells [2,3]. The interferons (IFNs) are a 
group of secreted cytokines, and compose a system particularly 
important for the regulation of the antiviral immune response, inducing 
the expression of proteins that interfere with viral processes, thus 
blocking viral replication [4,5]. 
The first potent IFN inducer to be identified was double-stranded RNA 
(dsRNA), a molecular pattern associated with viral infection, because it 
is produced by most viruses at some point in their replication [6]. 
Distinct pathogen-associated molecular patterns (PAMPs), uniquely 
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found in microbes (e.g., viral glycoproteins, viral RNA, bacterial 
endotoxin, bacterial flagella, CpG motifs, etc.) are recognized by 
specialized pattern recognition receptors (PRRs), such as membrane-
bound Toll like receptors (TLRs) or by cytoplasmic receptors (the 
retinoic acid-inducible gene (RIG)-I, the melanoma differentiation 
associated antigen 5 (MDA5), and also the DNA-dependent activator 
of IFN-regulatory factor (DAI)), triggering the release of type I IFN [7,8]. 
The TLR and the cytosolic pathways both converge on the activation of 
the downstream kinases and common transcription factors necessary 
for the induction of type I IFN. Induction of the IFN-β gene requires the 
activation of two families of transcription factors: the family of Nuclear 
Factors кB (NF-кB) and the family of Interferon Regulatory Factors 
(IRFs). Together with a c-jun/ATF-2 heterodimer, IRF-3, IRF-7 and NF-
кB form the enhanceosome, a complex that binds to the IFN-β 
promoter, inducing gene expression [9]. Several studies revealed that 
binding of IRF-3 and/or IRF-7 is indispensable for induction, but 
activation of NF-кB and c-jun/ATF-2 may not be essential [3].  
The Toll-like receptors are a family of PRRs that play central roles in 
innate immune defence against infection by binding to microbial 
molecules. All TLR family proteins consist of an intracellular signalling 
domain, a single transmembrane TM domain and an extracellular 
ligand binding domain with N-terminal leucine-rich repeats (LRR) 
motifs. Each TLR has a distinct LRR structure with specific adaptations 
that allow for improved interaction with either its respective ligand or a 
coreceptor-ligand complex. Ligand-mediated activation of the TLR 
receptors can lead to the formation of homo and sometimes 
heterodimers. The dimerization of the extracellular domains results in 
activation of the intracellular domain which contains an intracellular 
Toll/IL-1R (TIR) motif, important in protein-protein interactions. This 
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motif is also present in the signalling adaptors that are recruited to the 
ligand-activated TLR TIR domains, forming the first step in the 
signalling cascade leading to the expression of multiple genes involved 
in innate and adaptive immunity, including type I IFN [10]. Recently, a 
requirement for proteolytic processing of TLRs after ligand binding has 
been described [11]. 
Compartmentalization is an important feature of these membrane 
bound receptors that limits access to self molecules, preventing 
inappropriate activation of the downstream signalling pathways. TLRs 
involved in the recognition of microbial membrane components, are 
located on the cell surface, while those recognizing microbial nucleic 
acids are mainly located within endolysosomal compartments (e.g., 
TLR3). TLR4, normally present at the surface can also enter the 
endocytic pathway following ligand-mediated activation. In each case, 
the TIR motif resides in the cell cytoplasm while the LRR domain is 
positioned to detect either extracellular PAMPs (outside of the cell) or 
PAMPs acquired during sampling (within the endosomes). Trafficking 
of nucleotide-sensing TLRs to endolysosomal compartments by unc-
93 homolog B1 (UNC93B1) protein and proteolytic regulation of some 
TLRs (TLR7 and TLR9) are other strategies used to further control 
receptor activation [12,13,14]. 
Individual TLRs trigger different signal transduction pathways by 
engaging different adaptors, through interaction between the 
corresponding TIR domains. The particular signalling adaptor used 
determines which signalling pathway will be activated. The TIR-
containing adaptor MyD88 induces a pro-inflammatory response 
dependent on the activation of NF-кB and mitogen-activated protein 
(MAP) kinase, whereas TIR domain-containing adaptor protein 
inducing IFN-β (TRIF) is responsible for activation of IRF-3, IRF-7 and 
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NF-кB, culminating in the induction of type I IFN and inflammatory 
cytokines [15].  
The molecular signature of most viruses is double-stranded RNA 
(dsRNA), produced either as an intermediate of the viral replication 
cycle (e.g., for dsDNA viruses, such as ASFV) or as part of the viral 
RNA genome. Viral dsRNA is recognized by the Toll-like receptor 3 
(TLR3), inducing a signalling mechanism solely through TRIF, and not 
MyD88. Activated TRIF associates with TRAF3 and TRAF6 and 
subsequently with the noncanonical kinases TBK-1 and IKKɛ (Fig.1.2) 
which phosphorylate IRF-3 and IRF-7, leading to its dimerization and 
nuclear translocation to bind the promoter of type I IFN. TRIF also 
mediates the activation of NF-кB and activating protein 1 (AP-1) 
through the complex of kinases IKK-α/β/. These two transcription 
factors translocate into the nucleus, together with IRF-3 and IRF-7, 
and bind to the PRDI-IV positive regulatory elements of the IFN-β 
enhancer region [16]. TLR3-mediated signalling also leads to 
phosphorylation of specific tyrosines and the recruitment of 
phosphatiylinositol 3-kinase (PI3K), essential for full activation of IRF-3 
[17,18]. Virus infected cells mainly depend on TLR3, TLR7/TLR8 and 
TLR9 to induce the expression of type I IFN, following detection of viral 
nucleic acids. However, TLR4 is also capable of inducing type I IFN by 
the recognition of non-nucleic acid ligands, such as lipopolysaccharide 
(LPS). Upon LPS-binding, TLR4 initiates signalling transduction 
pathways through both MyD88 and TRIF adaptors. Signalling through 
MyD88 requires TRAM [19] and culminates in the activation of NF-кB, 
inducing an early pro-inflammatory response. TLR4 is then internalized 
into the endosome [20], where it requires the TIR domain-containing 
adaptor protein (TIRAP) to bind TRIF [21]. Through this pathway, 
TLR4 induces both a late pro-inflammatory response (NF-кB 
dependent) and type I IFN expression. 
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Recently, the conserved ASFV ORF I329L was reported as being able 
to impair the cellular responses controlled by TLR3 that lead to both 
IFN-β secretion and NF-κB activation. Bioinformatic analysis predicted 
ORF I329L to be a type I transmembrane protein containing 
extracellular putative leucine-rich repeats (LRRs) and an intracellular 
TIR domain homologue. The precise mechanism for the inhibition of 
TLR3 signalling remains to be elucidated but, based on the results, the 
authors suggested TRIF as a potential target for I329L inhibitory 
activity [1]. However, a modelling exercise on this viral protein 
supported the idea that pI329L may function as a TLR3 decoy, 
suggesting that the viral protein could hinder TLR3 dimerization, and in 
doing so, inhibit the downstream signalling pathway [22]. 
The work presented here is a more profound characterization of the 
mechanism of action of ASFV ORF I329L. Truncation mutants of I329L 
lacking either the ectodomain or the intracellular domain (TM/IC and 
EC/TM, respectively) were designed and tested by luciferase reporter 
assays for their impact on the TLR3 pathway, revealing a distinct 
inhibitory role for each of these domains. The TLR3 adaptor protein 
TRIF was identified as being one of the targets for this viral protein, but 
an additional role in the direct inhibition of TLR3 dimerization or TLR3-
dsRNA binding is also plausible. The proteolytic processing of pI329L 
is described and its relation to the full inhibitory potential of this viral 
protein is discussed. 
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2.3. Materials and methods 
2.3.1. Cell culture 
Human embryonic kidney (HEK)-293T and Vero cell lines were 
maintained in Dulbecco´s modified Eagle´s medium (DMEM) (Gibco) 
supplemented with 100U/ml penicillin G sodium /100μg/ml 
streptomycin sulfate (Gibco), 2mM L-Glutamine (Gibco) and 10% (v/v) 
heat-inactivated fetal bovine serum (FBS) (Gibco). The HEK-293-
hTLR3 stable cell line, kindly provided by Dr. A. Bowie, was 
maintained in DMEM supplemented with 100U/ml penicillin G sodium, 
100μg/ml streptomycin sulphate, 10μg/ml blasticidin (Invivogen), 2mM 
L-Glutamine and 10% (v/v) heat-inactivated FBS. 
2.3.2. Plasmids 
The ASFV I329L full length ORF (Gene ID: 1488904) was amplified by 
PCR from BA71V isolate genomic DNA and cloned into the pcDNA3 
plasmid, in frame with either a carboxyl-terminal or an amino-terminal 
influenza haemaglutinin (HA) tag. Using QuikChange II Site-Directed 
Mutagenesis kit (Stratagene), a point mutation leading to a nucleotide 
substitution (G108A) in the I329L coding region was performed, 
creating the mutant pcDNA3-I329Lmut-HA plasmid, coding for 
pI329L.G108A. 
Truncation mutants of I329L containing the putative ecto- and 
intracellular domains together with the putative transmembrane 
domain (EC/TM and TM/IC, respectively) were designed using specific 
primers to amplify the designated regions by PCR from BA71V isolate 
genomic DNA. The fragments were then cloned into the pcDNA3 
plasmid, in frame with an amino-terminal HA tag. 
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An alternative expression plasmid for the I329L ORF was constructed 
replacing the human cytomegalovirus immediate early promoter 
sequence of the pcDNA3 plasmid with a 282 bp sequence immediately 
upstream the I329L initiation codon. The I329L full length ORF was 
cloned into this plasmid, with an amino-terminal HA tag, being 
expressed under the control of its own promoter (pcDNA3-promI329L-
I329L-HA). 
For the construction of a recombinant lentivirus vector (pHR-CMV-HA-
I329L-eGFP), the I329L gene was excised from pcDNA3, together with 
the carboxy-terminal HA tag, and cloned into the vector pHR-CMV-
eGFP (kindly provided by Dr. Y. Ikeda), upstream of an internal 
ribosome entry site (IRES)-driven enhanced green fluorescent protein 
gene (eGFP). The same procedure was used to clone the TM/IC 
truncation mutant. 
The luciferase reporter plasmids containing the sequences of the IFN-
β promoter [pIF∆(-125/+72)lucter], the NF-κB binding site of the IFN-β 
promoter [p(PRD2)5tk∆(-39)lucter], as well as the expression vector for 
TRIF, RIG-I and MDA-5 were gifts of Dr. S. Goodbourn. The 
expression plasmid for MyD88 was provided by Dr. A. Bowie. The 
expression plasmid containing the human TLR3 fused with the yellow 
fluorescent protein (YFP) was provided by Dr. R. Medhzitov. 
The pCMVβ plasmid contains a β-galactosidase gene under the 
control of human cytomegalovirus immediate early promoter, and 
serves as an internal control for culture to culture variations in 
transfection efficiency. 
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2.3.3. Lentivirus production 
Lentivirus was produced by transient co-transfection of HEK-293T cells 
with the packaging and envelope plasmid together with the empty 
pHR-CMV-eGFP plasmid or the recombinant I329L and TM/IC 
plasmids at a weight ratio of 1:1:3, respectively, using FuGENE 6 
(Roche) according to the manufacturer’s instructions. Supernatants 
containing the lentivirus were collected at 48h and 72h post-
transfection, clarified by filtration, and lentivirus were collected by 
ultracentrifugation (125,000xg, 3h, 4°C). Virus pellets were 
resuspended in fresh DMEM, and frozen at −80°C. 
2.3.4. Lentivirus transduction of HEK-293T cells 
The HEK-I329L, HEK-TM/IC and HEK-eGFP stable cell lines were 
produced by lentivirus infection of HEK-293T cells with either one of 
the recombinant plasmids or the empty pHR-CMV-eGFP, respectively, 
using a multiplicity of infection (MOI) of 10 in DMEM. Confirmation of 
lentivirus infection was done by detecting eGFP-positive cells by 
optical microscopy at 48 h post-infection (p.i.), and protein expression 
was confirmed by Western blot. 
2.3.5. Luciferase reporter gene assay 
HEK-293T cells (6x104 cells/well, in a 24 well plate) were co-
transfected with 100ng of the indicated luciferase reporter plasmid, 
25ng of the β-galactosidase internal control plasmid (pCMVβ) and 
300ng of either pcDNA3-I329L-HA or the empty pcDNA3HA, according 
to the Lipofectamine 2000 (Invitrogen) protocol. Forty-eight hours post-
transfection, the cells were either stimulated with 35μg/ml Poly(I:C) 
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(Amersham Biosciences) for five hours, or left untreated. After the 
treatment, the cells were lysed. 
In an alternative protocol, the cells were co-transfected with 100ng of 
the indicated luciferase reporter plasmid, 25ng of pCMVβ, the 
indicated amounts of plasmids expressing the different components of 
the IFN-β induction pathway and increasing amounts of the pcDNA3- 
I329L-HA plasmid. The quantity of DNA in each transfection was kept 
constant by supplementation with empty pcDNA3HA. Forty eight hours 
post-transfection the cells were lysed. The luciferase activity was 
measured using the luciferase assay system (Promega) according to 
the manufacturer`s protocol. The β-galactosidase activity was 
measured using the Galacton-Plus kit from Tropix (Bedford, MA). The 
luciferase activity was normalized relatively to the β-galactosidase 
activity of each sample, as to correct transfection efficiency variations 
between different cells. 
2.3.6. Enzyme-linked Immunoabsorbent Assay (ELISA) 
HEK-293T cells (6x104 cells/well, in a 24 well plate) were transfected 
with 300ng of the pcDNA3-I329L-HA, the pcDNA3-I329Lmut -HA or the 
non-recombinant pcDNA3HA plasmid, according to the Lipofectamine 
2000 (Invitrogen) protocol. Cells were stimulated by co-transfection of 
20ng of TRIF expression plasmid. Forty-eight hours post-transfection, 
the medium of each well was collected and centrifuged for 15 minutes 
at 1000xg. Quantitative determination of human IFN-β concentration in 
the supernatants was performed using the Human Interferon β ELISA 
Kit (PBL Interferon Source), according to the manufacturers’ 
instructions. Absorbance at 450nm was measured using a BioRad 
ELISA reader (BioRad) and concentration of IFN-β was determined by 
comparison to a standard curve. 
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2.3.7. Western blot 
HEK-293T cells (3x105 cells/well, in a 6-well plate) were transfected 
with 3μg of either pcDNA3-promI329L-I329L-HA or the non-recombinant 
pcDNA3HA, and 500ng of TLR3 expression plasmid, according to the 
Lipofectamine 2000 (Invitrogen) protocol. Forty-eight hours post-
transfection, the cells were either stimulated with 100μg/ml Poly(I:C) 
(Amersham Biosciences), during the indicated amounts of time, or left 
untreated. In a second alternative protocol, cells were stimulated by 
co-transfection of 250ng of TRIF expressing plasmid.  
In other protocol, Vero cells were infected with ASFV Ba71V strain at a 
MOI of 3 or mock infected. After incubation for one hour to allow virus 
adsorption, cells were incubated in culture medium for the indicated 
times. 
Cells were harvested and lysed in lysis buffer (15 mM Tris-HCl, 
120mM NaCl, 25mM KCl, 2mM EDTA, 2mM EGTA, 0.1mM DTT and 
1%Triton X-100) containing a protease inhibitor cocktail (Sigma). Cell 
lysates were resolved by sodium dodecyl sulphate-polyacrilamide gel 
electrophoresis (SDS-PAGE) and proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (GE Healthcare). 
Membranes were blocked with 5% non-fat milk for one hour at room 
temperature and probed with the following antibodies: rabbit serum 
anti-I329L (provided by Vivian de Oliveira), rat anti-HA-horseradish 
peroxidase (HRP) conjugated (high affinity) (Roche), and rat-anti-β-
actin-HRP conjugated (Sigma) as loading control. Horseradish 
peroxidase-conjugated goat anti-rabbit secondary antibody was 
purchased from Invitrogen. Membranes were developed by enhanced 
chemiluminescence detection according to the manufacturer’s 
instructions (SuperSignal West Pico Chemiluminescent Substrate, 
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Thermo Scientific or Luminata Forte Western HRP Substrate, 
Millipore). 
2.3.8. Immunoprecipitation 
HEK-eGFP, HEK-I329L and HEK-TM/IC (5x105 cells/plate, in a 60 mm 
Ø plate) were transfected with 1μg of TLR3 expression plasmid, 
according to the Lipofectamine 2000 (Invitrogen) protocol. Forty-eight 
hours post-transfection, the cells were either stimulated with 100μg/ml 
Poly (I:C) (Amersham Biosciences) for 15 minutes, or left untreated. 
Cells were then harvested and lysed in lysis buffer (15 mM TrisHCl, pH 
7.4, 120 mM NaCl, 25 mM KCl, 2mM EDTA, 2mM EGTA, 0.1mM DTT 
and 1% Triton X-100) containing a protease inhibitor cocktail (Sigma). 
Immunoprecipitations were performed with Dynabeads protein A 
(Millipore), using rabbit anti-human TRIF antibody (Cell Signaling) and 
with Dynabeads protein G (Millipore), using mouse anti-HA (Santa 
Cruz). Washes were performed using commercially available lysis 
buffer (Sigma). Elution was done using 2X sample buffer. 
Immunoprecipitation eluates were resolved on a 12% SDS-PAGE gel 
and proteins were transferred to a PVDF membrane (GE Healthcare). 
Membranes were blocked with 5% non-fat milk for one hour at room 
temperature and probed with rabbit anti-human TRIF (Cell Signaling), 
mouse anti-human TLR3 (eBioscience), rat anti-HA-HRP conjugated 
(Roche) and anti-β-actin-HRP conjugated (Sigma) as a loading control 
for input samples. Horseradish peroxidase-conjugated rabbit anti-
mouse and goat anti-rabbit secondary antibodies were purchased from 
Invitrogen. 
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2.3.9. Immunofluorescence 
HEK-293T cells were seeded on glass coverslips (1.5x105) and 
transfected with pcDNA3-promI329L-I329L-HA or the non-recombinant 
pcDNA3HA. Forty-eight hours post-transfection, the cells were washed 
with phosphate buffered saline (PBS) and fixed with 4% 
paraformaldehyde for 20 minutes. The cells were washed with PBS 
and the coverslips were finally mounted in “Vectashield” (Vector 
laboratories) and examined under a fluorescence microscope. After 
washing, the cells were blocked with PBS + 0.05% Tween-20 
containing 5% normal goat serum for one hour. Early endosomes were 
detected with rabbit anti-EEA1 (Sigma), late endosomes were detected 
with rabbit anti-LAMP1 (Sigma) and TRIF expression was detected 
with rabbit anti-TRIF (Cell Signaling). To visualize I329L-HA tagged 
protein, coverslips were incubated with rat-anti HA (high affinity) 
(Roche). Coverslips were washed and incubated with the secondary 
antibodies goat anti-rabbit Alexa488-conjugated (Invitrogen) or goat 
anti-mouse Texas Red-conjugated (Molecular Probes), respectively. 
Cell nuclei were stained with DAPI. All the incubations were performed 
at room temperature. 
Confocal fluorescent images were obtained by a DeltaVision Core 
wide-field deconvolution inverted-base microscope (Applied 
Precision/Olympus), with a 100x objective. Images were analyzed by 
ImageJ 1.43u software. The term colocalization refers to the 
coincidence of green and red fluorescence, as measured by the 
confocal microscope. 
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2.3.10. Statistical Analysis 
Data were shown as mean values with standard deviations (SD). 
Differences between experimental groups were determined by a two-
tailed Student t test, using Excel software (Microsoft). 
2.4. Results 
2.4.1. The inhibition of IFN-β induction by I329L is MyD88 
independent and not through cytoplasmic sensors 
Although the ASFV ORF I329L has been described as an inhibitor of 
NF-κB activation, acting through a MyD88 independent pathway, the 
experiments performed did not test the activity of this viral gene in cells 
specifically activated by ectopic expression of MyD88. In order to 
definitively exclude this possibility, HEK-293T cells were co-transfected 
with the MyD88 expression plasmid and increasing quantities of I329L.  
A luciferase reporter plasmid containing only the NF-κB binding site of 
the IFN-β promoter, the positive regulatory domain (PRD)-II, was used. 
In the positive control, ectopic expression of MyD88 significantly 
increased the NF-κB promoter-mediated luciferase activity. As 
presented here, the expression of I329L has no effect on the activation 
of the NF-κB transcription factor by MyD88 (Fig 2.1). Therefore, the 
previously described inhibitory activity of I329L must be through a 
MyD88 independent pathway. 
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Figure 2.1 - ASFV I329L inhibition of Poly (I:C)-mediated IRF3 and NF-kB 
activation is MyD88 independent 
HEK-293T cells were co-transfected with the NF-kB binding luciferase 
reporter (PRD-II), the β-galactosidase control plasmid, 40ng of MyD88 
expression plasmid (■) and increasing amounts (200-600ng) of pcDNA3-
I329L-HA. Luciferase activity was normalized to β-galactosidase activity as a 
control for transfection efficiency. Data are expressed as means of RLU ± SD 
of triplicate well from one of three similar experiments. 
Both TLR3 and RLR signalling pathways are capable of recognizing 
dsRNA or its synthetic analogue, Poly (I:C), initiating a cascade of 
events that lead to the activation of NF-kB, IRF-3 and IRF-7, 
transcription factors necessary for the induction of IFN-β. Given that 
I329L has been described as an inhibitor of IFN-β induction in 
Poly (I:C) stimulated cells, we assessed the effect of this viral gene on 
the induction of IFN-β by ectopic expression of either RIG-I or MDA-5, 
the RLR family members involved in viral recognition and induction of 
type I IFN. 
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Figure 2.2 – ASFV I329L inhibition of Poly(I:C)-mediated IRF3 and NF-kB 
activation is independent of the RLR pathway 
HEK-293T cells were co-transfected with the IFN-β promoter luciferase 
reporter, the β-galactosidase control plasmid, 40ng of RIG-I expression 
plasmid (A) or MDA-5 expression plasmid (B) and increasing amounts (200-
600ng) of pcDNA3-I329L-HA. Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of RLU ± SD of triplicate well from one of three similar 
experiments. 
The results presented here (Fig. 2.2-A and 2.2-B) clearly demonstrate 
that I329L is not exerting its inhibitory activity over the RLR pathway. 
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2.4.2. The ASFV ORF I329L colocalizes to the early endosome 
The ASFV ORF I329L was previously described to be a surface 
membrane expression protein, also localizing to the endoplasmic 
reticulum (ER) and the Golgi complex, inside the cell [1]. However, it 
was also reported to inhibit both induction of IFN-β and NF-κB 
activation through the TLR3 pathway, a statement confirmed by the 
results depicted in Fig. 2.3. 
    
Figure 2.3 – The ASFV ORF I329L inhibits Poly (I:C) stimulated activation 
of IFN-β transcription in an NF-кB dependent manner. 
HEK-293T cells stably expressing TLR3 protein, were co-transfected with the 
pcDNA3HA (Control) or pcDNA3-I329L-HA plasmid, the β-galactosidase 
plasmid and either the (A) IFN-β promoter (IFNβ) or the (B) NF-кB promoter 
(PRDII) luciferase reporter. For both assays, forty-eight hours post-
transfection, the cells were either induced with 35μg/ml Poly (I:C) for five 
hours (■), or left untreated (□). Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of Relative Luciferase Units (RLU) ± SD of triplicate well 
from one of three similar experiments. Statistical significance is represented 
as p≤0.05 (*) or ≤0.01 (**). 
The TLR3 recognizes microbial nucleic acids and is mainly located 
within endolysosomal compartments, although some cell surface 
expression has been described in fibroblasts. Considering the 
suggested mechanism of action of I329L, one would expect it to be 
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associated to such cell compartments. Immunofluorescence assays 
were performed in HEK-293T cells stably expressing I329L protein 
with an HA tag.  
 
 
 
 
Figure 2.4 – The ASFV ORF I329L colocalizes to the early, but not late 
endosomes. 
HEK-293T cells stably expressing I329L-HA tagged protein were transfected 
with TLR3 plasmid. Forty-eight hours post-transfection, the cells were either 
stimulated with 100μg Poly(I:C) for 30min., or left untreated. Early endosomes 
(A) were visualized using rabbit anti-EEA1 antibody and late endosomes (B) 
were visualized using rabbit anti-LAMP1 antibody (red). The I329L protein 
was visualized using a monoclonal anti-HA antibody (blue). Bar, 10μm. 
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As presented here, I329L partially colocalizes with early, but not late, 
endosomes (Fig.2.4). Colocalization with early endosomes requires 
activation by Poly (I:C), suggesting that I329L is recruited for this 
subcellular compartment following activation of TLR3 signalling 
pathway. In non-stimulated cells, I329L is probably localised in the ER 
and the Golgi complex, as previously reported by de Oliveira et al., 
2011. 
Whereas the endoplasmic reticulum functions in concert with the Golgi 
complex to target new proteins to their proper destinations, early 
endosomes and the Golgi communicate bidirectionally. As such, it is 
reasonable that a viral membrane protein may be directed to the Golgi 
complex through the ER, and then sent to the early endosome, where 
it will inhibit TLR3 signalling. 
2.4.3. The ASFV ORF I329L interacts with TRIF 
The ASFV I329L protein was proposed to exert its effect in the TLR3 
pathway by interfering with the TRIF adaptor. Upon LPS-binding, and 
an early signalling event through MyD88, TLR4 initiates an endosomal 
phase, where it is able to induce a late pro-inflammatory response 
through TRIF. A luciferase assay was performed in which the impact of 
I329L protein expression in the LPS-mediated activation of NF-кB was 
assessed. 
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Figure 2.5 – The ASFV ORF I329L inhibits LPS-mediated activation of 
NF-кB. 
HEK-293T cells, were co-transfected with the pcDNA3HA (Control) or 
pcDNA3-I329L-HA plasmid, the TLR-4 expression plasmid, the β-
galactosidase plasmid and the NF-кB promoter (PRDII) luciferase reporter. 
Forty-eight hours post-transfection, the cells were either induced with 
100ng/ml LPS for five hours (■), or left untreated (□). Luciferase activity was 
normalized to β-galactosidase activity as a control for transfection efficiency. 
Data are expressed as means of Relative Luciferase Units (RLU) ± SD of 
triplicate well from one of three similar experiments. Statistical significance is 
represented as p≤0.05 (*). 
The fact that TLR4 is able to initiate an endosomal, TRIF-dependent 
pathway, and the observation that I329L is able to inhibit LPS-
mediated activation of NF-кB (Fig.2.5), are in agreement with the 
hypothesis that I329L interferes with TRIF. 
Immunofluorescence assays were performed to verify if I329L and 
TRIF colocalize to the same location. 
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Figure 2.6 – The ASFV ORF I329L colocalizes to TRIF. 
HEK-293T cells were co-transfected with pcDNA3-prom
I329L
-I329L-HA and 
TLR3 expression plasmid. Forty-eight hours post-transfection, the cells were 
either stimulated with 100μg Poly(I:C) for 30min., or left untreated. Expression 
of endogenous TRIF protein was visualized using rabbit anti-TRIF antibody 
(green). The I329L protein was visualized using a monoclonal anti-HA 
antibody (red). Bar, 10μm. 
As can be seen, I329L and TRIF partially colocalize on Poly (I:C) 
activated cells, but not on non-stimulated cells. The results presented 
in both Fig.2.4 and Fig.2.7, suggest that I329L is being recruited to the 
endosomes of stimulated cells, where it interferes with TRIF, inhibiting 
cytoplasmic signal transduction. 
The colocalization of I329L and TRIF are consistent with an interaction 
between these two proteins. An immunoprecipitation assay was 
performed, in order to verify this assumption. 
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Figure 2.7 – The ASFV ORF I329L co-immunoprecipitates with TRIF. 
HEK-293T cells stably expressing the C-terminally HA-tagged I329L protein 
were transfected with TLR3 expression plasmid. Forty-eight hours post-
transfection, the cells were stimulated with 100μg/ml Poly (I:C) for 20 minutes, 
or left untreated. Cell lysates were immunoprecipitated with rabbit anti-TRIF 
(αTRIF). The immunoprecipitates (IP) were analyzed by immunoblot with anti-
HA or anti-TRIF (upper panel). Expression of TRIF and I329L in the lysates 
was detected by immunoblot analysis with anti-TRIF and anti-HA (bottom 
panel). 
The results presented here (Fig.2.7) confirm that I329L directly 
interacts with TRIF, interfering with its function as an essential adaptor 
for the TLR3 signalling pathway. Intriguingly, the HA-tagged fragment 
immunoprecipitated with TRIF is ~25KDa, suggesting that some 
cleavage may be occurring prior to interaction of I329L with TRIF. 
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2.4.4. The ASFV ORF I329L inhibits TLR3 signalling pathway 
by two distinct mechanisms. 
Bioinformatic analysis of the I329L protein sequence, using the 
TMHMM program, revealed an N-terminal extracellular domain, a 
transmembrane domain (with a single transmembrane helix) and a C-
terminal intracellular domain. Based on these previously published 
results, and in order to define the domain involved in the inhibition of 
TLR3 signalling pathway, we cloned I329L truncated mutants 
containing the transmembrane domain sequence but lacking either the 
ectodomain (TM/IC) or the intracellular domain (EC/TM). 
2.4.4.1. Inhibition of stimulation with Poly (I:C) 
Luciferase reporter assays were performed on cells transfected with 
expression plasmids for the entire I329L and both truncated mutants, 
in order to assess their impact on the activation of the TLR3 signalling 
pathway through Poly (I:C). 
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Figure 2.8 – Both domains of the ASFV ORF I329L inhibit Poly (I:C) 
stimulated activation of IFN-β transcription (A) in an NF-кB dependent 
manner (B). 
HEK293-TLR3 stably expressing cells, were co-transfected with the 
pcDNA3HA (Control), pcDNA3-I329L-HA, pcDNA3-EC/TM-HA or pcDNA3-
TM/IC-HA plasmids, the β-galactosidase plasmid and either the (A) IFN-β 
promoter (IFNβ) or the (B) NF-кB promoter (PRDII) luciferase reporter. For 
both assays, forty-eight hours post-transfection, the cells were either induced 
with 35μg/ml Poly (I:C) for five hours (■), or left untreated (□). Luciferase 
activity was normalized to β-galactosidase activity as a control for transfection 
efficiency. Data are expressed as means of Relative Luciferase Units (RLU) ± 
SD of triplicate well from one of three similar experiments. Statistical 
significance is represented as p≤0.05 (*) or ≤0.01 (**). 
The results obtained using this reporter indicate that both I329L 
truncated mutants inhibit IFN-β induction in response to Poly (I:C) 
(Fig.2.8-A) through an NF-κB dependent pathway (Fig. 2.8-B). The 
same result was obtained with the expression of the entire I329L 
molecule.  
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2.4.4.2. Inhibition of stimulation by ectopically expressed TRIF 
The only TLR3 adaptor, TRIF, was suggested as a probable target for 
this viral protein, so a similar luciferase reporter assay was performed, 
activating the cells through ectopic expression of TRIF. 
 
Figure 2.9 – The intracellular, but not the extracellular domain of the 
ASFV ORF I329L, inhibits ectopic TRIF stimulated activation of IFN-β 
transcription (A) in an NF-кB dependent manner (B). 
HEK-293T cells were co-transfected with the pcDNA3HA (Control), pcDNA3-
I329L-HA, pcDNA3-EC/TM-HA or pcDNA3-TM/IC-HA plasmids, the β-
galactosidase plasmid and either the (A) IFN-β promoter (IFNβ) or the (B) NF-
кB promoter (PRDII) luciferase reporter. Cells were induced by co-transfection 
of TRIF expression plasmid. Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
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expressed as means of Relative Luciferase Units (RLU) ± SD of triplicate well 
from one of three similar experiments. Statistical significance is represented 
as p≤0.01 (**). 
These results clearly reveal an inhibitory role for the I329L intracellular 
domain in cells induced by TRIF ectopic expression (Fig. 2.9). 
Strikingly, the extracellular domain has no inhibitory effect on cells 
induced by TRIF expression, although it is capable of inhibiting 
Poly (I:C) stimulated induction of IFN-β (see Fig. 2.8).  
2.4.4.3. The extracellular domain of I329L inhibits stimulation 
with Poly (I:C) in a dose dependent manner 
A luciferase reporter assay was performed in cells expressing amounts 
of EC/TM truncated mutant and an IFN-β promoter luciferase reporter, 
stimulated by Poly (I:C). 
 
Figure 2.10 - The ectodomain-transmembrane domain fragment of I329L 
inhibits Poly (I:C)-mediated activation of the IFN-β promoter in a dose 
dependent manner. 
HEK293-TLR3 stably expressing cells were co-transfected with the IFN-β 
promoter luciferase reporter, the β-galactosidase control plasmid, the non-
recombinant pcDNA3HA and increasing amounts (300-900ng) of pcDNA3-
* 
0 
2 
4 
6 
8 
10 
–
 
–
 
+
 
–
 
+
 
+
 
+
 
R
L
U
 
(I
F
N
-β
 a
c
ti
v
a
ti
o
n
) 
EC/TM 
Poly (I:C) 
Chapter 2 
121 
EC/TM-HA plasmid (encoding for the ectodomain-transmembrane domain 
fragment). Forty-eight hours post-transfection, the cells were stimulated with 
35μg/ml Poly (I:C) for five hours (■), or left untreated (□).  Luciferase activity 
was normalized to β-galactosidase activity as a control for transfection 
efficiency. Data are expressed as means of RLU ± SD of triplicate well from 
one of three similar experiments. Statistical significance is represented as 
p≤0.05 (*). 
As presented here (Fig.2.10), the inhibition of Poly (I:C)-mediated 
activation of the IFN-β promoter by the ectodomain-transmembrane 
domain (EC/TM) fragment of I329L is dose dependent. Taken together 
with the observation that the EC/TM fragment does not inhibit the 
TRIF-mediated activation of the IFN-β promoter, these results suggest 
a role for I329L in inhibiting TLR3 function, either at the level of ligand 
binding or receptor dimerization. 
2.4.5. Proteolytic processing of I329L 
Recent evidence suggests that TLR9, TLR7 and TLR3 are 
proteolytically processed as an essential step in their signalling 
transmission mechanism [11]. Although I329L is present in transfected 
cells as a stable molecule of ~50KDa, the availability of a rabbit 
antibody (prepared by Parkhouse, R.M.E.) against the recombinant 
I329L protein allowed an examination of the stability of the I329L 
molecule in virus infected cells.  
 
 
 
 
Chapter 2 
122 
 
 
Figure 2.11 – The ASFV I329L protein is proteolytically processed during 
ASFV infection. 
Vero cells were infected with Ba71V ASFV strain at MOI=3 or mock infected 
(M). Cells were lysed at timepoints 8 to 22 hpi (hours post infection) and 
immunoblotted with rabbit anti-I329L serum. 
As can be seen (Fig.2.11), ten hours after infection of Vero cells with 
the tissue culture adapted Ba71V strain of ASFV, there is a dramatic 
conversion of I329L to a molecule of ~25KDa. 
This observation raised the question of whether the proteolytic 
degradation was a consequence of virus infection per se, or whether it 
was triggered by activation of the TLR pathway. Therefore, the stability 
of I329L was investigated in cells transfected with I329L cloned with a 
C-terminal HA sequence, and then stimulated with either Poly (I:C) or 
ectopically expressed TRIF. The cells were then lysed and examined 
by Western blot. 
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Figure 2.12- The ASFV ORF I329L expression and processing is 
dependent on activation by either Poly (I:C) or ectopic expression of 
TRIF and involves proteolytic cleavage. 
HEK293T cells stably expressing I329L-HA or non-recombinant eGFP were 
either induced with 100μg/mL Poly (I:C) for 1 hour or left untreated (A). 
Alternatively, cells were induced by transfection of 500ng (+) or 1μg (++) of 
TRIF expression plasmid (B). The cells were lysed and total cell extracts were 
immunobloted with anti-HA-HRP conjugated antibody to detect expression of 
I329L-HA tagged protein. Anti-β-actin antibody was used as loading control. 
As can be seen, with either stimulus, there was a similar degradation 
of I329L to a predominant fragment of about 25KDa (Fig.2.12), 
presumably an N-terminal fragment, as the Western blot was 
developed with an antibody recognizing a C-terminally expressed HA 
epitope. 
2.4.5.1. I329L has a potential cleavage site for ASFV and 
cellular proteases, such as cathepsin L. 
The observation of proteolytic processing of I329L in virus infected and 
in Poly (I:C) or ectopic TRIF stimulated, I329L transfected cells, clearly 
requires proteolytic susceptibility of the molecule. As the processing of 
TLRs has been shown to be the result of the activity of endosomal 
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cathepsins S, L and B, the presence of the sequence GGFGKE, 
recognized by cathepsin L, at aminoacid residues 107-112 in I329L 
sequence, could be relevant. Additionally, the sequence GGF, at 
aminoacid residues 107-109, is recognized by the ASFV polyprotein 
processing protease [23]. 
Accordingly, this sequence was mutated, at residue 108, to GAFGKE 
(or GAF), and the resulting mutant I329L protein was tested for 
inhibition of induction of IFN-β and NF-кB activation in transfected 
cells, with the wild type I329L sequence as a control. As can be seen, 
and in contrast to the control, the mutant I329L had no effect on the 
activation of either IFN-β or NF-кB luciferase reporters by ectopic 
expression of TRIF (Fig.2.13), although it resembled the wild type 
sequence in inhibiting activation stimulated by Poly (I:C) (Fig. 2.14). 
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Figure 2.13 - The ASFV mutant I329L gene has no effect on IFN-β 
induction (A) and NF-kB activation (B) on cells stimulated by ectopic 
expression of TRIF adaptor. 
HEK-293T cells were co-transfected with the non-recombinant pcDNA3HA 
(Control), pcDNA3-I329L-HA or pcDNA3-I329L.G108A-HA plasmids, the β-
galactosidase plasmid and either the (A) IFN-β promoter (IFNβ) or the (B) NF-
кB promoter (PRDII) luciferase reporter. Cells were induced by co-transfection 
of TRIF expression plasmid. Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of Relative Luciferase Units (RLU) ± SD of triplicate well 
from one of three similar experiments. Statistical significance is represented 
as p≤0.05 (*). 
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Figure 2.14 – The ASFV mutant I329L gene inhibits Poly(I:C) stimulated 
induction of IFN-β (A) or NF-кB activation (B). 
HEK-293T cells were co-transfected with the non-recombinant pcDNA3HA 
(Control), pcDNA3-I329L-HA or pcDNA3-I329L.G108A-HA plasmids, the β-
galactosidase plasmid and either the (A) IFN-β promoter (IFNβ) or the (B) NF-
кB promoter (PRDII) luciferase reporter. For both assays, forty-eight hours 
post-transfection, the cells were either induced with 35μg/ml Poly (I:C) for five 
hours (■), or left untreated (□). Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of Relative Luciferase Units (RLU) ± SD of triplicate well 
from one of three similar experiments. Statistical significance is represented 
as p≤0.05 (*) or ≤0.01 (**). 
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The amount of IFN-β secreted into the supernatants of cells 
expressing either wild type pI329L, the mutant pI329L.G108A, and 
stimulated by ectopic expression of TRIF, was determined by ELISA, 
to examine the impact of these proteins on the expression and 
secretion of IFN-β. Once again, the mutant failed to inhibit ectopic 
TRIF stimulation (Fig.2.15). 
 
Figure 2.15 – The ASFV mutant I329L has no impact on secretion of IFN-
β in cells induced by ectopic expression of TRIF. 
HEK-293T cells were co-transfected with the non-recombinant pcDNA3HA 
(Control), pcDNA3-I329L-HA or pcDNA3-I329L.G108A-HA plasmids. Cells 
were induced by co-transfection of TRIF expression plasmid. Supernatants 
were collected and IFN-β concentration (pg/ml) was measured by ELISA. 
Data are expressed as means ± SD of triplicate well from one of two similar 
experiments. ** Statistically significant when compared to control vector-
expressing cells (p≤0.01). 
It may be concluded, therefore, that the cathepsin L sensitive site in 
pI329L sequence is required for its inhibition of the TLR3 signalling at 
the level of TRIF, but not for signalling through Poly (I:C). 
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2.5. Discussion 
African swine fever virus (ASFV) is an economically important 
cytoplasmically replicating DNA virus of pigs, endemic in many African 
countries, and which entered Portugal with a disastrous economic 
impact [24]. There is no vaccine, and although ASFV is known to 
interfere with signalling pathways controlling the transcription of a large 
number of immunomodulatory genes such as cytokines [25,26,27], no 
individual virus gene manipulating the IFN response has been 
reported. This is all the more surprising as ASFV not only possess an 
early acute phase in macrophages, but may also persist. It is hard to 
imagine that a virus with this lifestyle could persist in the face of an 
efficient IFN response. 
Many viral genes evolved to mimic or block host cellular functions are 
likely to have been acquired from the host. It is also likely that some of 
the many non-homologous genes of the ASFV will have evolved for 
host manipulation and will only be detected by functional approaches, 
as indeed is reported in this thesis. 
The search for a TLR agonist in ASFV was prompted by the fact that 
the virus infects both vertebrate and invertebrate hosts, and only 
innate immunity, in particular TLR responses, is common to both 
hosts. Initial identification of an ASFV TLR homologue was negative. 
Bioinformatic analysis predicted ORF I329L to be a type I 
transmembrane protein containing extracellular putative leucine-rich 
repeats (LRRs) and an intracellular TIR domain homologue. Upon 
more focused bioinformatic analysis, a marginal homology to the TIR 
domain of TLR3 was reported and, in addition, I329L was recently 
reported to impair the cellular responses controlled by TLR3 that lead 
to both IFN-β secretion and NF-кB activation [1]. The precise 
mechanism for the inhibition of TLR3 signalling was not elucidated and 
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the adaptor TRIF was tentatively proposed as a potential target for 
I329L. A modelling exercise on this viral protein supported the idea 
that I329L might function as a TLR3 decoy, through the formation of 
TLR3-I329L heterodimers and, in doing so, inhibit the downstream 
signalling pathway [22]. 
The biochemical demonstration of the interaction between I329L and 
TRIF was a key observation, predicting that I329L could inhibit an NF-
кB dependent induction of IFN-β in cells stimulated by ectopic 
expression of TRIF. This indeed proved to be so and prompted the 
testing of the individual intra- and extracellular domains of I329L on the 
activation of NF-кB and IFN-β in cells stimulated with Poly (I:C) or by 
ectopic expression of TRIF. Interestingly, the extracellular domain 
inhibited activation in a dose dependent manner, an observation 
consistent with either direct competition of I329L for the Poly (I:C) 
ligand or the formation of a non-functional TLR3-I329L heterodimer. 
The intracellular domain similarly inhibited the NF-кB dependent 
activation of IFN-β stimulated by the Poly (I:C) ligand. On repeating 
similar assays, but this time with TRIF mediated ectopic stimulation, 
the extracellular domain was significantly without impact, whereas the 
intracellular domain continued to inhibit activation of IFN-β. We may 
conclude that the I329L mediated inhibition of TLR signalling pursues a 
dual strategy, with its extra- and intracellular domains evolved for 
interfering with the initiation and subsequent intracellular transmission 
of the dsRNA stimulus, respectively. 
TLR3, TLR7, and TLR9 localize to and exclusively signal from 
endolysosomal compartments. Recent studies have demonstrated that 
TLR9 is processed in endolysosomal compartments by resident 
proteases and that this processing is required to generate a functional 
receptor [12,14,28]. It has been demonstrated that TLR9 cleavage 
Chapter 2 
130 
occurs through a multistep process: the first step is mediated either by 
asparagine endopeptidase or by some members of the cathepsin 
family of proteases, particularly cathepsin L and S; the second 
processing event is an exclusively cathepsin–mediated N-terminal 
trimming, which is also required for optimal receptor function. It was 
also shown that TLR7 and TLR3 are processed in a similar manner, 
implying that receptor proteolysis is a conserved mode of regulating all 
nucleic acid–sensing TLRs that may have evolved alongside the ability 
to recognize nucleic acids as a signature of infection [11]. 
The dual strategy of I329L, in particular the inhibitory activity of the 
isolated intracellular domain is intriguing and, stimulated by these 
recent observations of proteolytic processing of TLRs, the possibility of 
a similar processing for I329L was pursued. As I329L is totally stable in 
transfected cells, the only rational possibility was to assume that 
proteolytic processing would be an event subsequent to viral activation 
of the TLR3 pathway. Thus I329L, in virus infected cells, was seen to 
be processed from its full size of 50KDa to a fragment of 25KDa. 
Following this, the next step was to test the stability of I329L in 
transfected cells, simultaneously stimulating the TLR3 pathway either 
with Poly (I:C) or through ectopic expression of TRIF. As described, a 
similar proteolytic processing of I329L occurred when the TLR3 
pathway was activated either by Poly (I:C) or ectopic expression of 
TRIF.  
Considering the requirement for endosomal TLR proteolytic processing 
and our observations of I329L processing, the presence of a cathepsin 
L sensitive site in the pI329L ectodomain sequence is an interesting 
feature, and a pI329L.G108A mutant was constructed in order to check 
its functional relevance. Interestingly, the mutant pI329L.G108A had 
no effect on the activation of either IFN-β or NF-кB luciferase reporters 
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by ectopic expression of TRIF, although it resembled the wild type 
I329L in inhibiting activation stimulated by Poly (I:C). Additionally, 
pI329L.G108A is also unable to inhibit IFN-β secretion in cells 
activated by ectopic expression of TRIF. Although it remains to be 
verified that this mutant I329L protein is not proteolytically processed in 
TLR3-stimulated cells, it is apparent that proteolytic processing of 
I329L is a necessary requirement for its inhibition of the TLR3 
signalling at the level of TRIF, but not for signalling through Poly (I:C). 
In conclusion, we suggest that the I329L molecule provides a dual viral 
strategy for inhibition of the TLR response: inhibition of its initiation via 
dsRNA, through formation of an I329L-TLR3 heterodimer, followed by 
proteolytic processing, resulting in an inhibition of the interaction 
between the intracellular domain of I329L and its target TRIF. This 
model is open to experimental confirmation, as are the precise details 
of the proteolytic processing. 
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3.  
3.1. Summary 
A previous screening performed in this laboratory (Correia, S.M., 
unpublished work) identified a member of the ASFV multigene family 
(MGF)-360, the DP148R gene (recently renamed MGF360-18R), as an 
inhibitor of the induction of IFN-β. Sequence comparison of the 
genomes of ASFV pathogenic and non-pathogenic strains revealed 
that MGF360-18R is a non-conserved open-reading frame (ORF). Two 
variants of this viral gene were studied: a 148a.a. variant, encoded by 
the non-pathogenic Ba71V ASFV isolate and a 254a.a. variant, 
encoded by the pathogenic Benin97/1 isolate, the virus responsible for 
a recent outbreak of ASF in Africa. 
Using luciferase reporter assays, both MGF360-18R variants were 
demonstrated to inhibit the induction of IFN-β in a NF-κB dependent 
manner. Similarly, an inhibition of IFN-β secretion was demonstrated 
by ELISA.  
Ectopic expression of IFN signalling intermediates of both Toll-like 
receptor (TLR) and RIG-I-like receptor (RLR) pathways allowed the 
identification of potential molecular targets. These experiments, and 
the intracellular colocalization of this virus gene with mitochondrial 
MAVS, indicated that both MGF360-18R variants inhibited IFN-β 
induction by targeting MAVS, a key adaptor protein of the RLR 
pathway. Additional luciferase reporter assays demonstrated that IRF-
3 is also targeted by the MGF360-18R variant from the Benin97/1 
isolate, but not by the Ba71V variant. 
In conclusion, the two variants of MGF360-18R were shown to inhibit 
IFN-β induction by an NF-κB dependent mechanism, both at the level 
of transcriptional activation and protein secretion. Molecular targets for 
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both variants of MGF360-18R have been identified, and the 
mechanism these two genes evolved for manipulation of the IFN 
response is discussed. 
3.2. Introduction 
Large DNA viruses, such as the ASFV, encode many proteins involved 
in the evasion of host immune responses. The ASFV contains a 
number of open reading frames ranging from 160 to 175, depending 
on the isolate.  Approximately 90 of the proteins encoded by the ASFV 
genome are predicted to be structural proteins or involved in virus 
replication [1]. Many of the remaining 70 to 85 proteins most probably 
will have evolved for host evasion.  
The modulation of the interferon response by ASFV has only been 
described in the comparison of transcriptional profiles of macrophage 
infected with wild type virus and a deletion mutant virus lacking six 
MGF360 and two MGF530 genes. These results suggest that MGF360 
and/or MGF530 genes are involved in the inhibition of IFN response. 
Indeed, in contrast with the wild type virus infection, the mutant virus 
infected culture supernatant contained significant amounts of IFN-α [2]. 
However, precisely which genes within the multigene families are 
responsible for this ability and their mechanism of action remains 
unknown. In addition, the MGF360 and 530 members were reported to 
be swine macrophage host range determinants that function by 
promoting the survival of infected cells [3]. More recently, and indeed 
very interestingly, MGF360 genes were proposed to be significant tick 
host range determinants, being required for efficient virus replication 
and generalization of infection in ticks [4]. 
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The activation of the different routes of induction of IFN depends upon 
the specific virus, the stage of infection and, particularly, on the ability 
of the host cell to detect the viral infection. Two major receptor 
systems recognize most viral pathogen-associated molecular patterns 
(PAMPs): endosomal TLRs detect viral nucleic acids in endosomes of 
specialized cell types, whilst RLRs detect cytoplasmically located viral 
nucleic acids produced upon- infection [5,6]. These two systems work 
in concert to fight infection, converging on the activation of common 
transcription factors, such as NF-кB, IRF-3 and IRF-7, to promote the 
production of type I IFN, in addition to inflammatory cytokines.  
The interferons (IFNs) are a group of secreted cytokines that are 
recognized as critical regulatory mediators of the immune response. 
The functions of IFNs are represented by three major biological 
activities: antiviral activity, antitumor activity and immunoregulatory 
activity [7]. Upon recognition of a viral infection, cells activate signal 
transduction pathways that culminate in establishment of an antiviral 
state and induction of type I IFN. The secreted cytokine then 
stimulates an antiviral state in neighbouring cells and induces the 
expression of proteins that interfere with viral processes, thus blocking 
viral replication [6,8]. Type II IFN, in turn, is produced by activated 
lymphocytes, further amplifies the IFN response to infection [9], and 
plays a key role in the orchestration of both the innate and acquired 
immune responses. 
Induction of the IFN-β gene requires the activation of two families of 
transcription factors: the family of Nuclear Factors кB (NF-кB) and the 
family of Interferon Regulatory Factors (IRFs). Each of the transcription 
factors bind to the IFN-β promoter with limited affinity. Thus optimal 
induction requires cooperativity between these two factors. Together 
with a c-jun/ATF-2 heterodimer, IRF-3, IRF-7 and NF-кB form the 
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enhanceosome, a complex that binds to the IFN-β promoter, inducing 
gene expression [10]. Several studies revealed that binding of IRF-3 
and/or IRF-7 is indispensable for induction, but activation of NF-кB and 
c-jun/ATF-2 may not be essential (reviewed by Versteeg & García-
Sastre, 2010) [6]. Positive feedback models propose that IRF-3 alone 
may directly induce expression of the IFN-β gene, which feeds back 
onto cells and induces the synthesis of IRF-7. In the presence of a 
continued infection, IRF-7 enhances the transcription of the IFN-β 
gene and allows transcription of the IFN-α genes [8]. Subsequently, 
type I IFNs are produced and secreted, acting both in an autocrine and 
paracrine manner by binding to cell surface  type I IFN receptors, 
activating the Jak-Stat signalling pathway and ultimately leading to the 
expression of hundreds of genes and inducing an “anti-viral” state in 
adjacent cells [11]. 
Finally, this brief summary would not be complete without the remark 
that this is only what we know today and there is still much to be 
learned about the organisation and function of the interferon system. 
As the interferon system plays a major role as an early host defence 
system against virus infections [12], viruses have evolved a number of 
counter strategies to antagonise this response. The final objective of 
any viral evasion strategy is to prevent upregulation of type I IFN by 
host cells, thereby avoiding the antiviral activity of ISGs [13]. 
In a previous study performed in this laboratory (Correia, S.M., 
unpublished results), 17 early genes with unassigned functions were 
tested for their capability to inhibit the expression of IFN-β (7 from 
MGF360 and 1 from MGF530). The genes were selected for early 
expression as this is a predicted feature for host evasion genes that 
have evolved for manipulation of IFN responses. Of the 17 genes that 
were tested, four inhibited the induction of IFN-β. Two of these (A276R 
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and MGF360-18R) are from MGF360 and one (A528R) is from 
MGF530. 
The non-conserved ORF MGF360-18R, a member of MGF360, was 
selected as the focus for this work and investigated in detail in order to 
define how it inhibits the induction of IFN-β following the stimulation of 
cells with an analogue of dsRNA, Poly (I:C). Two variants of this viral 
gene were studied: a 148a.a. variant, encoded by the tissue culture-
adapted non-pathogenic ASFV isolate (Ba71V) and a 254a.a. variant, 
encoded by the pathogenic Benin97/1 isolate. The results indicate that, 
in both isolates, this inhibition is occurring at the level of MAVS, a key 
adaptor protein of the RLR pathway, thereby preventing activation of 
the transcription factors NF-кB, IRF-3 and IRF-7. Of note, is the fact 
that the ‘pathogenic’ MGF360-18R variant (254a.a.) is also inhibiting 
IFN-β induction at the level of IRF-3, which may give the virus an extra 
advantage, as a result of a more efficient abrogation of the IFN 
response. 
3.3. Materials and methods 
3.3.1. Bioinformatic analysis  
Full-length DNA sequences of MGF360-18R ORF from different ASFV 
isolates were aligned and compared to the known DNA sequence of 
MGF360-18R ORF from ASFV Benin97/1 isolate, using the nucleotide-
nucleotide BLAST tool from the National Center for Biotechnology 
Information (NCBI). Screening for patterns was performed using 
Prosite 20.78 database [14]. The transmembrane region prediction 
was performed by TransMembrane Helix prediction using Hidden 
Markov Models 2.0 (TMHMM) program [15]. Secondary structure 
prediction was performed using the PSIPRED server [16]. 
Chapter 3 
140 
3.3.2. Cell culture 
African green monkey Vero and COS-1 cells were cultured in 
Dulbecco´s Modified Eagle´s Medium (DMEM) (Gibco) supplemented 
with 100U/ml penicillin G sodium /100μg/ml streptomycin sulfate 
(Gibco), 2mM L-Glutamine (Gibco) and 10% (v/v) heat-inactivated fetal 
bovine serum (FBS) (Gibco).  
Immature porcine alveolar macrophage cell line (IPAM) was cultured in 
RPMI 1640 + GlutaMAX (Sigma) supplemented 100U/ml penicillin G 
sodium/ 100μg/ml streptomycin sulfate (Gibco) and 10%(v/v) heat-
inactivated fetal bovine serum (FBS) (Gibco). Cells were incubated at 
37ºC, in 5%CO2. 
3.3.3. Plasmids 
The two variants of the ASFV MGF360-18R ORF were amplified by 
PCR from either BA71V or Benin-97/1 isolate genomic DNA and 
cloned into the pcDNA3 plasmid, in frame with an amino-terminal 
influenza haemaglutinin (HA) tag.  
For construction of a recombinant lentivirus vector (pHR-CMV-HA-
18R-eGFP), the MGF360-18R (Ba71V) or MGF360-18R (Benin97/1) 
coding sequences were excised from pcDNA3, together with the 
amino-terminal HA tag, and cloned into the vector pHR-CMV-eGFP 
(kindly provided by Dr. Y. Ikeda), upstream of an internal ribosome 
entry site (IRES)-driven enhanced green fluorescent protein gene 
(eGFP). 
The luciferase reporter plasmids containing the sequences of the IFN-
β promoter [pIF∆(-125/+72)lucter], the NF-κB binding site of the IFN-β 
promoter [p(PRD2)5tk∆(-39)lucter], the IRF-3-binding site of the ISG15 
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promoter [p(ISG15ISRE)4tk∆(-39)lucter], as well as the expression 
vectors for IKKɛ, TBK1 and MAVS, were gifts of Dr. S. Goodbourn. 
The expression plasmid containing the human IRF-3 fused with the 
green fluorescence protein (GFP) was provided by Dr. J. Hiscott. 
The pCMVβ plasmid contains a β-galactosidase gene under the 
control of human cytomegalovirus immediate early promoter, and 
serves as an internal control for culture to culture variations in 
transfection efficiency.  
3.3.4. Lentivirus production 
Lentivirus was produced by transient co-transfection of HEK-293T cells 
with the packaging and envelope plasmid together with the empty 
pHR-CMV-eGFP plasmid or the recombinant MGF360-18R (either the 
Ba71V or Benin97/1 variant) plasmid at a weight ratio of 1:1:3, 
respectively, using FuGENE 6 (Roche) according to the 
manufacturer’s instructions. Supernatants containing the lentivirus 
were collected at 48h and 72h post-transfection, clarified by filtration, 
and lentivirus were collected by ultracentrifugation (125,000xg, 3h, 
4°C). Virus pellets were resuspended in fresh DMEM and frozen at 
−80°C. 
3.3.5. Lentivirus transduction of COS1 cells 
The COS-18R (Ba71V), COS-18R (Benin97/1) and COS-eGFP stable 
cell lines were produced by lentivirus infection of COS-1 cells with 
either one of the recombinant plasmids or the empty pHR-CMV-eGFP, 
respectively, using a multiplicity of infection (MOI) of 10 in DMEM. 
Confirmation of lentivirus infection was done by detecting eGFP-
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positive cells by optical microscopy at 48 h post-infection (p.i.), and 
recombinant protein expression was confirmed by Western blot. 
3.3.6. Luciferase reporter gene assay 
Vero cells (6x104 cells/well, in a 24 well plate) were co-transfected with 
100ng of the indicated luciferase reporter plasmid, 25 ng of the β-
galactosidase internal control plasmid (pCMVβ) and 300ng of either 
pcDNA3HA-18R (Ba71V), pcDNA3HA-18R (Benin97/1) or non-
recombinant pcDNA3HA, according to the Lipofectamine 2000 
(Invitrogen) protocol. Seventy two hours post-transfection, the cells 
were either stimulated with 35μg/ml Poly (I:C) (Amersham 
Biosciences) for five hours, or left untreated. After the treatment, the 
cells were lysed. 
In an alternative protocol, the cells were co-transfected with 100ng of 
the indicated luciferase reporter plasmid, 25ng of pCMVβ, the 
indicated amounts of plasmids expressing the different components of 
the IFN-β induction pathway and increasing amounts of the indicated 
pcDNA3HA-18R (Ba71V or Benin97/1) plasmid. The quantity of DNA 
in each transfection was kept constant by supplementation with the 
non-recombinant pcDNA3HA. Forty eight hours post-transfection the 
cells were lysed. The luciferase activity was measured using the 
luciferase assay system (Promega) according to the manufacturer`s 
protocol. The β-galactosidase activity was measured using the 
Galacton-Plus kit from Tropix (Bedford, MA). The luciferase activity 
was normalized relatively to the β-galactosidase activity of each 
sample, as to correct transfection efficiency variations between 
different cells. 
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3.3.7. Enzyme-linked Immunoabsorbent Assay (ELISA) 
IPAM cells (6x104 cells/well, in a 24 well plate) were transfected with 
300ng of the indicated pcDNA3HA-18R (Ba71V or Benin97/1) or the 
non-recombinant pcDNA3HA plasmid, according to the Lipofectamine 
2000 (Invitrogen) protocol. Forty-eight hours post-transfection, the cells 
were either stimulated with 100μg/ml Poly (I:C) (Amersham 
Biosciences) for 16 hours, or left untreated. The medium of each well 
was collected and centrifuged for 15 minutes at 1000xg. Quantitative 
determination of porcine IFN-β concentration in the supernatants was 
performed using the Porcine Interferon β ELISA Kit (Cusabio), 
according to the manufacturers’ instructions. Absorbance at 450nm 
was measured using a BioRad ELISA reader (BioRad) and 
concentration of IFN-β was determined by comparison to a standard 
curve. 
3.3.8. Western blot 
Lentivirus infected COS-1 cells, stably expressing MGF360-18R 
(Benin97/1) (3x105 cells/well, in a 6-well plate) were transfected with 
either 250ng of IKKɛ expressing vector or 200ng of MAVS expressing 
vector, according to the Lipofectamine 2000 (Invitrogen) protocol. 
Forty-eight hours post-transfection, the cells were harvested and lysed 
using a non-ionic lysis buffer (15mM TrisHCl, pH 7.4, 120mM NaCl, 
25mM KCl, 2mM EDTA, 2mM EGTA, 0.1mM DTT and 1% Triton X-
100) containing a protease inhibitor cocktail (Sigma). Cell lysates were 
resolved on a 12% sodium dodecyl sulphate-polyacrilamide gel (SDS-
PAGE). The separated proteins were transferred to a polyvinylidene 
difluoride (PVDF) membrane (GE Healthcare). Membranes were 
blocked with 5% non-fat milk for one hour at room temperature and 
incubated with the following antibodies: rabbit anti-phospho-hIRF3 
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(Cell Signaling), rat anti-HA-HRP conjugated (high affinity) (Roche) 
and anti-β-actin-HRP conjugated (Sigma) as a loading control. 
Horseradish peroxidase-conjugated goat anti-rabbit secondary 
antibody was purchased from Invitrogen. Membranes were developed 
by enhanced chemiluminescence detection according to the 
manufacturer’s instructions (SuperSignal West Pico Chemiluminescent 
Substrate, Thermo Scientific or Luminata Forte, Millipore).  
3.3.9. Immunofluorescence 
Vero cells (1.5x105 cells/well, in a 6-well plate) were cultured on sterile 
glass coverslips and transfected with 3μg of pcDNA3HA-18R (either 
Ba71V or Benin97/1) or the non-recombinant pcDNA3HA plasmid, 
according to the Lipofectamine 2000 (Invitrogen) protocol. Forty-eight 
hours post-transfection, the cells were either stimulated with 100μg/ml 
Poly (I:C) (Amersham Biosciences) for 30 minutes, or left untreated. 
Mitochondria were stained incubating live cells with MitoTracker Red 
CMXRos (Molecular Probes) for 45 minutes, according to the 
manufacturers’ instructions. In an alternative protocol, cells were co-
transfected with 3μg of pcDNA3HA-18R (either Ba71V or Benin97/1) 
or the non-recombinant pcDNA3HA plasmid and 100ng of IRF3-GFP 
or 250ng of IKKɛ expressing vector. After the treatment, cells were 
washed with phosphate buffered saline (PBS) solution, fixed with 4% 
paraformaldehyde (PFA) for 20 minutes and permeabilized with PBS + 
0.1% Triton-X100 for 20 minutes. After washing, the cells were blocked 
with PBS + 0.05% Tween-20 containing 5% normal goat serum for one 
hour. To visualize MGF360-18R HA tagged proteins (Ba71V or 
Benin97/1), coverslips were incubated with either rabbit anti-HA 
(Sigma) or rat-anti HA (high affinity) (Roche). Coverslips were washed 
and incubated with the secondary antibodies goat anti-rabbit 
Alexa488-conjugated (Invitrogen) or goat anti-mouse Texas Red-
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conjugated (Molecular Probes), respectively. Cell nuclei were stained 
with DAPI. All the incubations were performed at room temperature.  
Confocal fluorescent images were obtained by a DeltaVision Core 
wide-field deconvolution inverted-base microscope (Applied 
Precision/Olympus), with a 100x objective. Images were analyzed by 
ImageJ 1.43u software. The term colocalization refers to the 
coincidence of green and red fluorescence, as measured by the 
confocal microscope. 
3.3.10. Immunoprecipitation 
Vero cells (5x105 cells/plate, in a 60 mm Ø plate) were transfected with 
6μg of either pcDNA3HA-18R (Ba71V or Benin97/1) or the non-
recombinant pcDNA3HA plasmid, according to the Lipofectamine 2000 
(Invitrogen) protocol. Forty-eight hours post-transfection, the cells were 
either stimulated with 100μg/ml Poly (I:C) (Amersham Biosciences) for 
30 minutes, or left untreated. 
Cells were then harvested and lysed in lysis buffer (15 mM TrisHCl, pH 
7.4, 120 mM NaCl, 25 mM KCl, 2mM EDTA, 2mM EGTA, 0.1mM DTT 
and 1% Triton X-100) containing a protease inhibitor cocktail (Sigma). 
Immunoprecipitation was performed with Dynabeads protein G 
(Millipore), using mouse anti-human MAVS antibody (Millipore). 
Washes were performed using commercially available lysis buffer 
(Sigma). Elution was done using 2X sample buffer. 
Immunoprecipitation eluates were resolved on a 12% SDS-PAGE gel 
and proteins were transferred to a PVDF membrane (GE Healthcare). 
Membranes were blocked with 5% non-fat milk for one hour at room 
temperature and probed with mouse anti-human MAVS (Millipore), 
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anti-HA-HRP conjugated (Roche). Horseradish peroxidase-conjugated 
rabbit anti-mouse secondary antibody was purchased from Invitrogen. 
3.3.11. Statistical Analysis 
Data were shown as mean values with standard deviations (SD). 
Differences between experimental groups were determined by a two-
tailed Student t test, using Excel software (Microsoft). 
3.4. Results 
3.4.1. MGF360-18R is a non-conserved ORF of the ASFV 
Several isolates of ASFV have already been fully sequenced and 
genome sequences are available at the Nucleotide database of the 
NCBI. Screening of each available ASFV genomic sequence with the 
nucleotide sequence of the MGF360-18R ORF (Benin97/1 isolate), 
revealed that this MGF360 gene is non-conserved amongst the 
several isolates. Both the tissue culture-attenuated and the non-
pathogenic isolates of the ASFV (Ba71V and OURT88_3, respectively) 
code for a predicted C-terminal truncated protein of 148a.a.. 
Conversely, the pathogenic isolates code for predicted proteins 
ranging from 237 to 254a.a.. The pathogenic Benin97/1 isolate codes 
for the largest version of this protein, with 254a.a. (see Anex). 
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MGF360-18R (Benin97/1 isolate) – 254 a.a. 
 
MGF360-18R (Ba71V isolate) – 148 a.a. 
 
Figure 3.1 – MGF360-18R is a globular integral membrane protein.  
The predicted MGF360-18R protein sequences of the Ba71V and 
Benin97/1 isolates were analysed for the presence of conserved 
patterns, using Prosite 20.78 [14] and the TMHMM program (see 
Fig.3.1) [15]. Secondary structure of both sequences was determined 
using the PSIPRED server, revealing a globular structure with two and 
three putative transmembrane domains, respectively [16]. 
To characterize the mechanism of action of this viral gene and also to 
define potential differences in the activity of each MGF360-18R 
variant, both variants (Ba71V and Benin97/1) were cloned into 
expression vectors and assessed for their cell localization and ability to 
inhibit the IFN response. 
3.4.2. The MGF360-18R colocalizes with the mitochondria 
The bioinformatic analysis suggested that both variants of the 
MGF360-18R are integral membrane proteins. In order to determine 
the cell compartment in which these proteins are located, 
immunofluorescence assays were performed. 
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Figure 3.2 – Both variants of the ASFV MGF360-18R protein colocalize 
with the mitochondria. 
Vero cells were transfected with pcDNA3HA-18R (either Ba71V or Benin97/1 
variant). Mitochondria were visualized using MitoTracker Red CMXRos (red). 
The MGF360-18R proteins were visualized using a monoclonal anti-HA 
antibody (green). Cell nuclei were stained with DAPI (blue). Bar, 10μm. 
Both ASFV ORF MGF360-18R proteins from either Ba71V or 
Benin97/1 isolates colocalize with the mitochondria. These cellular 
organelles are known to be involved in several steps of the innate 
immune response and, in particular, are essential for the signalling 
function of mitochondrial antiviral signalling protein (MAVS). This 
protein functions as an adaptor recruited by two cytosolic RNA 
sensors, the retinoic acid-inducible gene-1 (RIG-I) and the melanoma 
differentiation-associated gene 5 (MDA5). Signalling of these two 
receptors through MAVS leads to activation of IRF-3, IRF-7 and NF-
кB, transcription factors responsible for IFN-β induction. 
 
18R (Benin97/1) Mitochondria Nuclei Merge B 
18R (Ba71V) Mitochondria Nuclei Merge A 
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3.4.3. The inhibition of IFN-β transcription by ASFV ORF 
MGF360-18R is NF-кB dependent 
In order to confirm and determine the effect of the two variants of the 
MGF360-18R ORF in the induction of IFN-β, both ORFs were 
screened using a luciferase reporter assay. This assay is based on 
transfection into Vero cells of an IFN-β promoter cloned into a 
luciferase reporter plasmid and its subsequent activation by the type I 
IFN inducer, the synthetic dsRNA analogue Poly (I:C). The Vero cell 
line has the additional advantage of lacking the type I IFN locus, which 
facilitates the interpretation of the results, since the IFN amplification 
loop is absent in these cells and so control background levels are low. 
In this screening, expression plasmids of either variant of the MGF360-
18R gene (Ba71V or Benin97/1) were co-transfected with the IFN-β 
luciferase reporter plasmid and were found to inhibit IFN-β induction in 
response to Poly (I:C) (see Fig.3.3-A). The Benin97/1 variant 
consistently inhibited more than the Ba71V variant. 
The dsRNA added to the medium can be recognized by either TLR3 or 
RIG-I/MDA5 (RLR pathway), resulting in the activation of both NF-кB 
and IRF transcription factors [17]. In order to determine if MGF360-
18R mediated inhibition of IFN-β induction is also affecting NF-кB 
activation, a luciferase reporter plasmid containing only the NF-κB 
binding site of the IFN-β promoter, the positive regulatory domain 
(PRD)-II, was used. Again, Vero cells were transfected with the empty 
plasmid or the expression plasmid for either variant of MGF360-18R 
gene. The results obtained using this reporter indicate that both 
MGF360-18R variants inhibit IFN-β induction in response to Poly (I:C) 
through an NF-κB dependent pathway (see Fig.3.3).  
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Figure 3.3 – Both variants of the ASFV MGF360-18R gene inhibit 
Poly (I:C) stimulated activation of IFN-β transcription in an NF-кB 
dependent manner. 
Vero cells were co-transfected with the pcDNA3HA (Control) or pcDNA3HA-
18R plasmid expressing the MGF360-18R variant from Ba71V or Benin97/1, 
the β-galactosidase plasmid and either the (A) IFN-β promoter (IFNβ) or the 
(B) NF-кB promoter (PRDII) luciferase reporter. For both assays, seventy-two 
hours post-transfection, the cells were either induced with 35μg/ml Poly (I:C) 
for five hours (■), or left untreated (□). Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of Relative Luciferase Units (RLU) ± SD of triplicate well 
from one of three similar experiments. Statistical significance is represented 
as p≤0.05 (*) or ≤0.01 (**). 
* 
** 
0 
10 
20 
30 
Control 18R 
(Ba71v) 
18R 
(Benin97/1) 
R
L
U
 
(I
F
N
β
 a
c
ti
v
a
ti
o
n
) 
No Poly I:C 
+ Poly I:C 
** 
** 
0 
10 
20 
30 
Control 18R  
(Ba71V) 
18R 
(Benin97/1) 
R
L
U
 
(N
F
-к
B
 a
c
ti
v
a
ti
o
n
) 
No Poly I:C 
+ Poly I:C 
A 
B 
Chapter 3 
151 
3.4.4. The ASFV MGF360-18R ORF inhibits induction of IFN-β 
secretion 
To examine the inhibition of IFN-β induction at the level of protein 
expression, the amount of IFN-β secreted into the supernatants of cells 
expressing either MGF360-18R variant (Ba71V or Benin97/1) or empty 
control plasmid was determined by ELISA. Due to the fact that Vero 
cell line lacks the IFN gene, another cell line had to be used to 
measure IFN production. The IPAM cell line was chosen as, 
appropriately, it is the cell type (porcine macrophage) naturally infected 
by the ASFV. 
 
Figure 3.4 – MGF360-18R inhibits IFN-β secretion. 
IPAM cells were transfected with pcDNA3HA (Control) or pcDNA3HA-18R 
plasmid expressing the MGF360-18R variant from Ba71V or Benin97/1. Forty-
eight hours post-transfection, the cells were stimulated with 100μg/ml 
Poly (I:C) for 16 hours (■), or left untreated (□). Supernatants were collected 
and IFN-β concentration (pg/ml) was measured by ELISA. Data are 
expressed as means ± SD of triplicate well from one of two similar 
experiments. ** Statistically significant when compared to control vector-
expressing cells (p≤0.01). 
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Control cells stimulated with Poly (I:C) expressed significantly higher 
levels of IFN-β when compared to non stimulated control cells, as 
expected. The expression of IFN-β protein by Poly (I:C) stimulated 
cells expressing either variant of MGF360-18R (Ba71V or Benin97/1), 
on the other hand, was almost completely inhibited (see Fig.3.4). 
These results are consistent with the MGF360-18R mediated inhibition 
of IFN-β transcription previously observed. In conclusion, MGF360-
18R inhibits IFN-β induction both at the level of transcriptional 
activation and protein secretion. 
3.4.5. The ASFV MGF360-18R ORF inhibits activation of IFN-β 
transcription by targeting MAVS 
The cytosolic dsRNA recognition receptors (RLRs) signal through a 
common adaptor protein, MAVS, which is anchored to the outer 
mitochondrial membrane, a location known to be essential for its 
function. Signalling through MAVS activates two pathways: a TRAF6-
dependent pathway that culminates in the activation of NF-кB, and a 
pathway through TBK1 and IKKԑ, two IкB kinase-related kinases 
responsible for the phosphorylation of both IRF3 and IRF-7. Following 
activation, these transcription factors translocate into the nucleus and 
initiate transcription of IFN genes. Considering the mitochondrial 
localization of both MGF360-18R variants, as well as their inhibitory 
effect on both the induction of IFN-β promoter and NF-кB activation, 
MAVS is an immediately plausible candidate as a possible target for 
the viral protein. 
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In order to determine if both MGF360-18R variants are able to inhibit 
IFN induction signalling mediated by MAVS, Vero cells were co-
transfected with the MAVS expression plasmid and the IFN-β 
luciferase reporter plasmid, in the presence of increasing quantities of 
MGF360-18R (either Ba71V or Benin97/1). In the positive control, 
ectopic expression of MAVS significantly increased the IFN-β 
promoter-mediated luciferase activity. As presented here, the 
expression of both variants of the MGF360-18R gene inhibits the 
activation of IFN-β gene transcription by MAVS (see Fig.3.5). Once 
again, the Benin97/1 variant was consistently a more potent inhibitor 
than the Ba71V variant. 
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Figure 3.5 – Both variants of the ASFV MGF360-18R gene inhibit 
activation of IFN-β transcription by MAVS. 
Vero cells were co-transfected with the IFN-β promoter luciferase reporter, the 
β-galactosidase control plasmid, 40ng of MAVS (■) and increasing amounts 
(200-600ng) of pcDNA3HA-18R plasmid expressing the MGF360-18R variant 
from Ba71V (A) or Benin97/1 (B). Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of RLU ± SD of triplicate well from one of three similar 
experiments. Statistical significance, compared to control vector-expressing 
cells, is represented as p≤0.05 (*) or ≤0.01 (**). 
To further investigate the impact of both MGF360-18R variants on 
MAVS signalling, increasing amounts of the adaptor protein were 
expressed in cells transfected with MGF360-18R expression plasmid 
(either Ba71V or Benin97/1 variant) and stimulated with Poly (I:C), or 
left untreated. The impact of the viral gene on the IFN- luciferase 
reporter activity was measured. 
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Figure 3.6 – Overexpression of MAVS reverses MGF360-18R mediated 
inhibition of the IFN-β transcription. 
Vero cells were co-transfected with increasing amounts (40-100ng) of MAVS 
plasmid in the presence of either pcDNA3HA (Control) or pcDNA3HA-18R 
plasmid expressing the MGF360-18R variant from Ba71V (A) or 18R-
Benin97/1 (B), the IFN-β promoter luciferase reporter and the β-galactosidase 
control plasmid. Seventy-two hours post-transfection, the cells were 
stimulated with 35μg/ml Poly(I:C) for five hours (■), or left untreated (□). 
Luciferase activity was normalized to β-galactosidase activity as a control for 
transfection efficiency. Data are expressed as means of RLU ± SD of triplicate 
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well from one of three similar experiments. ** Statistically significant when 
compared to control vector-expressing cells (p≤0.01). 
As can be seen (Fig. 3.6), overexpression of MAVS reversed the 
MGF360-18R mediated inhibition of the Poly (I:C) activated IFN-β 
reporter, in a dose-dependent manner. This result is consistent with 
the hypothesis that both variants of the ASFV MGF360-18R ORF 
target MAVS signalling. 
A potential target for evading antiviral responses is the adaptor protein 
MAVS itself. Immunofluorescence assays were performed to verify if 
both variants of MGF360-18R and MAVS colocalize to the same 
location. 
 
 
 
Figure 3.7 – Both variants of the MGF360-18R colocalize with MAVS. 
Vero cells were transfected with pcDNA3HA-18R (either Ba71V or Benin97/1 
variant). MAVS protein was visualized using mouse anti-MAVS antibody 
(Santo Cruz) (red). The MGF360-18R proteins were visualized using a 
monoclonal anti-HA antibody (green). Cell nuclei were stained with DAPI 
(blue). Bar, 10μm. 
18R (Ba71V) Mitochondria Nuclei Merge A 
18R (Benin97/1) Mitochondria Nuclei Merge B 
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As can be seen, Ba71V variant of MGF360-18R protein is being 
expressed to the same location of MAVS, while the Benin97/1 variant 
shows only a partial colocalization. The MAVS adaptor has been 
reported to be present in both mitochondria and peroxisome. The 
results presented in both Fig.3.2 and Fig.3.7, suggest that both 
variants of MGF360-18R colocalize to mitochondrial MAVS. 
The colocalization of MGF360-18R and MAVS indicate that there may 
be an interaction between these two proteins. An immunoprecipitation 
assay was performed, in order to verify this assumption. 
 
 
 
 
 
 
 
 
Figure 3.8 – The ASFV ORF MGF360-18R (Ba71V) co-immunoprecipitates 
with MAVS. 
Vero cells were transfected with either non-recombinant pcDNA3HA or 
pcDNA3HA-18R plasmid expressing the MGF360-18R variant from Ba71V. 
Forty-eight hours post-transfection, the cells were stimulated with 100μg/ml 
Poly (I:C) for 30 minutes, or left untreated. Cell lysates were 
immunoprecipitated with control mouse IgG (Ig) or anti-MAVS (αMAVS). The 
immunoprecipitates (IP) were analyzed by immunoblot with anti-HA or anti-
MAVS (upper panel). Expression of MAVS and MGF360-18R (Ba81V) in the 
lysates was detected by immunoblot analysis with anti-MAVS and anti-HA 
(bottom panel). 
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The results presented here (see Fig.3.8) confirm that MGF360-18R 
(Ba71V variant) directly interacts with MAVS, possibly interfering with 
its function as an essential adaptor for the RLR signalling pathway. 
This same assay is to be performed using cells expressing the 
Benin97/1 variant of MGF360-18R protein, in order to confirm if both 
variants of this viral gene directly interact with MAVS. 
3.4.6. The MGF360-18R (Benin97/1) ASFV gene, but not the 
Ba71V variant, inhibits both TLR and cytosolic IFN-β 
induction pathways, acting at the level of IRF-3 
To verify if the action of both variants of the MGF360-18R gene over 
the IFN-β induction in response to Poly (I:C) is limited to interfering 
with the MAVS adaptor protein, we assayed for impact of the viral 
genes on the activation of downstream signalling intermediates of the 
RLR pathway. Vero cells were co-transfected with IRF-3 expression 
plasmid and the ISG15 luciferase reporter plasmid, in the presence of 
increasing quantities of MGF360-18R (either Ba71V or Benin97/1). In 
the positive control, ectopic expression of IRF-3 significantly increased 
the ISG15 promoter-mediated luciferase activity. As presented here, 
the expression of the Benin97/1 variant of the MGF360-18R gene also 
inhibits the activation of the IRF-3 transcription factor. In contrast, the 
Ba71V variant did not (see Fig 3.9). 
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Figure 3.9 – Expression of Benin97/1 variant of MGF360-18R, but not 
Ba71V variant, inhibits the activation of IRF-3 
Vero cells were co-transfected with the ISG15 promoter luciferase reporter, 
the β-galactosidase control plasmid, 100ng of IRF-3 (■) and increasing 
amounts (200-600ng) of pcDNA3HA-18R plasmid expressing the MGF360-
18R variant from Ba71V (A) or Benin97/1 (B). Luciferase activity was 
normalized to β-galactosidase activity as a control for transfection efficiency. 
Data are expressed as means of RLU ± SD of triplicate well from one of three 
similar experiments. * Statistically significant when compared to control 
vector-expressing cells (p≤0.05). 
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In order to verify if the MGF360-18R (Ba71V variant) protein is 
interfering with any other signalling intermediates in the IFN-β 
induction pathway, the IFN-β luciferase reporter activity was measured 
in cells ectopically expressing the upstream signalling intermediates 
TBK1 or IKKɛ. 
 
 
Figure 3.10 – ASFV ORF MGF360-18R (Ba71V variant) does not inhibit 
IFN-β induction by ectopic expression of TBK1 (A) or IKKɛ (B). 
Vero cells were co-transfected with the IFN-β promoter luciferase reporter, the 
β-galactosidase control plasmid, 100ng of TBK1 (A) or IKKɛ (B) (■) and 
increasing amounts (200-600ng) of pcDNA3HA-18R plasmid expressing the 
MGF360-18R variant from Ba71V. Luciferase activity was normalized to β-
galactosidase activity as a control for transfection efficiency. Data are 
expressed as means of RLU ± SD of triplicate well from one of three similar 
experiments. 
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As presented here, the Ba71V variant of the MGF360-18R gene had 
no effect over the activation of IFN-β gene transcription by ectopic 
expression of either TBK1 (Fig.3.10-A) or IKKɛ (Fig.3.10-B). This 
confirms that the inhibitory action of the Ba71V variant of MGF360-18R 
over the signalling mechanism leading to induction of IFN-β is limited 
to interfering with the MAVS adaptor. 
The Benin97/1 variant of MGF360-18R, however, has an additional 
inhibitory role over the activity of IRF-3, a critical transcription factor 
necessary for induction of type I IFN. To further understand the 
mechanism by which this viral protein inhibits the activation of IRF-3, 
Vero cells were transfected with MGF360-18R (Benin97/1 variant) 
expression plasmid, and the levels of phosphorylated and total IRF-3 
were estimated by immunoblot analysis using specific antibodies. 
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Figure 3.11 – Expression of the ASFV MGF360-18R (Benin97/1 variant) 
protein results in a reduction of the levels of phosphorylated IRF3 and 
total IRF3, on activated cells. 
COS-1 cells stably expressing MGF360-18R (Benin97/1) were stimulated by 
either ectopic expression of MAVS (A) or IKKԑ (B). Forty-eight hours post-
transfection, the cells were lysed and total cell lysates were immunobloted 
with anti-phosphorylated IRF-3 and anti-IRF-3. Anti-β-actin antibody was used 
as loading control. Expression of MGF360-18R (Benin97/1) was detected 
using an anti-HA-HRP conjugated antibody. WB signal was quantified by 
determining the integrated optical density (I.O.D.) of a given band, normalized 
to the corresponding loading control, using ImageJ 1.43u software. 
This assay revealed that expression of the Benin97/1 variant of 
MGF360-18R is able to effectively reduce the cellular levels of IRF-3 
on activated cells. This can be seen on cells activated by ectopic 
expression of either MAVS or IKKԑ, two proteins acting at different 
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levels of the RLR signalling pathway. These observations are in 
accordance to the results obtained by luciferase reporter assays (see 
Fig.3.5-B and Fig.3.9-B). 
3.5. Discussion 
ASFV inhibits production of IFN 
African swine fever virus (ASFV) is an economically important 
cytoplasmically replicating DNA virus of pigs, endemic in many African 
countries, and which has entered Portugal with a disastrous economic 
impact [18]. There is no vaccine and, although ASFV is known to 
interfere with signalling pathways controlling the transcription of a large 
number of immunomodulatory genes, such as cytokines [19,20,21], no 
individual virus gene manipulating the IFN response has been 
reported. This is all the more surprising as ASFV not only results in an 
acute phase, but may also persist. It is hard to imagine that a virus 
could persist in the face of an efficient IFN response. 
The ORF MGF360-18R, which has been identified in a previous 
screening performed in our laboratory (Correia, S.M., unpublished 
work) as an inhibitor of the IFN-β induction, belongs to the ASFV 
MGF360 family. Several studies have established that proteins 
encoded by the MGF360 and MGF530 genes are involved in the 
modulation of the interferon response by ASFV [2]. The individual 
family members, however, have not been investigated as possible 
inhibitors of the IFN response. 
A sequence comparison of the genomic sequence of different ASFV 
isolates revealed that MGF360-18R is a non-conserved ORF. The 
pathogenic isolates code for significantly larger proteins, relatively to 
the attenuated and non-pathogenic isolates. The Benin97/1 isolate 
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codes for the largest variant of this protein, with 254a.a., while the 
attenuated variant of this protein encompass only 148a.a. (see Anex).  
Both variants of ORF MGF360-360 were shown to inhibit the induction, 
expression and secretion of IFN-β. To determine the intracellular target 
of the MGF36018R gene, luciferase assays were performed, in which 
different components of the IFN induction pathway were ectopically 
expressed. It was possible to determine that both variants inhibited the 
RLR pathway at the level of MAVS adaptor, thereby interfering with 
both NF-κB activation and induction of type I IFN. Both variants were 
also shown to inhibit the Poly (I:C) stimulated secretion of the IFN-β 
protein by the porcine cell line (IPAM), thus emphasising the biological 
significance of this viral gene in the inhibition of IFN response by 
ASFV. Interaction of MGF360-18R with MAVS was confirmed by 
intracellular colocalization of the two proteins and by co-
immunoprecipitation. Immunofluorescence analysis revealed a clear 
co-localization with mitochondria, but not peroxisome, thus indicating 
that MGF360-18R protein acts upon the more sustained antiviral 
response, inhibiting the RLR mitochondria-dependent pathway that 
leads to the induction of IFN-β expression through the activation of 
IRF-3 and NF-κB. 
Moreover, MGF360-18R variant from Benin97/1 was shown to inhibit 
the induction of ISG15 promoter on cells ectopically induced by 
overexpression of IRF3. This indicates that, in addition to its inhibitory 
role in the RLR pathway by interfering with MAVS, this variant of the 
MGF360-18R is able to inhibit the activity of the IRF3 transcription 
factor, hence directly affecting IRF-3 stimulated ISG transcription. The 
results indicate that expression of MGF360-18R (Benin97/1) protein 
results in diminished quantities of IRF-3 in the cell, which might 
Chapter 3 
165 
indicate an increased degradation of this transcription factor. The exact 
mechanism, however, remains to be completely elucidated. 
MAVS as a target for virus strategies to inhibit the IFN response 
The Melanoma Differentiation-Associated Gene (MDA)-5 and the 
Retinoic Acid Inducible Gene (RIG)-I are RLR family members 
involved in viral recognition and induction of type I IFN. Both have a 
caspase recruitment domain (CARD) that allows for interaction with 
their common adaptor, Mitochondrial Antiviral Signalling (MAVS), and 
the subsequent antiviral responses. Recently, these cytosolic RNA 
receptors were described to be involved in antiviral signalling in 
response to viruses containing a dsDNA genome, such as Epstein–
Barr virus (EBV) [22] and vaccinia virus [23], respectively. Some 
viruses attack RLRs themselves, either through cleavage or direct 
inhibition of the receptor. Another potential target for evading antiviral 
responses is the adaptor protein MAVS. 
The C-terminal transmembrane domain of the adaptor protein MAVS 
anchors it to the mitochondrial outer membrane, suggesting a crucial 
role for mitochondria as a platform for the signalling pathways leading 
to type I IFN induction [24]. Recent studies showed that, in response to 
viral infection, MAVS redistributes in the mitochondria, forming large 
aggregates that are potent activators of IRF-3 [25]. A mitochondrial 
membrane protein, Mitofusin (MFN)-1, is known to be involved in the 
redistribution of MAVS along the mitochondria, following RLR 
activation, as well as in the fusion of the mitochondrial network. This 
fusion promotes the interaction between MAVS and the STimulator of 
Interferon Genes (STING), an antiviral signalling adaptor localized in 
the endoplasmic reticulum membrane, thereby amplifying the antiviral 
response. Another protein also involved in the regulation of 
mitochondrial fusion, MFN-2, is a direct MAVS inhibitor, counteracting 
Chapter 3 
166 
the action of MFN-1 and possibly contributing to the fine-tuning of 
MAVS-mediated signalling [24]. These observations support the view 
that basic mitochondrial functions are integrated with innate immunity, 
and that innate immune signalling based on the mitochondria largely 
depends on this organelle’s activity and fitness. 
Very recently, MAVS was also identified on the peroxisome 
membrane, and it was proposed that peroxisomal MAVS is required for 
the rapid induction of antiviral effectors, mediated by the transcription 
factors IRF-1 and IRF-3. Mitochondrial MAVS is necessary for a more 
sustained response, inducing IFN-β expression through the activation 
of IRF-3 [26]. Antiviral immunity through the RLR pathway requires 
MAVS signalling from both organelles, an indication that both 
pathways are interconnected, cooperating for the establishment of an 
antiviral state. Interaction of both variants of MGF360-18R with 
peroxisomal MAVS was excluded by immunofluorescence assays. The 
clear colocalization of the viral proteins with the mitochondria and 
MAVS, are suggestive of an interaction with mitochondrial MAVS. Both 
variants of MGF360-18R most possibly interfere with RLR signalling 
through the mitochondria, thus preventing the establishment of a more 
sustained antiviral response. Immunoprecipitation of mitochondrial 
fractions with MAVS antibody could help to clarify if MGF360-18R 
indeed interacts with mitochondrial MAVS. 
Proteolytic cleavage of MAVS is a frequent strategy used by viruses to 
inhibit RIG-I dependent type I IFN expression. The NS3/4A protease of 
hepatitis C virus [27], the 3ABC protease of hepatitis A virus [28] or the 
3Cpro cysteine protease of coxsackievirus B3 [29] are known 
examples of such a strategy. Poliovirus infection triggers a caspase-
dependent cleavage of MAVS, whereas rhinovirus degrades MAVS in 
a caspase independent manner. In fact, overexpression of caspase 
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inhibitors or the anti-apoptotic factor Bcl-xL prevents MAVS cleavage 
during viral infection, suggesting that MAVS may be involved in 
apoptosis of virus-infected cells [30]. The murine gamma herpesvirus 
68 (HV68) exploits innate antiviral signalling pathways to evade the 
innate immune response. It hijacks MAVS and IKK-β in order to 
promote site-specific (Ser468) phosphorylation of RelA, a crucial 
subunit of the transcriptionally active NF-кB dimer. In result of this 
phosphorylation, RelA is primed for ubiquitination and proteasome-
mediated degradation. As such, HV68 efficiently abrogates NF-кB 
activation and inflammatory cytokine expression [31].  
Although the results presented here point out MAVS as a target for 
MGF360-18R (both Ba71V and Benin97/1 variants), the exact 
mechanism of action of these viral proteins remains to be clarified. 
There is no indication that MAVS is being degraded or processed by 
proteolysis. The direct interaction of MGF360-18R with MAVS may 
impede its association with the RLR receptors, thereby blocking the 
signalling mechanism. Another possibility is that the viral protein 
prevents MAVS redistribution and aggregation in the mitochondria, an 
event that is crucial for the activation and propagation of the antiviral 
signalling cascade. 
IRF3 as a target for virus strategies to inhibit the IFN response 
Significantly, the MGF360-18R (Benin97/1 variant) gene impaired the 
activation of both the IFN-β promoter and the ISG15 promoter (ISRE 
element) through ectopic expression of IRF-3. While this is indicative 
that the Benin97/1 variant of MGF360-18R, in addition to interfering 
with MAVS, also targets IRF-3, the precise mechanism being used to 
modulate this transcription factor is yet to be completely elucidated. 
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The induction of Type I IFN is primarily regulated at the level of 
transcription and involves the formation of a large, multi-subunit 
complex called the “enhanceosome”, which comprises the binding of 
promoter-specific transcription factors, associated structural elements 
and basal transcriptional machinery to the enhancer DNA sequence 
[32]. The IRF-3 transcription factor is a critical player in the induction of 
IFN-β. It is expressed constitutively and in the absence of infection it 
localizes in the cytoplasm as an inactive monomer [33], which has 
been described to constitutively shuttle in and out of the nucleus [34].  
Many viruses have evolved efficient ways of subverting the host 
immune system by targeting IRF-3 activity. The different mechanisms 
described include its targeting for degradation, and the inhibition of its 
phosphorylation and thus its subsequent nuclear translocation and 
binding to the promoter region of IFN-β gene. For instance, E3 
ubiquitin ligase RBCC protein interacting with PKC1 (RBCK1) binds to 
IRF3 and targets it for ubiquitination and subsequent degradation 
through a proteasome-dependent pathway [35]. Our results are 
indicative that the MGF360-18R gene might be targeting IRF-3 for 
degradation. A luciferase assay in the presence of the proteasomal 
inhibitor MG132 should be performed, in order to determine if this 
variant of the MGF360-18R gene would be capable of inhibiting the 
luciferase activity of the IFN-β promoter reporter gene in such 
conditions.  
In conclusion, both variants of the ASFV MGF360-18R protein impair 
activation of IFN-β induction through targeting MAVS, a key adaptor 
protein of the RLR pathway. The MGF360-18R variant from the 
Benin97/1 isolate, also targets IRF-3, which might give the virus an 
extra advantage. The full details of the mechanism of action of both 
variants of this viral gene remain to be elucidated. 
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4.  
4.1. Summary 
The IFN system is an important first line of defence against virus 
infections. Viruses have evolved defence strategies, not only to inhibit 
the expression of IFN, but also to modulate the establishment of the 
antiviral state, thereby inhibiting the antigen presentation through 
increased MHC class I expression. 
The main focus of this work is MGF360-18R, a non-conserved protein 
of the ASFV that evolved for the inhibition of IFN responses. Here, its 
ability to modulate IFN-mediated signalling is demonstrated. The 
results presented show that the ASFV MGF360-18R protein is able to 
impair the host cell response to both IFN-α and IFN- (Jak-STAT 
pathway) inducing STAT1 degradation by the 26S proteasome. 
4.2. Introduction 
In order to establish an effective antiviral response, the response to 
IFNs released by infected or activated cells must be rapid and efficient. 
These cytokines can stimulate an antiviral state in an autocrine or 
paracrine manner by binding to distinct receptors on the surface of 
infected or neighbouring target cells. One of the major signalling 
cascades activated by IFNs is the Jak-STAT signalling pathway, which 
leads to induction of ISGs and the resulting synthesis of proteins that 
are able to interfere with several cellular and viral processes. As a 
result, replication of the virus can be blocked or impaired, and both 
infected and neighbouring cells are made more susceptible to 
apoptosis, limiting virus spread. In addition, interferons also have a 
role in the priming and activation of several cell types of both the 
innate and adaptive immune system. 
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Type I and type II IFNs bind to specific cell surface receptors, 
activating distinct but related signalling pathways, known as the Jak-
STAT pathways. Binding of type I IFN to its specific receptor results in 
the activation of the Janus tyrosine kinases, Jak1 and Tyk2, which will 
phosphorylate STAT1 (at Tyr701) and STAT2 (at Tyr690), respectively. 
The activated STATs dissociate from the type I IFN receptor, forming a 
stable heterodimer that associates with IRF-9, forming the ISGF3 
tertiary complex. This transcription factor translocates to the nucleus 
and bind to IFN-stimulated response elements (ISRE) present in the 
promoter region of IFN-stimulated genes (ISGs) [1,2,3], thereby 
resulting in the transcription of several genes associated with this arm 
of the IFN response. Type III IFNs have type I IFN-like biological 
functions and, although binding to a distinct receptor, are able to 
activate the same Jak-STAT pathway [4]. 
Type II IFN acts by a separate Jak-STAT pathway. The binding of IFN-
 to the Type II IFN receptor activates both Jak1 and Jak2, leading to 
the phosphorylation of STAT1 (at Tyr701) and posterior 
homodimerization. STAT1 homodimers translocate to the nucleus and 
bind to unique elements of IFN-γ stimulated genes, the gamma-
activation sequence (GAS), and stimulate transcription of genes 
characteristic of responses to IFN type II. Of note is the fact that type I 
IFN stimulation can also lead to formation of STAT1-homodimers and 
leads to the induction of genes containing GAS elements in their 
promoter region [1]. 
The response to IFNs must be tightly regulated and terminated once 
the viral threat is over, in order to avoid damage to the host. A 
common mechanism for the regulation of several cellular processes is 
proteolysis following the conjugation of ubiquitin to proteins. 
Ubiquitination of STAT proteins results in their degradation by the 26S 
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proteasome-dependent pathway. This is the only mechanism that 
reduces the levels of STAT proteins in the cell, helping to regulate 
STAT signalling and restrain the inflammatory response. Regulation of 
IFN-activated STAT1 levels by the ubiquitin-proteasome pathway was 
demonstrated in 1996, by Kim and Maniatis [5] and, some years later, 
PDLIM2 protein was identified as a STAT1 ubiquitin E3 ligase [6]. It 
was later reported that phosphorylation of PDLIM2 Ser-137 is required 
for Ub-P-STAT1 formation and degradation by the 26 S proteasome 
system [7].  
Given that interferon-mediated signalling plays an important role in 
anti-viral immunity, it is not surprising that viruses have evolved 
multiple means for its downregulation. Type I and type II IFN activate 
downstream components that can be either unique or common to both 
signalling pathways. Thus, viruses can block the impact of IFN at 
several levels, inhibiting only one of these two pathways or both. 
Modulation of STAT activity, either directly or indirectly, is a very 
common viral strategy. Viral proteins can inhibit the Jak kinases, 
preventing STAT activation [8], act by binding to STAT proteins, 
inducing their degradation [9], or prevent nuclear accumulation of 
STAT [10]. Other viruses induce expression of cellular inhibitors of the 
Jak-STAT pathways [11]. All these strategies share the common 
objective of inhibiting the signal transduction pathways triggered upon 
binding of IFN to its specific receptor.  
Deletion of members of the ASFV multigene families (MGF) 360 and 
530 has been shown to increase production of type I IFN and 
activation of IFN induced genes in infected macrophages. This 
suggests that these genes may have a role in inhibiting transcription of 
ISGs, although this remains to be demonstrated [12]. 
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The non-conserved ORF MGF360-18R, a member of MGF360, was 
investigated in detail in order to understand the mechanism by which it 
inhibits the response to both type I and type II IFN. Two variants of this 
viral gene, the pathogenic Benin97/1 isolate variant and the shorter 
tissue culture-adapted Ba71V variant, characterized in the previous 
chapter, were studied. Both inhibit the induction of IFN-β and in this 
chapter we define how the same two variants inhibit the impact of 
secreted Type I and Type II IFN. The results indicate that both ASFV 
MGF360-18R proteins inhibit the impact of type I and type II IFN (Jak-
STAT pathway) by inducing STAT1 degradation by the 26S 
proteasome. 
4.3. Materials and methods 
4.3.1. Cell culture 
African green monkey Vero cells were cultured in Dulbecco´s Modified 
Eagle´s Medium (DMEM) (Gibco) supplemented with 100U/ml 
penicillin G sodium /100μg/ml streptomycin sulfate (Gibco), 2mM L-
Glutamine (Gibco) and 10% (v/v) heat-inactivated fetal bovine serum 
(FBS) (Gibco). Cells were incubated at 37ºC, in 5%CO2. 
4.3.2. Plasmids 
The two variants of the ASFV open reading frame MGF360-18R were 
amplified by PCR from either BA71V or Benin-97/1 isolate DNA and 
cloned into the pcDNA3 plasmid in frame with an amino-terminal 
influenza haemaglutinin (HA) tag. 
The IFN-α/β responsive plasmid [p(9-27ISRE)4tk∆(-39)lucter] and the 
IFN- responsive plasmid [p(IRF-1*GAS)6tk∆(-39)lucter] were gifts of 
Dr. S. Goodbourn. The first contain four tandem copies of the 9-27 
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ISRE sequence (AGGAAATAGAAACTG) fused to the firefly luciferase 
gene and the latter contain six tandem copies of the IRF-1 GAS site 
(TTTCCCCGAAA) also fused to the firefly luciferase gene. 
The pCMVβ plasmid contains a β-galactosidase gene under the 
control of human cytomegalovirus immediate early promoter, and 
serves as an internal control for culture to culture variations in 
transfection efficiency. 
4.3.3. Luciferase reporter gene assay 
Vero cells (6x104 cells/well, in a 24 well plate) were co-transfected with 
100ng of the indicated luciferase reporter plasmid, 25ng of the β-
galactosidase internal control plasmid (pCMVβ) and 300ng of either 
pcDNA3HA-18R (Ba71V), pcDNA3HA-18R (Benin97/1) or non-
recombinant pcDNA3HA, according to the Lipofectamine 2000 
(Invitrogen) protocol. Seventy two hours post-transfection the cells 
were either stimulated with 1U/μl human IFN- (cells transfected with 
GAS reporter) or 1U/μl human IFN-α (cells transfected with the ISRE 
reporter) for five hours, or left untreated.  
In an alternative protocol using the proteasome inhibitor MG132 
(Calbiochem), the cells were either treated with 10μM MG132, or with 
DMSO, together with 1U/μl human IFN-.  
After the treatment, the cells were lysed. The luciferase activity was 
measured using the luciferase assay system (Promega) according to 
the manufacturer`s protocol. The β-galactosidase activity was 
measured using the Galacton-Plus kit from Tropix (Bedford, MA). The 
luciferase activity was normalized relatively to the β-galactosidase 
activity of each sample, as to correct transfection efficiency variations 
between different cells. 
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4.3.4. Western blot 
Vero cells (3x105 cells/well, in a 6 well plate) were transfected with 3μg 
of either pcDNA3HA-18R (Ba71V) or the non-recombinant pcDNA3HA, 
according to the Lipofectamine 2000 (Invitrogen) protocol. 
Alternatively, lentivirus infected COS-1 cells, stably expressing 
MGF360-18R (Benin97/1), were used. Forty-eight hours post-
transfection, the cells were stimulated with 1U/μl human IFN- 
(ImmunoTools) or 1U/μl human IFN-α/β (ImmunoTools), during the 
indicated amounts of time, or left untreated. In an alternative protocol 
using the proteasome inhibitor MG132 (Calbiochem), the cells were 
either treated with 10μM MG132, or with DMSO, together with 1U/μl 
human IFN-, for the indicated amounts of time. 
Cells were then harvested and lysed using a non-ionic lysis buffer 
(15mM Tris-HCl, pH 7.4, 120mM NaCl, 25mM KCl, 2mM EDTA, 2mM 
EGTA, 0.1mM DTT and 1%Triton X-100) containing a protease 
inhibitor cocktail (Sigma). Cell lysates were resolved on a 12% sodium 
dodecyl sulphate-polyacrilamide gel (SDS-PAGE). The separated 
proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane (GE Healthcare). Membranes were blocked with 5% non-
fat milk for one hour at room temperature and probed with the following 
antibodies: rabbit anti-human phospho-STAT1(Tyr701) (Cell Signaling), 
rabbit anti-human STAT1 (CT) (Millipore), rabbit anti-human phospho-
STAT2(Tyr690) (Cell Signaling), rabbit anti-human STAT2(CT) (Santa 
Cruz), rat anti-HA-HRP conjugated (high affinity) (Roche) and anti-β-
actin-HRP conjugated (Sigma) as a loading control. Horseradish 
peroxidase-conjugated goat anti-rabbit secondary antibody was 
purchased from Invitrogen. Membranes were developed by enhanced 
chemiluminescence detection according to the manufacturer’s 
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instructions (SuperSignal West Pico Chemiluminescent Substrate, 
Thermo Scientific or Luminata Forte, Millipore). 
4.3.5. Immunoprecipitation 
Vero cells (5x105 cells/plate, in a 60 mm Ø plate) were transfected with 
6μg of either pcDNA3HA-18R (Ba71V) or the non-recombinant 
pcDNA3HA. Forty-eight hours post-transfection, the cells were either 
stimulated or not stimulated with 1U/μl human IFN- during 45 minutes, 
in the presence of either 10μM MG132 or DMSO. Cells were then 
harvested and lysed in lysis buffer (15 mM TrisHCl, pH 7.4, 120 mM 
NaCl, 25 mM KCl, 2mM EDTA, 2mM EGTA, 0.1mM DTT and 1% 
Triton X-100) containing a protease inhibitor cocktail (Sigma). 
Immunoprecipitation was performed with Dynabeads protein G 
(Millipore), using rabbit anti-human STAT1(CT) antibody (Millipore). 
Washes were performed using commercially available lysis buffer 
(Sigma). Elution was done using 2X sample buffer. 
Immunoprecipitation eluates were resolved on a 12% SDS-PAGE gel 
and proteins were transferred to a PVDF membrane (GE Healthcare). 
Membranes were blocked with 5% non-fat milk for one hour at room 
temperature and probed with the following antibodies: rabbit anti-
human STAT1(CT) (Millipore), anti-HA-HRP conjugated (Roche) and 
rabbit anti-ubiquitin (Cell Signaling). Detection of native antibodies on 
immunoblot membranes was performed using Clean-Blot IP Detection 
Reagent (HRP) (Thermo Scientific). 
4.3.6. Statistical Analysis 
Data were shown as mean values with standard deviations (SD). 
Differences between experimental groups were determined by a two-
tailed Student t test, using Excel software (Microsoft). 
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4.4. Results 
4.4.1. The ASFV MGF360-18R protein inhibits response to both 
type I and type II IFN 
As interferon-mediated signalling plays an important role in anti-viral 
immunity, not only in the induction of cellular, anti-viral proteins but 
also in stimulating antigen presentation through increased MHC class I 
expression, there is an obvious advantage for viruses to block IFN 
signalling. The objective of this work was to determine whether the 
MGF360-18R protein, already described as an inhibitor of the induction 
of IFNs in the previous chapter, was capable of impacting on the 
cellular response to both type I and type II IFNs. In addition, both 
variants of this ASFV ORF were tested and compared, regarding their 
inhibitory effect on the impact of type I and type II IFN. 
Reporter plasmids containing the luciferase gene under the control of 
ISRE or GAS elements were used to quantify the response of cells to 
IFN-α and IFN-, respectively. As can be observed, the luciferase 
activities of both reporter plasmids were strongly induced after 
stimulation with IFN-α and IFN- (Fig.4.1). In cells expressing either 
variants of the MGF-18R protein, however, the induction of both 
reporters was clearly and similarly reduced. This indicates that the two 
variants of MGF360-18R are able to inhibit type I (Fig.4.1-A) and type 
II (Fig.4.1-B) IFN signalling pathways. 
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Figure 4.1 – The two MGF360-18R variants (Ba71V and Benin97/1) inhibit 
signalling by both type I and type II IFN receptors. 
Vero cells were co-transfected with the pcDNA3HA (empty plasmid) or 
pcDNA3HA-18R plasmid expressing the MGF360-18R variant from Ba71V or 
Benin97/1, the β-galactosidase plasmid and either the (A) ISRE or the (B) 
GAS promoter luciferase reporter. For both assays, seventy-two hours post-
transfection, the cells were either induced with 1U/μl IFN-α or 1U/μl human 
IFN- for five hours (■), respectively, or left untreated (□). Luciferase activity 
was normalized to β-galactosidase activity as a control for transfection 
efficiency. Data are expressed as means of Relative Luciferase Units (RLU) ± 
SD of triplicate well from one of three similar experiments. Statistical 
significance is represented as p≤0.05 (*) or ≤0.01 (**). 
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4.4.2. The MGF360-18R protein diminishes the total amount of 
cellular STAT1 but has no effect on STAT2 
Upon binding of type I and type II IFN to their cognate receptors, the 
Jak-STAT pathways are activated, culminating in the nuclear 
translocation of activated STATs, initiating transcription of antiviral 
genes. It is not surprising that viruses have evolved mechanisms to 
inhibit IFN signalling, particularly by interfering with the activity of 
STATs. These proteins are modulated by different cellular 
mechanisms that can be exploited by viruses to their own advantage, 
such as proteasomal degradation, inhibition of phosphorylation by the 
Jak tyrosine kinases and finally inhibition of translocation into the 
nucleus [1,8,13]. 
To further understand the mechanism by which the ASFV MGF360-
18R protein inhibits the response to both type I and type II IFN, Vero 
cells were transfected with MGF360-18R expression plasmid, and the 
levels of endogenous STAT1 and STAT2 were estimated by 
immunoblot analysis using specific antibodies.  
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Figure 4.2 – Cells expressing MGF360-18R (Ba71V) protein show a 
reduction in the levels of STAT1, but not STAT2. 
Vero cells were transfected with non-recombinant pcDNA3HA or pcDNA3HA-
18R (Ba71V) expressing plasmid. Forty-eight hours post-transfection, cells 
were either induced with 1U/μl human IFN-β (A, C) or IFN- (B) for the 
indicated times, or left untreated. The cells were lysed and total cell extracts 
were immunobloted with anti-phosphorylated STAT1(Tyr
701
) and anti-
STAT1(CT) (A, B) or anti-phosphorylated STAT2(Tyr
690
) and anti-STAT2(CT) 
(C). Anti-β-actin antibody was used as loading control. Expression of 
MGF360-18R (Ba71V) was detected using an anti-HA-HRP conjugated 
antibody. 
Immunoblot analysis using antibodies against STAT1 revealed that 
there is less STAT1 in MGF360-18R expressing cells. When activated 
by either IFN-β or IFN-, cells expressing the viral gene also show a 
reduction in the levels of phosphotyrosine (701) for of STAT1, when 
compared to control cells (Fig.4.2-A and C). In contrast, the levels of 
STAT2 are not affected (Fig.4.2-B). 
A B 
C 
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4.4.3. MG132, a proteasome inhibitor, reverts the inhibition of 
GAS reporter by MGF360-18R 
No obvious degradation products of STAT1, such as breakdown 
intermediates originated by the action of sequence-specific 
endoproteases, were visible in the immunoblots. This observation 
suggested that the STAT1 protein is being degraded by a processive 
protease such as the ones acting in proteasome-mediated 
degradation.  
To test this hypothesis, Vero cells were treated with the proteasome 
inhibitor MG132, and the response of cells to IFN- was measured 
using the GAS luciferase reporter plasmid, containing a STAT1 binding 
promoter sequence. As can be observed, the luciferase activity of this 
reporter plasmid, when compared to control cells, was reduced in cells 
expressing either variants of the MGF360-18R protein, as expected. 
When these cells were treated with MG132, the luciferase activity was 
the same as in control cells (Fig.4.3). This demonstrates that, by 
blocking the proteasome-mediated degradation of STAT1, there is a 
reversion of the MGF360-18R mediated inhibition of the impact of type 
II IFN.  
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Figure 4.3 – Addition of MG132 reverts MGF360-18R-mediated inhibition 
of the impact of both type I and type II IFN. 
Vero cells were co-transfected with the empty pcDNA3HA (Control) or 
pcDNA3HA-18R plasmid expressing the MGF360-18R variant from Ba71V or 
Benin97/1, the β-galactosidase plasmid and the (A) ISRE or (B) GAS 
promoter luciferase reporter. Seventy-two hours post-transfection, the cells 
were either induced with 1U/μl human IFN- in the presence of 10μM of 
MG132 (■) or DMSO (■) for five hours, or left untreated (□). Luciferase activity 
was normalized to β-galactosidase activity as a control for transfection 
efficiency. Data are expressed as means of Relative Luciferase Units (RLU) ± 
SD of triplicate well from one of three similar experiments. Statistical 
significance is represented as p≤0.05 (*) or ≤0.01 (**). 
4.4.4. The proteasome inhibitor MG132 blocks degradation of 
STAT1 in cells expressing MGF360-18R 
To confirm that the results obtained in Fig. 4.3 are due to the inhibitory 
activity of MG132 on the proteasomal degradation of STAT1, the levels 
of STAT1 were examined in cells treated with this proteasome inhibitor 
(Fig.4.4 and 4.5). 
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Figure 4.4 – The proteasome inhibitor MG132 blocks degradation of 
STAT1 in cells expressing ASFV MGF360-18R (Ba71V). 
Vero cells were transfected with control pcDNA3HA or pcDNA3HA-18R 
(Ba71V) plasmid. Forty-eight hours post-transfection, cells were induced with 
1U/μl human IFN-, either in the absence or presence of MG132, during the 
indicated amounts of time. The cells were lysed and total cell extracts were 
immunobloted with anti-phosphorylated STAT1(Tyr
701
) (A) and anti-
STAT1(CT) (B). Anti-β-actin antibody was used as loading control. 
Expression of MGF360-18R (Ba71V) was confirmed using an anti-HA-HRP 
conjugated antibody. WB signal was quantified by determining the integrated 
optical density (I.O.D.) of a given band, normalized to the corresponding 
loading control, using ImageJ 1.43u software. 
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Figure 4.5 – The proteasome inhibitor MG132 blocks degradation of 
STAT1 in cells expressing ASFV MGF360-18R (Benin97/1). 
COS-1 cells stably expressing MGF360-18R (Benin97/1) or eGFP, were 
induced with 1U/μl human IFN-, either in the absence or presence of MG132, 
during the indicated amounts of time. The cells were lysed and total cell 
extracts were immunobloted with anti-phosphorylated STAT1(Tyr
701
) (A) and 
anti-STAT1(CT) (B). Anti-β-actin antibody was used as loading control. WB 
signal was quantified by determining the integrated optical density (I.O.D.) of 
a given band, normalized to the corresponding loading control, using ImageJ 
1.43u software. 
The results are consistent with the hypothesis that both variants of the 
MGF360-18R are targeting STAT1 for degradation. However, the 
results presented in Fig.4.5 are not conclusive, since the expression of 
the MGF360-18R (Benin97/1) could not be confirmed. 
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4.5. Discussion 
African swine fever virus (ASFV) has evolved a variety of strategies to 
evade host innate defence mechanisms, such as inflammation, 
interferon and cell death [14]. Since the interferon response is one of 
the first lines of defence against viral infections, it would be surprising if 
the virus had not evolved mechanisms to inhibit the induction of IFN 
and, as well, the impact of the subsequent secretion of IFN, after 
binding to its cellular receptors [3,15]. However, nothing is known of 
the precise mechanisms by which the virus might downregulate the 
impact of IFN. Here we demonstrate that the non-conserved ASFV 
ORF MGF360-18R inhibits the impact of both type I and type II IFNs 
through inducing degradation of the critical signalling intermediate 
STAT1. 
The Jak-STAT signalling pathway, which is able to induce the 
expression of specific genes, the ISGs, is the major signalling cascade 
activated by IFNs. In direct consequence, an antiviral state is elicited in 
the infected cells, which will either block or impair viral replication or 
make infected cells more susceptible to apoptosis, thereby limiting 
virus spread. In addition, interferons also have a role in the priming, 
activation and differentiation of several cell types of both the innate 
and adaptive immune system. 
Afonso et al. reported that deletion of some members of the ASFV 
multigene families (MGF) 360 and 530 increases production of type I 
IFN and activation of IFN induced genes in infected macrophages, 
leading to the suggestion that these genes may have a role in 
inhibiting transcription of ISGs [12]. The non-conserved ORF MGF360-
18R was identified, in a previous screening performed in our laboratory 
(Correia, S.M., unpublished work), as an inhibitor of the impact of both 
type I and type II IFN. Here we demonstrate that both the full length 
Chapter 4 
189 
variant of this gene from the pathogenic Benin97/1 isolate and the 
truncated gene from the non-pathogenic, tissue-culture adapted 
Ba71V virus, similarly inhibit the impact of type I and type II IFNs 
through degradation of the critical intracellular signalling intermediate 
STAT1.  
Specifically, the results indicate that in cells expressing the ASFV 
MGF360-18R protein and stimulated with either type I or type II IFN, 
both phosphorylated and unphosphorylated STAT1 levels are reduced, 
but the levels of STAT2 remain unaffected. Modulation of STAT activity 
is a very common viral tactic, which can be achieved by employing 
several strategies, with the common objective of inhibiting the signal 
transduction pathways triggered upon binding of IFN to its specific 
receptor. By reducing the levels of STAT1 protein present in IFN 
activated cells, the ASFV protein MGF360-18R is able to inhibit the 
impact of both type I and type II IFN, given that this transcription factor 
is common to both signalling pathways (see Fig.1.4). 
The observed reduction of STAT1 levels could be explained by an 
interference of the viral gene at either the level of transcription, 
translation or reduction of the protein half-life. The fact that no 
breakdown intermediates of STAT1 were observed in the immunoblots 
performed with lysates containing protease inhibitors is consistent with 
degradation via the proteasome rather than a result of the action of 
sequence-specific endoproteases.  
Previous studies have demonstrated that the levels of activated STAT1 
are regulated by the ubiquitin-proteasome pathway [5]. This raised the 
possibility that the polyubiquitination pathways of the cell could have 
been highjacked by the MGF360-18R protein, inducing 
polyubiquitination of STAT1 and its concomitant degradation by the 
proteasome. The assays performed using MG132, a proteasome 
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inhibitor, confirmed this hypothesis. In cells treated with MG132, a 26S 
proteasome inhibitor, both variants of the MGF360-18R protein no 
longer inhibited the expression of genes controlled by ISRE and GAS 
sequences in their promoter regions upon stimulation with IFN-α and 
IFN-, respectively. Additionally, the expression of either variants of the 
MGF360-18R protein no longer downregulate STAT1 levels. In cells 
where the 26S proteasome was blocked by MG132, the viral protein 
loses its ability to inhibit the impact of both type I and type II IFN. This 
indicates that the Jak-STAT pathway is being inhibited as a result of an 
increased proteasomal degradation of STAT1 induced by expression 
of MGF360-18R. It is possible that the MGF360-18R is hijacking the 
polyubiquitination pathways, inducing the ubiquitination of STAT1, and 
targeting it for degradation by the 26S proteasome. In order to test this 
hypothesis, lysates of cells expressing MGF360-18R can be 
immunoprecipitated with anti-STAT1 antibody and immunoblotted with 
anti-ubiquitin antibody, to verify if there is an accumulation of 
ubiquitinated STAT1 in IFN- activated cells treated with MG132, when 
compared to control cells. 
Further studies are needed to clarify the role of the ASFV protein in the 
induction of STAT1 polyubiquitination and define its mechanism of 
action. Protein ubiquitination is a common form of post-translational 
modification that regulates a broad spectrum of protein substrates in 
diverse cellular pathways. The attachment of ubiquitin to proteins 
occurs through a three-enzyme (E1–E2–E3) cascade. The E3 ubiquitin 
ligase, which is best represented by the superfamily of the Cullin-RING 
complexes, catalyses the ubiquitin attachment to its specific target. 
Previous studies on molecular mechanisms governing the stability of 
activated/phosphorylated STAT1 suggest that different E3 ligases 
target STAT1 for proteasomal breakdown, depending on its 
phosphorylation status [6,7,16]. The Cullin4A (Cul4A)-RING ubiquitin 
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E3-ligases (CRL4) are protein complexes that include the DNA-
Damage-Binding protein 1 (DDB1), a protein that functions as an 
adaptor protein to link CUL4A and CUL4-associated factors (DCAFs). 
The Cul4A-DDB1 core complex maintains efficient and timely 
assembly with different DCAFs to target distinct cellular substrates for 
ubiquitination, forming more than 90 E3–ligase complexes, responsible 
for the regulation of a broad spectrum of cellular processes(reviewed 
by Iovine B. et al., 2011) [17]. It was demonstrated that the V protein of 
simian virus 5 (SV5) is able to hijack this ubiquitin ligase machinery 
through interaction with DDB1, recruiting STAT1 and targeting it for 
degradation [18]. It is now known that RNA viruses of the 
Paramyxoviridae family (Mononegavirales order) code for V proteins 
whose expression greatly reduces the half life of STAT1 and/or 
STAT2, thereby inhibiting the Jak-STAT IFN signalling pathway 
(reviewed by Naijar & Fagard, 2010) [19]. 
Regarding the role of SV5 V protein in the ubiquitination of STAT1, a 
model has been proposed in which, after infection with SV5, the V 
protein acts as a linker bringing DDB1/Cul4A complexes into a close 
and stable association with STAT1/STAT2 complexes. An E3 ligase 
complex is formed and STAT1 becomes polyubiquitinated, being 
subsequently degraded by the proteasome. The DDB1/SV5-V/STAT2 
complex then becomes destabilized and STAT2 either captures 
another STAT1 to form a new degradation complex or dissociates from 
the complex and binds a free STAT1 molecule, with the resulting 
STAT1/STAT2 complex being recaptured by the DDB1/SV5 V-
containing E3 ligase. In uninfected cells DDB1/Cul4A complexes do 
not associate with STAT1 and STAT2, which can associate together in 
the absence of IFN stimulated phosphorylation [20]. 
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SV5 can only target STAT1 in cells that express STAT2, the same 
being true for mumps virus. For instance, SV5 does not replicate 
efficiently or cause STAT1 degradation in the mouse, where the 
murine STAT2 protein is unusually divergent in amino acid sequence. 
STAT2 can thus act as a host range determinant for this virus. 
(reviewed by Horvath C.M., 2004) [21]. Considering that STAT2 is 
required for STAT1 turnover, the fact that HEK-293T cells have low 
levels of endogenous STAT2 was pointed as a possible explanation of 
why it is not possible to see a loss of STAT1 in HEK-293T cells 
transiently transfected with the SV5 V protein [18]. 
It is tempting to speculate whether MGF360-18R could be inducing 
STAT1 ubiquitination and proteasomal degradation by highjacking the 
DDB1/Cul4A-RING ubiquitin ligase machinery. An obvious experiment 
would be to attempt the co-immunoprecipitation of DDB1 with the 
MGF360-18R protein. This viral protein fails to inhibit type I and type II 
IFN signalling in HEK-293T cells (data not shown), and it would be 
worth to set up a luciferase assay using GAS and ISRE luciferase 
reporters in HEK-293T cells transfected with STAT2 expression 
plasmid, and see if this could rescue the inhibitory activity of MGF360-
18R. In addition, it is known that most DCAFs possess an α-helical 
motif with a conserved DxR sequence, responsible for binding to 
DDB1 [22]. MGF360-18R does have an α-helical motif with identical 
characteristics, which could be further characterized through 
bioinformatic analysis. The construction of a deletion mutant protein 
lacking this motif could prove useful to verify if this motif is necessary 
for the MGF360-18R mediated inhibition of the Jak-STAT pathway.  
Up to now, no ASFV gene has been described that interferes with the 
Jak-STAT signalling pathway. The work described in this chapter 
demonstrates that the MGF360-18R protein of ASFV inhibits both type 
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I and type II IFN signalling cascades as well as the previously 
described inhibition of IFN-β induction (Chapter 4). Thus MGF360-18R 
is a multifunctional virus host evasion molecule which, through its 
impact at both the induction and impact of IFN responses, may affect 
virus pathogenesis through its activity at different stages of the virus 
replication cycle.  
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5. Jg 
5.1. Final Considerations 
Viral genomes encode essential proteins, such as structural proteins, 
enzymes, and a number of proteins, not necessarily essential, that 
have evolved for host cell evasion. The latter, as they modulate the 
host-pathogen interaction, contribute to the pathogenesis of a viral 
infection and may have practical applications for the manipulation of 
cell biology and immune responses.  
For ASFV, most of the structural proteins, and the enzymes required 
for virus replication, and some of the proteins that are involved in viral 
host evasion have been already identified by sequence homology and 
biochemical studies. There are, in addition, a large number of genes 
without homology to cellular genes (reviewed by Dixon, 2008) [1], that 
have most likely evolved for host cell manipulation. The function of 
such “unassigned” virus genes can only be revealed through functional 
approaches. Being an early innate host defence mechanism, the 
interferon system is a key player against virus infections and, as such, 
viruses have evolved a number of counter strategies to antagonise this 
response [2].  
Two ASFV genes subverting IFN responses with entirely different 
strategies have been pursued in the work presented in this thesis; one 
with no homology (MGF360-18R) and the other (I329L) with a marginal 
homology only revealed after extensive bioinformatic analysis. The 
results and implications have been extensively discussed in each of 
the three experimental chapters, and so the following discussion will 
be a brief recapitulation of the key points. 
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Modulation of IFN-β expression by the MGF360-18R protein of 
ASFV 
The comparison of the transcriptional profiles of macrophage infected 
with wild type ASFV and a deletion mutant virus lacking six MGF360 
and two MGF530 genes, resulted in the observation that some of the 
genes belonging to any of these two multigene families might have 
evolved to manipulate interferon responses [3]. A functional screening 
of 17 non-homologous ASFV genes, previously performed at our 
laboratory (Correia SM, unpublished work), identified four genes that 
are able to inhibit the induction of the IFN-β in response to Poly (I:C). 
One of these, the MGF360-18R gene, a member of MGF360, was 
investigated in detail in order to understand its mechanism for 
inhibiting the induction and impact of IFN-β. 
Sequence comparison of the genomes of several ASFV isolates 
revealed that MGF360-18R is a non-conserved open-reading frame 
(ORF). For this work, we selected two variants of this viral gene: the 
Benin97/1 variant, with 254a.a., which the largest known variant of this 
protein, and the Ba71V variant, with 148a.a., encoded by the tissue 
culture attenuated ASFV strain (see Anex). 
Both MGF360-18R variants were demonstrated to inhibit the induction, 
expression and secretion of IFN-β in a NF-κB dependent manner. 
Moreover, both variants were found to colocalize to mitochondria and 
to target MAVS, a key adaptor protein of the RIG-I-like receptors (RLR) 
pathway. All viruses, even those replicating within the nucleus (e.g. 
herpes viruses), include a cytoplasmic phase in their replication 
strategy, and the RLRs specifically recognize viral dsRNA in the 
cytoplasm. Interestingly, these cytosolic receptors were recently 
described to be involved in antiviral signalling in response to viruses 
containing a dsDNA genome, such as Epstein–Barr virus [4] and 
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vaccinia virus [5]. By interfering with MAVS, MGF360-18R is able to 
block the cytosolic antiviral recognition mechanism, inhibiting both NF-
κB activation and induction of type I IFN. The interaction between 
MGF360-18R (Ba71V variant) and MAVS was demonstrated by 
biochemical evidence, but this same assay was not yet performed for 
the Benin97/1 variant of MGF360-18R. On the other hand, the exact 
mechanism by which this viral protein is interfering with MAVS function 
remains to be clarified. Several observations support that basic 
mitochondrial functions are integrated with innate immunity, and that 
innate immune signalling based on the mitochondria largely depend on 
this organelle’s activity and fitness (reviewed by Arnoult, 2011) [6]. 
Considering its mitochondrial location, it should be interesting to verify 
if MGF360-18R has any effect on the mitochondrial potential, thus 
affecting this organelle’s fitness. 
Moreover, MGF360-18R variant from Benin97/1 was shown to inhibit 
the activity of the IRF3 transcription factor, hence directly affecting 
IRF-3 stimulated ISG transcription, in addition to its inhibitory role in 
the RLR pathway by interfering with MAVS. Several possibilities for the 
mechanism by which this variant of the MGF360-18R protein inhibits 
the activity of IRF3 were extensively discussed in the respective 
experimental chapter. This additional inhibitory action of this MGF360-
18R variant is particularly interesting as it corresponds to the variant 
found in pathogenic isolates of the ASFV. Comparatively to the tissue 
culture adapted, non-pathogenic variant, the MGF360-18R protein 
encoded by the Benin97/1 ASFV isolate is able to block IFN response 
in a more effective manner, by interfering at two distinct and crucial 
stages of mechanisms leading to induction of type I IFN. The 
transcription factor IRF3 is common to most mechanisms leading to 
induction of IFN, thus inhibition of IRF-3 efficiently blocks induction of 
IFN by all remaining anti-viral recognition mechanisms. 
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In conclusion, both variants of the ASFV MGF360-18R protein impair 
activation of IFN-β induction through targeting MAVS, a key adaptor 
protein of the RLR pathway. The MGF360-18R variant from the 
Benin97/1 isolate, also targets IRF-3, which may give the virus an 
extra advantage. 
Modulation of the impact of both type I and type II IFN by the 
MGF360-18R protein of ASFV 
Deletion of members of the ASFV multigene families (MGF) 360 and 
530 has also been shown to increase activation of IFN induced genes 
in infected macrophages. This suggests that these genes may have a 
role in inhibiting transcription of ISGs, although this remains to be 
demonstrated [3]. 
The non-conserved ORF MGF360-18R was investigated in detail in 
order to understand the mechanism by which it modulates IFN-
mediated signalling. The results indicated that the impact of both type I 
and type II IFN on the Jak-STAT signalling cascades is impaired by the 
expression of both variants of ASFV MGF360-18R. As the STAT 
transcription factors are key regulators in this signalling pathway, their 
activation was examined on cells expressing either variants of 
MGF360-18R. The results presented show that both variants of ASFV 
MGF360-18R protein are able to reduce the cellular levels of both 
phosphorylated and unphosphorylated STAT1, but the levels of STAT2 
remain unaffected. 
The response to IFNs is a tightly regulated cellular process, as it must 
be terminated once the viral threat is over, in order to avoid damage to 
the host. Ubiquitination of STAT proteins results in their degradation by 
the 26S proteasome-dependent pathway, and this is the only known 
mechanism to reduce the levels of STAT proteins in the cell, helping to 
regulate STAT signalling and restrain the inflammatory response [7]. 
Chapter 5 
201 
Given that interferon-mediated signalling plays an important role in 
anti-viral immunity, it is not surprising that viruses have evolved 
multiple means for its downregulation. Type I and type II IFN activate 
downstream components that can be either unique or common to both 
signalling pathways. Thus, viruses can block the impact of IFN at 
several levels, inhibiting only one of these two pathways or both. In this 
case, we describe an ASFV non-conserved gene, MGF360-18R, that 
impairs the host cell response to both type I and type II IFN (Jak-STAT 
pathway) inducing STAT1 degradation by the 26S proteasome. 
STAT1 not only plays important roles in the response to type I and 
type II IFN, but is also involved in the response to various stressful 
stimuli that induce cell cycle arrest and apoptosis. Indeed, STAT1 has 
been reported to regulate the transcription of several genes involved in 
cell cycle control and is able to upregulate the expression of 
procaspases, the latent forms of the caspases, which are proteases 
that transmit the apoptotic pathway in the cytoplasm by sequential 
cleavage in response to external or internal stimuli (reviewed by Naijar 
& Fagard, 2010) [8]. Programmed cell death during ASFV infection is a 
tightly regulated process in which the action of inducers is balanced by 
the expression of antiapoptotic genes. Although ASFV induces 
apoptosis in the cell in a postbinding step, during or after virus 
uncoating, this cellular process is delayed up to 13h after the infection, 
a time at which viral morphogenesis is well under way [9]. Several 
ASFV genes have been shown to be involved in the inhibition of 
apoptosis using different mechanisms [10,11,12]. Here we studied 
another ASFV gene, MGF360-18R, which induces the degradation of 
STAT1, with loss of its pro-apoptotic and cell cycle regulation 
functions. 
An interesting observation, when comparing the effect of the 
expression of either variant of the ASFV ORF MGF360-18R in the anti-
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viral mechanisms studied in this work, is their distinct roles regarding 
the inhibition of IFN-β induction pathway. On the other hand, in the 
Jak-Stat pathway (STAT1), both MGF360-18R variants target the 
same cellular protein and the results indicate that the mechanism of 
action of either MGF360-18R variant, in this pathway, is the same. 
Regarding the IFN-β induction pathway, however, the Benin97/1 
variant of MGF360-18R clearly has a greater impact, and is able to 
target two distinct and crucial proteins involved in the induction of IFN-
β subsequently to viral infection. The peptide region that is truncated in 
the tissue culture adapted strain (Ba71V) should be more extensively 
studied, as it possibly accounts for the extra inhibitory role of the 
Benin97/1 variant. Phylogenetic analysis of the available ASFV 
genome sequences revealed considerable genetic diversity at the 
genome level, in particularly at the level of the composition of the 
variable regions [13]. The most variable genes belong to the multigene 
families, and ASFV MGF360/530 genes have been reported to affect 
viral growth in macrophage cell cultures and virulence in pigs [14]. 
Comparison of pathogenic and non-pathogenic strains could prove 
useful in identifying new ASFV genes involved in the virus 
pathogenesis. 
Mechanism of ASFV ORF I329L-mediated inhibition of type I IFN 
induction 
In a recent report, the conserved ASFV ORF I329L was described as 
an inhibitor of the TLR3 pathway, downmodulating both IFN-β 
secretion and NF-κB activation. Several observations raised the 
possibility that I329L might exert its inhibitory activity through 
interaction with TRIF, the TLR3 adaptor protein [15]. 
Here we present formal biochemical proof of an interaction between 
the I329L protein and TRIF. Functional analyses of I329L truncated 
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mutants were performed, to further define the role of each I329L 
domain. The expression of the transmembrane + intracellular domain 
(TM/IC) fragment of I329L inhibited induction of IFN-β and NF-кB 
activation by ectopically expressed TRIF, indicating a disruption of 
signal transduction through the impact of I329L intracellular domain on 
TRIF. Intriguingly, the extracellular + transmembrane domain (EC/TM) 
fragment of I329L inhibited Poly (I:C)-mediated, but not TRIF-
mediated, induction of IFN-β. This observation suggests that I329L 
also inhibits dsRNA-mediated activation of the TLR3 pathway via its 
EC/TM domain, perhaps through formation of a non-signalling I329L-
TLR3 heterodimer. In conclusion, the I329L mediated inhibition of TLR 
signalling pursues a dual strategy, with its extra- and intracellular 
domains evolved for interfering with the initiation and subsequent 
intracellular transmission of the dsRNA stimulus, respectively. 
Considering the recent observations of proteolytic processing of 
endosomal TLRs, we tested the possibility of a similar processing for 
I329L, as this could help understanding the dual strategy of I329L, in 
particular the inhibitory activity of the TM/IC fragment [16]. Evidence 
was obtained indicating proteolytic processing of I329L as a 
consequence of viral infection or activation of TLR3 signalling, either 
by Poly (I:C) or TRIF. Consistent with the requirement of this 
processing for the full inhibitory activity of I329L, a mutant I329L 
protein lacking a cathepsin L sensitive site continued to inhibit 
Poly (I:C)-mediated induction of IFN-β, but was no longer able to inhibit 
IFN-β induction and secretion, nor NF-кB activation, through 
ectopically expressed TRIF. 
Structural studies of the TLR3 ectodomain bound to Poly (I:C) indicate 
that a C-terminal cleavage product of TLR3 would contain residues 
implicated in direct interaction between the two TLR3 molecules within 
the dimer as well as the leucine-rich repeats [LRR] 19–21, required for 
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ligand binding [17,18]. The finding that TLR3 is proteolytically 
processed does not explain how this event results in TLR3 activation 
and optimal response to Poly (I:C). Proteolysis may be required for a 
conformational shift in dimer structure, enhancing binding to TRIF and 
intracellular signalling. Alternatively, receptor cleavage may lead to 
altered affinity for ligand, which could also increase the likelihood of 
receptor activation. It would be interesting to find if proteolytic cleavage 
of TLR3 is affected by expression of the ASFV I329L protein.  
The I329L proteolysis mechanism was not clarified in this work. 
Proteolytic processing as a mechanism of protein maturation is a well 
known feature of ASFV [19]. The ASFV late protein pS273R belongs to 
the family of SUMO-1-processing cysteine proteinases, and is capable 
of cleaving viral proteins at specific Gly-Gly-X sites. Such a site is 
present in the I329L protein sequence and is coincident with the 
cathepsin L sensitive site. We must consider the possibility of I329L 
proteolysis resulting in two smaller, mature proteins, which will have 
distinct roles in the inhibition of type I IFN induction. Functional studies 
with the extracellular fragment of I329L, corresponding to the N-
terminal residues being removed upon proteolysis, could elucidate if 
this fragment has any inhibitory activity. 
Based in the results presented here, a model was suggested in which 
the I329L molecule inhibits the TLR response using a dual strategy: 
I329L forms a non-functional heterodimer with TLR3, thereby inhibiting 
the activation of the pathway via dsRNA binding, and, following 
proteolytic processing, the resulting TM/IC fragment of I329L is able to 
target TRIF, inhibiting the intracellular signalling initiation. This model 
is open to experimental confirmation, as are the precise details of the 
proteolytic processing. 
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In conclusion, in this work, we were able to demonstrate how two 
ASFV genes, MGF360-18R and I329L, use different strategies to 
modulate the IFN response. The deletion of virus “evasion” genes 
offers a rational strategy for the development of non-pathogenic, 
deletion mutant viruses. Specifically, mutant viruses unable to 
counteract the IFN response are in fact excellent candidates for live 
attenuated vaccines as they can be produced at high titers in IFN-
deficient cultures. Finally, the work does support the suspicion that the 
non-homologous, non assigned portion of the ASFV (and hence other 
virus) genomes may be considered as a repository of the host evasion 
genes. 
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Screening of different ASFV isolates for the MGF360-18R 
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Characterization of the ASFV isolates screened for the sequence of the MGF360-18R gene 
Abbreviation Virus designation Host species Country Continent Virulence 18R variant 
ASFV-Ba71V Ba71V Vero cell adapted Spain Europe Atenuated A 
ASFV-OurT88_3 OurT88_3 Tick Portugal Europe Low A 
ASFV-Pret Pretorisuskop-96-4 Tick South Africa Africa High B 
ASFV-Ten62 Tengani62 Warthog Malawi Africa High B 
ASFV-War Warthog Warthog Namibia Africa Unknown B 
ASFV-Georgia Georgia 2007/1 Domestic Pig Georgia Europe High B 
ASFV-Ken Kenya 1950 Domestic Pig Kenya Africa High C 
ASFV-Mal Malawi Lil-20-1 1983 Domestic Pig Malawi Africa High C 
ASFV-Mku Mkuzi 1979 Tick (1978) Zululand Africa Unknown D 
ASFV-Benin97/1 Benin97 Domestic Pig Benin Africa High D 
ASFV-E75 E75 Domestic pig Spain Europe High D 
ASFV-Warm Warmbaths Tick South Africa Africa Unknown D 
Variant A: 148a.a.; Variant B: 237a.a.; Variant C: 241a.a.; Variant D: 254a.a. 
 
Anex 
 
Alignment of putative MGF360-18R protein sequences expressed by different ASFV isolates 
 
      --------------------------------------------------        ASFV-BA71V 
      --------------------------------------------------        ASFV-OURT88_3 
  1   MQNKIPNFNLFFFFLYRMLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    50  ASFV-E75 
  1   MQNKIPNFNLFFFFLYRMLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    50  ASFV-Benin97/1 
  1   MQNKIPNFNLFFFFLYRMLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    50  ASFV-Mku 
  1   MQNKIPNFNLFFFFLYRMLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    50  ASFV-Warm 
  1   -----------------MLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    33  ASFV-War 
  1   -----------------MLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    33  ASFV-Pret 
  1   -----------------MLEIVLATLLGDLQRLRVLTPQQRAVAFFRANT    33  ASFV-Teng 
  1   -----------------MLEIVLATLLGDLQKLKDLTPPQRAVAFFRANT    33  ASFV-Ken 
  1   -----------------MLEIVLATLLGDLQKLRDLTPMQRAVAFFRVNT    33  ASFV-Mal 
 
 
 
      --------------------------------------------------        ASFV-BA71V 
      --------------------------------------------------        ASFV-OURT88_3 
 51   KELEDFLRSDGQSEEILSGPLLNRLLEPSCPLDILTGYHLFRQNPKAGQL   100  ASFV-E75 
 51   KELEDFLRSDGQSEEILSGPLLNRLLEPSCPLDILTGYHLFRQNPKAGQL   100  ASFV-Benin97/1 
 51   KELEDFLCSDGQSEEILSGPLLNRLLEPSGPLDILTGYHLFRQNPKAGQL   100  ASFV-Mku 
 51   KELEDFLCSDGQSEEILSGPLLNRLLEPSGPLDILTGYHLFRQNPKAGQL   100  ASFV-Warm 
 34   KELEDFLCSDGQSEEILSGPLLNRLLEPSGPLDILTGYHLFRQNPKAGQV    83  ASFV-War 
 34   KEVEDFLCSDGQSEEVLSGPLLNRLLEPSGPLDILTGYHLFRQNPKAGQV    83  ASFV-Pret 
 34   KELEDFLCPDGQSEEVLSGSLLNRLLEPSGPLDILTGYHLFRQNPKAGQL    83  ASFV-Teng 
 34   KELEDFLYPDGQSEELLPGLLLNRLLEPSGSIDILTGYHLFRENPKAGRL    83  ASFV-Ken 
 34   KELEDFLYPDGQSEELLPGLLLNRLLEPSGPIDILTGYHLFRENPKAGRL    83  ASFV-Mal 
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  1   ------MLERLYDANIYNILSRLRPEKVRNKAIELYWVFRAIHICHAPLV    44  ASFV-BA71V 
  1   ------MLERLYDANIYNILSRLRPEKVRNKAIELYWVFRAIHICHAPLV    44  ASFV-OURT88_3 
101   RGLEVKMLERLYDANIYNILSRLRPEKVRNKAIELYWVFRAIHICHAPLV   150  ASFV-E75 
101   RGLEVKMLERLYDANIYNILSRLRPKKVRNKAIELYWVFRAIHICHAPLV   150  ASFV-Benin97/1 
101   RGLEVKMLERLYDANIYNILSRLRPEKVRNKAIELYWVFRAIHICHAPLV   150  ASFV-Mku 
101   RGLEVKMLERLYDANIYNILSRLRPEKVRNKAIELYWVFRAIHICHAPLV   150  ASFV-Warm 
 84   RGLEVKMLERLYDANIYNILSRLRPEKVRNKAVELYWVFRAINMCHAPLV   133  ASFV-War 
 84   RGLEVKMLERLYDANIYNILSRLRPEKVRNKAVELYWVFRAINMCHAPLV   133  ASFV-Pret 
 84   RGLEVKMLERLYDANIYNILSRLRPEKVRNKAVELYWVFRAINMCHAPLV   133  ASFV-Teng 
 84   RGLEVKMLERLYDANIYNMLARLRPELVRDKAIELYWLFRAILMCHSPLV   133  ASFV-Ken 
 84   RGLEVKLLERLYDANIYNMLAQIRPELVRIKAIELYWLFRAILMCHSPLV   133  ASFV-Mal 
            :***********:*:::**: ** **:****:**** :**:*** 
 
 
 45   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIQISL    94  ASFV-BA71V 
 45   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIQISL    94  ASFV-OURT88_3 
151   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIQISL   200  ASFV- 
151   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIQISL   200  ASFV- 
151   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIRISL   200  ASFV- 
151   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIRISL   200  ASFV- 
134   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIQISL   183  ASFV- 
134   LDIVRYEEPDFAELAFICAAYFGEPQVMYLLYKYMPLSRAVLTDAIQISL   183  ASFV- 
134   LDIVRNEELDFAELAFICAAYFGEPQVMYLLYKYMPLTRAVLTDAIQISL   183  ASFV- 
134   LEIVRHETMDFAETAFICAAYFSEPQVMYALYKFIPISRAVLADAIQMCL   183  ASFV- 
134   LEIVRHETMDFAELAFICAAYFSEPQVMYALYKFIPISRAVLADAIEMSL   183  ASFV- 
      *:*** *  **** ********.*********::*::****:***.:.** 
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 95   ESNNQVGICYAYLMGGSLKGLVSAPLRKRLRAK-LRSQRKKKDVLSPHDFLLLLQ--  148  ASFV-BA71V 
 95   ESNNQVGICYAYLMGGSLKGLVSAPLRKRLRAK-LRSQRKKKDVLSPHDFLLLLQ--  148  ASFV-OURT88_3 
201   ESNNQVGICYAYLMGGSLKGLVSAPLRKRLRAK-LRSQRKKKDVLSPHDFLLLLQ--  254  ASFV-E75 
201   ESNNQVGICYAYLMGGSLKGLVSAPLRKRLRAK-LRSQRKKKDVLSPHDFLLLLQ--  254  ASFV-Benin97/1 
201   ESNNQVGICYAYLMGGSLKGLVSAPLRKRLCAK-LRSQRKKKDVLSPHDFLLLLQ--  254  ASFV-Mku 
201   ESNNQVGICYAYLMGGSLKGLVSAPLRKRLRAK-LRSQRKKKDVLSPHDFLLLLQ--  254  ASFV-Warm 
184   ESNSQVGICYAYLMGGSLKGLVRAPLRKRLRAK-LRSQRKKKDVLPPHDFLLLLQ--  237  ASFV-War 
184   ESNSQVGICYAYLMGGSLKGLVRAPLRKRLRAK-LRSQRKKKDVLPPHDFLLLLQ--  237  ASFV-Pret 
184   ESNSQVGICYAYLMGGSLKGLVRAPLRKRLRAK-LRSQRKKKDVLPPHDFLLLLQ--  237  ASFV-Teng 
184   ESNSEAGICYAYLMGGSLKGKVPGSLRKRLRASPLRQERKKKNVLPPHEFLLMLHGI  240  ASFV-Ken 
184   ESNSETGICYAYLMGGSLKGKVPGPLRKRLRASPLRQERKKKNVLPPHEFLLMLHGI  240  ASFV-Mal 
      **.:.*************** *...***** *. **.:****:**.**:***:*:        
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Cladogram showing the relationship between the several variants 
of MGF360-18R 
 
 
ASFV-E75-165
ASFV-BA71V-153
ASFV-OURT88 3-154
ASFV-Benin97 1-154
ASFV-War-169
ASFV-Pret-171
ASFV-Teng-166
ASFV-Ken-166
ASFV-Mal-165
ASFV-Mku-171
ASFV-Warm-170
Anex 
 
Sequence and location of the MGF360-18R transmembrane 
domains predicted by the TMHMM program 
 
Virus 
designation 
Start End TM sequence 
Benin97/1 4 30 KIPNFNLFFFFLYRMLEIVLATLLGDL 
127 147 KVRNKAIELYWVFRAIHICHA 
160 180 DFAELAFICAAYFGEPQVMYL 
Ba71V 21 41 KVRNKAIELYWVFRAIHICHA 
54 74 DFAELAFICAAYFGEPQVMYL 
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